<!DOCTYPE html><html lang="en" class="bg-surface-base antialiased"><head><meta charSet="utf-8"/><meta name="viewport" content="width=device-width, initial-scale=1, interactive-widget=resizes-content"/><link rel="stylesheet" href="/_next/static/css/62c4caba71dfda84.css" nonce="ZDI3MzMxYzUtYzY2YS00M2M3LThmMmMtODg3ZDMzYTJjZmMw" data-precedence="next"/><link rel="stylesheet" href="/_next/static/css/eb3d87f98fe1565f.css" nonce="ZDI3MzMxYzUtYzY2YS00M2M3LThmMmMtODg3ZDMzYTJjZmMw" data-precedence="next"/><link rel="stylesheet" href="/_next/static/css/1b5e561215938d4d.css" nonce="ZDI3MzMxYzUtYzY2YS00M2M3LThmMmMtODg3ZDMzYTJjZmMw" data-precedence="next"/><link rel="stylesheet" href="/_next/static/css/0227d069a630d414.css" nonce="ZDI3MzMxYzUtYzY2YS00M2M3LThmMmMtODg3ZDMzYTJjZmMw" data-precedence="next"/><link rel="stylesheet" href="/_next/static/css/f87fff2ab93d05a7.css" nonce="ZDI3MzMxYzUtYzY2YS00M2M3LThmMmMtODg3ZDMzYTJjZmMw" data-precedence="next"/><link rel="preload" as="script" fetchPriority="low" nonce="ZDI3MzMxYzUtYzY2YS00M2M3LThmMmMtODg3ZDMzYTJjZmMw" href="/_next/static/chunks/webpack-e121ed42680f327e.js"/><script src="/_next/static/chunks/78a669d9-e7993486b22c4915.js" async="" nonce="ZDI3MzMxYzUtYzY2YS00M2M3LThmMmMtODg3ZDMzYTJjZmMw"></script><script src="/_next/static/chunks/40c4a5a7-abdabb07419d1cfc.js" async="" nonce="ZDI3MzMxYzUtYzY2YS00M2M3LThmMmMtODg3ZDMzYTJjZmMw"></script><script src="/_next/static/chunks/2230-f7c87dc9fa57c408.js" async="" nonce="ZDI3MzMxYzUtYzY2YS00M2M3LThmMmMtODg3ZDMzYTJjZmMw"></script><script src="/_next/static/chunks/main-app-536d4b8fca62396a.js" async="" nonce="ZDI3MzMxYzUtYzY2YS00M2M3LThmMmMtODg3ZDMzYTJjZmMw"></script><script src="/_next/static/chunks/63f0ec43-8ee6a76d70472249.js" async="" nonce="ZDI3MzMxYzUtYzY2YS00M2M3LThmMmMtODg3ZDMzYTJjZmMw"></script><script src="/_next/static/chunks/7670-7326298c9856172b.js" async="" nonce="ZDI3MzMxYzUtYzY2YS00M2M3LThmMmMtODg3ZDMzYTJjZmMw"></script><script src="/_next/static/chunks/282-691fffb366e24ca5.js" async="" nonce="ZDI3MzMxYzUtYzY2YS00M2M3LThmMmMtODg3ZDMzYTJjZmMw"></script><script src="/_next/static/chunks/7515-336759ef5dad2b52.js" async="" nonce="ZDI3MzMxYzUtYzY2YS00M2M3LThmMmMtODg3ZDMzYTJjZmMw"></script><script src="/_next/static/chunks/927-34e2a6da3e15e26b.js" async="" nonce="ZDI3MzMxYzUtYzY2YS00M2M3LThmMmMtODg3ZDMzYTJjZmMw"></script><script src="/_next/static/chunks/5855-243eeca8f0e4cabd.js" async="" nonce="ZDI3MzMxYzUtYzY2YS00M2M3LThmMmMtODg3ZDMzYTJjZmMw"></script><script src="/_next/static/chunks/4393-1c8dff25ec904469.js" async="" nonce="ZDI3MzMxYzUtYzY2YS00M2M3LThmMmMtODg3ZDMzYTJjZmMw"></script><script src="/_next/static/chunks/2225-454cf9f44775e7ce.js" async="" nonce="ZDI3MzMxYzUtYzY2YS00M2M3LThmMmMtODg3ZDMzYTJjZmMw"></script><script src="/_next/static/chunks/7618-43536a8fb0dd3bfe.js" async="" nonce="ZDI3MzMxYzUtYzY2YS00M2M3LThmMmMtODg3ZDMzYTJjZmMw"></script><script src="/_next/static/chunks/app/page/%5Bslug%5D/layout-55a344716dd57c44.js" async="" nonce="ZDI3MzMxYzUtYzY2YS00M2M3LThmMmMtODg3ZDMzYTJjZmMw"></script><script src="/_next/static/chunks/7720-3a1e7e411adba2d3.js" async="" nonce="ZDI3MzMxYzUtYzY2YS00M2M3LThmMmMtODg3ZDMzYTJjZmMw"></script><script src="/_next/static/chunks/7086-1f1c4891d766e04f.js" async="" nonce="ZDI3MzMxYzUtYzY2YS00M2M3LThmMmMtODg3ZDMzYTJjZmMw"></script><script src="/_next/static/chunks/app/page/%5Bslug%5D/not-found-69a3edc7db5749d6.js" async="" nonce="ZDI3MzMxYzUtYzY2YS00M2M3LThmMmMtODg3ZDMzYTJjZmMw"></script><script src="/_next/static/chunks/app/global-error-4d07d20223cd4b4c.js" async="" nonce="ZDI3MzMxYzUtYzY2YS00M2M3LThmMmMtODg3ZDMzYTJjZmMw"></script><script src="/_next/static/chunks/8208b75a-a48e5a4507a0de91.js" async="" nonce="ZDI3MzMxYzUtYzY2YS00M2M3LThmMmMtODg3ZDMzYTJjZmMw"></script><script src="/_next/static/chunks/5497-ab85ef3ea59dd353.js" async="" nonce="ZDI3MzMxYzUtYzY2YS00M2M3LThmMmMtODg3ZDMzYTJjZmMw"></script><script src="/_next/static/chunks/6281-c6e84786dade3614.js" async="" nonce="ZDI3MzMxYzUtYzY2YS00M2M3LThmMmMtODg3ZDMzYTJjZmMw"></script><script src="/_next/static/chunks/2660-d983a7f287e89f18.js" async="" nonce="ZDI3MzMxYzUtYzY2YS00M2M3LThmMmMtODg3ZDMzYTJjZmMw"></script><script src="/_next/static/chunks/5002-9735c25beda556ba.js" async="" nonce="ZDI3MzMxYzUtYzY2YS00M2M3LThmMmMtODg3ZDMzYTJjZmMw"></script><script src="/_next/static/chunks/3655-6717081f7512305a.js" async="" nonce="ZDI3MzMxYzUtYzY2YS00M2M3LThmMmMtODg3ZDMzYTJjZmMw"></script><script src="/_next/static/chunks/8945-e4e3cf487f5e27c7.js" async="" nonce="ZDI3MzMxYzUtYzY2YS00M2M3LThmMmMtODg3ZDMzYTJjZmMw"></script><script src="/_next/static/chunks/9214-a10614844a67ba31.js" async="" nonce="ZDI3MzMxYzUtYzY2YS00M2M3LThmMmMtODg3ZDMzYTJjZmMw"></script><script src="/_next/static/chunks/4789-2080f6497f78b5b6.js" async="" nonce="ZDI3MzMxYzUtYzY2YS00M2M3LThmMmMtODg3ZDMzYTJjZmMw"></script><script src="/_next/static/chunks/app/layout-226f2bd71acf9f9e.js" async="" nonce="ZDI3MzMxYzUtYzY2YS00M2M3LThmMmMtODg3ZDMzYTJjZmMw"></script><script src="/_next/static/chunks/24cf1b50-159cca90b09285e0.js" async="" nonce="ZDI3MzMxYzUtYzY2YS00M2M3LThmMmMtODg3ZDMzYTJjZmMw"></script><script src="/_next/static/chunks/9ffa21ba-c069766d809bd4c7.js" async="" nonce="ZDI3MzMxYzUtYzY2YS00M2M3LThmMmMtODg3ZDMzYTJjZmMw"></script><script src="/_next/static/chunks/600-9a9fcafaaa6c1c4c.js" async="" nonce="ZDI3MzMxYzUtYzY2YS00M2M3LThmMmMtODg3ZDMzYTJjZmMw"></script><script src="/_next/static/chunks/5448-2a3cfd853d899c9a.js" async="" nonce="ZDI3MzMxYzUtYzY2YS00M2M3LThmMmMtODg3ZDMzYTJjZmMw"></script><script src="/_next/static/chunks/8-8ca70ca619d8e099.js" async="" nonce="ZDI3MzMxYzUtYzY2YS00M2M3LThmMmMtODg3ZDMzYTJjZmMw"></script><script src="/_next/static/chunks/app/page/%5Bslug%5D/page-540a27b6839afde5.js" async="" nonce="ZDI3MzMxYzUtYzY2YS00M2M3LThmMmMtODg3ZDMzYTJjZmMw"></script><script src="/_next/static/chunks/app/error-4a29e9399afba038.js" async="" nonce="ZDI3MzMxYzUtYzY2YS00M2M3LThmMmMtODg3ZDMzYTJjZmMw"></script><script src="/_next/static/chunks/app/not-found-dd95690acf732f18.js" async="" nonce="ZDI3MzMxYzUtYzY2YS00M2M3LThmMmMtODg3ZDMzYTJjZmMw"></script><meta name="next-size-adjust" content=""/><title>Grokipedia</title><meta name="description" content="Grokipedia is an open source, comprehensive collection of all knowledge."/><link rel="icon" type="image/x-icon" href="/favicon.ico" sizes="48x48"/><link rel="icon" href="/images/icon-dark.png" media="(prefers-color-scheme: light)" type="image/png"/><link rel="icon" href="/images/icon-light.png" media="(prefers-color-scheme: dark)" type="image/png"/><link rel="apple-touch-icon" href="/icon-192x192.png"/><link rel="manifest" href="/manifest.webmanifest"/><meta name="robots" content="index, follow"/><meta name="googlebot" content="index, follow, max-snippet:-1"/><meta property="og:title" content="Grokipedia"/><meta property="og:description" content="Grokipedia is an open source, comprehensive collection of all knowledge."/><meta property="og:url" content="https://grokipedia.com"/><meta property="og:site_name" content="Grokipedia"/><meta property="og:locale" content="en_US"/><meta property="og:type" content="website"/><meta property="og:image" content="https://grokipedia.com/icon-512x512.png"/><meta property="og:image:width" content="512"/><meta property="og:image:height" content="512"/><meta property="og:image:alt" content="Grokipedia"/><meta name="twitter:card" content="summary"/><meta name="twitter:creator" content="@Grokipedia"/><meta name="twitter:title" content="Grokipedia"/><meta name="twitter:description" content="Grokipedia is an open source, comprehensive collection of all knowledge."/><meta name="twitter:image" content="https://grokipedia.com/icon-512x512.png"/><title>Kidney cancer</title><meta name="description" content="Kidney cancer , also known as renal cancer , is a group of cancers that starts in the kidney.[4] Symptoms may include blood in the urine, a lump in the abdomen, or back pain.[1][2][3] Fever, weight loss, and tiredness may also occur.[1][2][3] Complications can include spread to the lungs or brain.[6] The main types of kidney cancer are renal cell cancer (RCC), transitional cell cancer (TCC), and Wilms&#x27; tumor.[7] RCC makes up approximately 80% of kidney cancers, and TCC accounts for most of the..."/><meta name="author" content="system"/><link rel="manifest" href="/manifest.webmanifest"/><meta name="keywords" content="Renal cancer, Renal cell carcinoma, RCC"/><meta name="robots" content="index, follow"/><meta name="googlebot" content="index, follow, max-snippet:-1"/><link rel="canonical" href="https://grokipedia.com/page/Kidney_cancer"/><meta property="og:title" content="Kidney cancer"/><meta property="og:description" content="Kidney cancer , also known as renal cancer , is a group of cancers that starts in the kidney.[4] Symptoms may include blood in the urine, a lump in the abdomen, or back pain.[1][2][3] Fever, weight loss, and tiredness may also occur.[1][2][3] Complications can include spread to the lungs or brain.[6] The main types of kidney cancer are renal cell cancer (RCC), transitional cell cancer (TCC), and Wilms&#x27; tumor.[7] RCC makes up approximately 80% of kidney cancers, and TCC accounts for most of the..."/><meta property="og:url" content="https://grokipedia.com/page/Kidney_cancer"/><meta property="og:site_name" content="Grokipedia"/><meta property="og:locale" content="en"/><meta property="og:image" content="https://grokipedia.com/icon-512x512.png"/><meta property="og:image:width" content="512"/><meta property="og:image:height" content="512"/><meta property="og:image:alt" content="Kidney cancer"/><meta property="og:type" content="article"/><meta property="article:modified_time" content="1970-01-21T09:19:13.636Z"/><meta name="twitter:card" content="summary"/><meta name="twitter:creator" content="@Grokipedia"/><meta name="twitter:title" content="Kidney cancer"/><meta name="twitter:description" content="Kidney cancer , also known as renal cancer , is a group of cancers that starts in the kidney.[4] Symptoms may include blood in the urine, a lump in the abdomen, or back pain.[1][2][3] Fever, weight loss, and tiredness may also occur.[1][2][3] Complications can include spread to the lungs or brain.[6] The main types of kidney cancer are renal cell cancer (RCC), transitional cell cancer (TCC), and Wilms&#x27; tumor.[7] RCC makes up approximately 80% of kidney cancers, and TCC accounts for most of the..."/><meta name="twitter:image" content="https://grokipedia.com/icon-512x512.png"/><link rel="icon" href="/favicon.ico" type="image/x-icon" sizes="16x16"/><meta name="sentry-trace" content="6db95871d3951009d4e67ad5cd54f594-85586168db06dc31-1"/><meta name="baggage" content="sentry-environment=production,sentry-public_key=5f2258f71198ee26a355127af230c3a6,sentry-trace_id=6db95871d3951009d4e67ad5cd54f594,sentry-org_id=4508179396558848,sentry-transaction=GET%20%2Fpage%2F%5Bslug%5D,sentry-sampled=true,sentry-sample_rand=0.2855152267239094,sentry-sample_rate=1"/><script src="/_next/static/chunks/polyfills-42372ed130431b0a.js" noModule="" nonce="ZDI3MzMxYzUtYzY2YS00M2M3LThmMmMtODg3ZDMzYTJjZmMw"></script></head><body class="flex h-[100svh] w-full flex-col __variable_13c637 __variable_8a0ba0 __variable_779740 __variable_2484fd __variable_525cc3 __variable_13486b"><div hidden=""><!--$--><!--/$--></div><script nonce="ZDI3MzMxYzUtYzY2YS00M2M3LThmMmMtODg3ZDMzYTJjZmMw">((a,b,c,d,e,f,g,h)=>{let i=document.documentElement,j=["light","dark"];function k(b){var c;(Array.isArray(a)?a:[a]).forEach(a=>{let c="class"===a,d=c&&f?e.map(a=>f[a]||a):e;c?(i.classList.remove(...d),i.classList.add(f&&f[b]?f[b]:b)):i.setAttribute(a,b)}),c=b,h&&j.includes(c)&&(i.style.colorScheme=c)}if(d)k(d);else try{let a=localStorage.getItem(b)||c,d=g&&"system"===a?window.matchMedia("(prefers-color-scheme: dark)").matches?"dark":"light":a;k(d)}catch(a){}})("class","theme","dark",null,["light","dark"],null,true,true)</script><header class="h-16 bg-surface-base fixed top-0 z-50 w-full"><div class="hidden h-full grid-cols-[1fr_3fr_1fr] items-center gap-4 !py-0 md:grid max-w-full py-6 px-4 w-full mx-auto"><div class="-ml-2 justify-self-start"><a class="cursor-pointer" href="/"><svg width="200" height="auto" viewBox="0 0 955 225" fill="none" xmlns="http://www.w3.org/2000/svg"><path d="M99.6937 159.214C90.008 159.214 81.5652 157.414 74.3652 153.814C67.1652 150.214 61.5509 144.986 57.5223 138.129C53.5794 131.271 51.608 123.043 51.608 113.443C51.608 103.843 53.5794 95.4857 57.5223 88.3714C61.5509 81.2572 67.1652 75.7286 74.3652 71.7857C81.6509 67.8429 90.1794 65.8714 99.9509 65.8714C103.208 65.8714 106.679 66.1286 110.365 66.6429C114.051 67.0714 117.222 67.6714 119.879 68.4429C121.508 68.8714 123.008 69.2572 124.379 69.6C125.751 69.9429 127.122 70.1143 128.494 70.1143C129.522 70.1143 130.551 69.9857 131.579 69.7286C131.751 73.5 131.922 77.4 132.094 81.4286C132.265 85.4572 132.522 89.6572 132.865 94.0286C131.065 94.2857 129.565 94.3714 128.365 94.2857C126.651 86.4 123.522 80.5714 118.979 76.8C114.437 72.9429 108.394 71.0143 100.851 71.0143C94.8509 71.0143 89.708 72.1286 85.4223 74.3572C81.2223 76.5 77.7937 79.4572 75.1366 83.2286C72.5652 87 70.6794 91.3714 69.4794 96.3429C68.2794 101.229 67.6794 106.457 67.6794 112.029C67.6794 120.171 68.9223 127.371 71.408 133.629C73.8937 139.886 77.6652 144.814 82.7223 148.414C87.8652 151.929 94.2937 153.686 102.008 153.686C104.408 153.686 107.065 153.471 109.979 153.043C112.894 152.529 115.679 151.757 118.337 150.729V134.529C118.337 131.871 118.208 129.814 117.951 128.357C117.779 126.814 117.222 125.7 116.279 125.014C115.422 124.329 114.008 123.857 112.037 123.6C110.151 123.257 107.537 122.957 104.194 122.7C103.937 121.329 103.937 119.957 104.194 118.586C105.994 118.586 108.179 118.629 110.751 118.714C113.322 118.714 115.894 118.757 118.465 118.843C121.122 118.843 123.308 118.843 125.022 118.843C127.679 118.843 130.722 118.8 134.151 118.714C137.665 118.629 140.665 118.586 143.151 118.586C143.322 119.871 143.322 121.2 143.151 122.571C139.637 123 137.108 123.429 135.565 123.857C134.022 124.286 133.079 125.143 132.737 126.429C132.394 127.714 132.222 129.9 132.222 132.986V137.1C132.222 141.129 132.308 144.514 132.479 147.257C132.737 150 132.951 151.971 133.122 153.171C121.208 157.2 110.065 159.214 99.6937 159.214ZM148.19 157.414C147.933 156.043 147.933 154.714 148.19 153.429C151.105 153.257 153.248 153 154.619 152.657C155.99 152.229 156.89 151.371 157.319 150.086C157.748 148.8 157.962 146.743 157.962 143.914V115.114C157.962 111.771 157.79 109.286 157.448 107.657C157.19 106.029 156.376 104.914 155.005 104.314C153.719 103.629 151.49 103.071 148.319 102.643C148.062 101.443 148.062 100.329 148.319 99.3C151.748 98.6143 155.09 97.8429 158.348 96.9857C161.605 96.0429 165.033 94.8429 168.633 93.3857L170.819 94.1572V105.471C176.819 97.8429 182.948 94.0286 189.205 94.0286C192.205 94.0286 194.433 94.8429 195.89 96.4714C197.348 98.0143 198.076 99.7714 198.076 101.743C198.076 104.057 197.305 105.857 195.762 107.143C194.219 108.343 192.462 108.943 190.49 108.943C188.862 108.943 187.233 108.514 185.605 107.657C184.062 106.8 182.905 105.471 182.133 103.671C179.219 103.671 176.605 104.829 174.29 107.143C172.062 109.371 170.948 111.986 170.948 114.986V142.629C170.948 145.971 171.119 148.371 171.462 149.829C171.89 151.286 172.919 152.229 174.548 152.657C176.262 153 179.005 153.257 182.776 153.429C182.948 154.629 182.948 155.957 182.776 157.414C179.862 157.414 176.862 157.371 173.776 157.286C170.69 157.2 167.519 157.157 164.262 157.157C161.09 157.157 158.262 157.2 155.776 157.286C153.376 157.371 150.848 157.414 148.19 157.414ZM229.285 158.829C223.028 158.829 217.542 157.5 212.828 154.843C208.199 152.1 204.599 148.371 202.028 143.657C199.457 138.857 198.171 133.371 198.171 127.2C198.171 120.514 199.499 114.686 202.157 109.714C204.899 104.743 208.714 100.886 213.599 98.1429C218.485 95.4 224.099 94.0286 230.442 94.0286C236.699 94.0286 242.142 95.4 246.771 98.1429C251.399 100.886 254.999 104.657 257.571 109.457C260.142 114.257 261.428 119.7 261.428 125.786C261.428 132.043 260.057 137.7 257.314 142.757C254.657 147.729 250.928 151.671 246.128 154.586C241.328 157.414 235.714 158.829 229.285 158.829ZM212.699 125.657C212.699 134.4 214.114 141.343 216.942 146.486C219.857 151.543 224.185 154.071 229.928 154.071C235.414 154.071 239.614 151.671 242.528 146.871C245.442 141.986 246.899 135.471 246.899 127.329C246.899 118.671 245.442 111.771 242.528 106.629C239.614 101.486 235.371 98.9143 229.799 98.9143C224.314 98.9143 220.071 101.271 217.071 105.986C214.157 110.7 212.699 117.257 212.699 125.657ZM267.394 157.414C267.308 157.071 267.265 156.729 267.265 156.386C267.265 156.043 267.265 155.7 267.265 155.357C267.265 155.014 267.265 154.714 267.265 154.457C267.265 154.114 267.308 153.771 267.394 153.429C270.308 153.257 272.451 153 273.822 152.657C275.194 152.229 276.094 151.371 276.522 150.086C276.951 148.8 277.165 146.743 277.165 143.914V79.5C277.165 76.8429 276.908 74.8714 276.394 73.5857C275.965 72.2143 274.979 71.2714 273.437 70.7572C271.979 70.1572 269.751 69.7286 266.751 69.4714C266.665 69.1286 266.622 68.8286 266.622 68.5714C266.622 68.3143 266.622 68.0572 266.622 67.8C266.622 67.4572 266.622 67.1572 266.622 66.9C266.622 66.6429 266.665 66.3429 266.751 66C270.179 65.5714 273.694 64.9286 277.294 64.0714C280.894 63.1286 284.579 61.8429 288.351 60.2143L290.537 60.9857C290.451 62.8714 290.365 65.0143 290.279 67.4143C290.279 69.8143 290.279 72.4286 290.279 75.2572V122.957C291.308 122.957 292.165 122.786 292.851 122.443C293.537 122.1 294.094 121.757 294.522 121.414C294.694 121.243 295.037 120.943 295.551 120.514C296.065 120 296.965 119.1 298.251 117.814C299.537 116.529 301.379 114.6 303.779 112.029C306.008 109.543 307.765 107.614 309.051 106.243C310.422 104.786 311.108 103.586 311.108 102.643C311.108 101.957 310.508 101.4 309.308 100.971C308.194 100.457 306.651 100.157 304.679 100.071C304.594 99.7286 304.551 99.3857 304.551 99.0429C304.551 98.7 304.551 98.3572 304.551 98.0143C304.551 97.6714 304.551 97.3286 304.551 96.9857C304.551 96.6429 304.594 96.3 304.679 95.9572C306.394 95.9572 308.537 96 311.108 96.0857C313.765 96.1714 316.122 96.2143 318.179 96.2143C319.208 96.2143 320.665 96.2143 322.551 96.2143C324.522 96.1286 326.494 96.0857 328.465 96.0857C330.437 96.0857 331.894 96.0857 332.837 96.0857C332.922 96.4286 332.965 96.7714 332.965 97.1143C333.051 97.4572 333.094 97.8 333.094 98.1429C333.094 98.4857 333.051 98.8286 332.965 99.1714C332.965 99.4286 332.922 99.7286 332.837 100.071C328.379 100.157 324.608 101.271 321.522 103.414C318.437 105.471 315.479 107.914 312.651 110.743L303.394 120L321.137 143.4C323.022 145.886 324.565 147.857 325.765 149.314C327.051 150.686 328.422 151.671 329.879 152.271C331.337 152.871 333.351 153.257 335.922 153.429C336.094 154.629 336.094 155.957 335.922 157.414C334.808 157.414 333.137 157.371 330.908 157.286C328.765 157.2 325.379 157.157 320.751 157.157C320.065 157.157 319.037 157.157 317.665 157.157C316.294 157.157 315.008 157.243 313.808 157.414C313.808 156.471 313.294 155.186 312.265 153.557C311.237 151.843 310.422 150.6 309.822 149.829C309.565 149.4 308.922 148.5 307.894 147.129C306.865 145.671 305.622 144 304.165 142.114C302.794 140.143 301.379 138.171 299.922 136.2C298.465 134.143 297.137 132.343 295.937 130.8C294.994 129.514 294.094 128.529 293.237 127.843C292.465 127.071 291.479 126.686 290.279 126.686V142.629C290.279 145.971 290.408 148.371 290.665 149.829C291.008 151.286 291.737 152.229 292.851 152.657C294.051 153 295.851 153.257 298.251 153.429C298.422 154.714 298.422 156.043 298.251 157.414C296.022 157.414 293.665 157.371 291.179 157.286C288.779 157.2 286.165 157.157 283.337 157.157C280.594 157.157 277.894 157.2 275.237 157.286C272.579 157.371 269.965 157.414 267.394 157.414ZM369.34 157.414C366.94 157.414 364.454 157.371 361.883 157.286C359.311 157.2 356.526 157.157 353.526 157.157C350.783 157.157 347.997 157.2 345.169 157.286C342.426 157.371 339.769 157.414 337.197 157.414C336.94 156.043 336.94 154.714 337.197 153.429C340.111 153.257 342.254 153 343.626 152.657C344.997 152.229 345.897 151.371 346.326 150.086C346.754 148.8 346.969 146.743 346.969 143.914V115.114C346.969 111.771 346.84 109.286 346.583 107.657C346.326 106.029 345.511 104.914 344.14 104.314C342.854 103.629 340.583 103.071 337.326 102.643C337.069 101.443 337.069 100.329 337.326 99.3C341.097 98.6143 344.697 97.7572 348.126 96.7286C351.554 95.7 354.854 94.5857 358.026 93.3857L360.211 94.1572C360.126 96.8143 360.04 99.3 359.954 101.614C359.954 103.929 359.954 106.114 359.954 108.171V142.629C359.954 145.971 360.126 148.371 360.469 149.829C360.897 151.286 361.754 152.229 363.04 152.657C364.411 153 366.511 153.257 369.34 153.429C369.597 154.714 369.597 156.043 369.34 157.414ZM343.626 71.5286C343.626 69.0429 344.483 66.9429 346.197 65.2286C347.997 63.5143 350.14 62.6572 352.626 62.6572C355.026 62.6572 357.083 63.5143 358.797 65.2286C360.597 66.9429 361.497 69 361.497 71.4C361.497 73.6286 360.64 75.6857 358.926 77.5715C357.211 79.3714 355.026 80.2714 352.369 80.2714C349.969 80.2714 347.911 79.4143 346.197 77.7C344.483 75.9857 343.626 73.9286 343.626 71.5286ZM372.678 188.914C372.592 187.543 372.592 186.214 372.678 184.929C375.678 184.757 377.864 184.457 379.235 184.029C380.607 183.6 381.464 182.743 381.807 181.457C382.235 180.257 382.45 178.286 382.45 175.543V115.114C382.45 111.771 382.278 109.286 381.935 107.657C381.678 106.029 380.864 104.914 379.492 104.314C378.207 103.629 375.978 103.071 372.807 102.643C372.635 101.443 372.635 100.329 372.807 99.3C376.321 98.6143 379.75 97.8 383.092 96.8572C386.435 95.9143 389.907 94.7572 393.507 93.3857L395.307 94.2857C395.221 96.4286 395.178 98.2714 395.178 99.8143C395.178 101.271 395.178 102.686 395.178 104.057C398.521 100.543 401.821 98.0143 405.078 96.4714C408.335 94.8429 411.807 94.0286 415.492 94.0286C420.892 94.0286 425.435 95.4429 429.121 98.2714C432.892 101.1 435.764 104.786 437.735 109.329C439.707 113.871 440.692 118.8 440.692 124.114C440.692 130.371 439.321 136.157 436.578 141.471C433.921 146.7 430.192 150.9 425.392 154.071C420.592 157.243 415.021 158.829 408.678 158.829C406.192 158.829 403.835 158.614 401.607 158.186C399.378 157.843 397.278 157.329 395.307 156.643V174C395.307 177.343 395.564 179.743 396.078 181.2C396.592 182.657 397.707 183.557 399.421 183.9C401.135 184.329 403.835 184.629 407.521 184.8C407.607 186.171 407.607 187.543 407.521 188.914C404.607 188.914 401.65 188.871 398.65 188.786C395.735 188.7 392.521 188.657 389.007 188.657C385.664 188.657 382.792 188.7 380.392 188.786C377.992 188.871 375.421 188.914 372.678 188.914ZM395.178 146.1C398.864 151.414 403.75 154.071 409.835 154.071C414.121 154.071 417.507 152.871 419.992 150.471C422.564 148.071 424.407 144.943 425.521 141.086C426.721 137.229 427.321 133.157 427.321 128.871C427.321 124.586 426.764 120.386 425.65 116.271C424.535 112.157 422.692 108.771 420.121 106.114C417.635 103.371 414.207 102 409.835 102C404.607 102 399.721 104.529 395.178 109.586V146.1ZM477.335 158.829C471.25 158.829 466.107 157.414 461.907 154.586C457.707 151.757 454.493 147.986 452.264 143.271C450.121 138.471 449.05 133.2 449.05 127.457C449.05 121.543 450.164 116.057 452.393 111C454.707 105.943 458.05 101.871 462.421 98.7857C466.793 95.6143 472.107 94.0286 478.364 94.0286C485.907 94.0286 491.778 96.3 495.978 100.843C500.264 105.3 502.407 111.086 502.407 118.2C502.407 119.057 502.364 119.829 502.278 120.514C502.278 121.114 502.235 121.629 502.15 122.057L461.65 121.671C461.65 122.014 461.65 122.314 461.65 122.571C461.65 130.971 463.578 137.571 467.435 142.371C471.293 147.171 476.693 149.571 483.635 149.571C489.464 149.571 495.207 147.686 500.864 143.914C501.721 144.943 502.364 145.929 502.793 146.871C495.507 154.843 487.021 158.829 477.335 158.829ZM462.035 116.914L488.65 116.4C488.735 116.229 488.778 116.014 488.778 115.757C488.778 115.414 488.778 115.2 488.778 115.114C488.778 110.486 487.75 106.629 485.693 103.543C483.721 100.457 480.764 98.9143 476.821 98.9143C473.135 98.9143 469.921 100.414 467.178 103.414C464.435 106.414 462.721 110.914 462.035 116.914ZM559.644 158.957L557.587 158.057L557.073 149.186C554.073 152.443 550.987 154.886 547.816 156.514C544.73 158.057 541.302 158.829 537.53 158.829C532.216 158.829 527.544 157.414 523.516 154.586C519.573 151.671 516.53 147.9 514.387 143.271C512.244 138.643 511.173 133.629 511.173 128.229C511.173 121.971 512.502 116.271 515.159 111.129C517.902 105.986 521.716 101.871 526.602 98.7857C531.573 95.6143 537.359 94.0286 543.959 94.0286C545.93 94.0286 547.987 94.2 550.13 94.5429C552.273 94.8 554.502 95.2714 556.816 95.9572V79.5C556.816 76.8429 556.559 74.8714 556.044 73.5857C555.53 72.2143 554.502 71.2714 552.959 70.7572C551.502 70.1572 549.273 69.7286 546.273 69.4714C546.016 68.3572 546.016 67.2 546.273 66C549.702 65.5714 553.216 64.9286 556.816 64.0714C560.416 63.1286 564.102 61.8429 567.873 60.2143L570.059 60.9857C569.973 62.8714 569.887 65.0143 569.802 67.4143C569.802 69.8143 569.802 72.4286 569.802 75.2572V139.029C569.802 142.286 569.93 144.729 570.187 146.357C570.445 147.986 571.216 149.143 572.502 149.829C573.787 150.429 575.973 150.986 579.059 151.5C579.316 152.614 579.316 153.771 579.059 154.971C575.63 155.486 572.287 156.043 569.03 156.643C565.773 157.243 562.644 158.014 559.644 158.957ZM556.944 106.886C553.259 101.829 548.416 99.3 542.416 99.3C536.502 99.3 532.044 101.486 529.044 105.857C526.044 110.143 524.544 116.1 524.544 123.729C524.544 128.186 525.144 132.471 526.344 136.586C527.544 140.7 529.516 144.086 532.259 146.743C535.002 149.4 538.644 150.729 543.187 150.729C548.93 150.729 553.516 148.243 556.944 143.271V106.886ZM615.699 157.414C613.299 157.414 610.813 157.371 608.242 157.286C605.67 157.2 602.885 157.157 599.885 157.157C597.142 157.157 594.356 157.2 591.527 157.286C588.785 157.371 586.127 157.414 583.556 157.414C583.299 156.043 583.299 154.714 583.556 153.429C586.47 153.257 588.613 153 589.985 152.657C591.356 152.229 592.256 151.371 592.685 150.086C593.113 148.8 593.327 146.743 593.327 143.914V115.114C593.327 111.771 593.199 109.286 592.942 107.657C592.685 106.029 591.87 104.914 590.499 104.314C589.213 103.629 586.942 103.071 583.685 102.643C583.427 101.443 583.427 100.329 583.685 99.3C587.456 98.6143 591.056 97.7572 594.485 96.7286C597.913 95.7 601.213 94.5857 604.385 93.3857L606.57 94.1572C606.485 96.8143 606.399 99.3 606.313 101.614C606.313 103.929 606.313 106.114 606.313 108.171V142.629C606.313 145.971 606.485 148.371 606.827 149.829C607.256 151.286 608.113 152.229 609.399 152.657C610.77 153 612.87 153.257 615.699 153.429C615.956 154.714 615.956 156.043 615.699 157.414ZM589.985 71.5286C589.985 69.0429 590.842 66.9429 592.556 65.2286C594.356 63.5143 596.499 62.6572 598.985 62.6572C601.385 62.6572 603.442 63.5143 605.156 65.2286C606.956 66.9429 607.856 69 607.856 71.4C607.856 73.6286 606.999 75.6857 605.285 77.5715C603.57 79.3714 601.385 80.2714 598.727 80.2714C596.327 80.2714 594.27 79.4143 592.556 77.7C590.842 75.9857 589.985 73.9286 589.985 71.5286ZM665.837 158.571C660.18 158.571 656.623 155.743 655.165 150.086C649.08 155.914 642.865 158.829 636.523 158.829C632.151 158.829 628.423 157.543 625.337 154.971C622.337 152.314 620.837 148.671 620.837 144.043C620.837 132.729 632.365 125.614 655.423 122.7C655.423 120.643 655.423 118.543 655.423 116.4C655.508 114.257 655.551 111.986 655.551 109.586C655.551 106.586 654.437 104.271 652.208 102.643C650.065 100.929 647.451 100.071 644.365 100.071C642.137 100.071 640.251 100.414 638.708 101.1C638.708 103.071 638.28 105.086 637.423 107.143C636.565 109.2 635.365 110.957 633.823 112.414C632.365 113.786 630.565 114.471 628.423 114.471C626.537 114.471 625.037 113.957 623.923 112.929C622.894 111.814 622.38 110.486 622.38 108.943C622.38 106.886 623.323 104.957 625.208 103.157C627.18 101.271 629.665 99.6857 632.665 98.4C635.665 97.0286 638.794 95.9572 642.051 95.1857C645.308 94.4143 648.223 94.0286 650.794 94.0286C653.965 94.0286 656.88 94.6286 659.537 95.8286C662.28 96.9429 664.465 98.6572 666.094 100.971C667.808 103.2 668.665 105.986 668.665 109.329C668.665 111.386 668.623 114.086 668.537 117.429C668.451 120.686 668.365 124.2 668.28 127.971C668.28 131.657 668.237 135.171 668.151 138.514C668.065 141.857 668.023 144.557 668.023 146.614C668.023 149.357 669.223 150.729 671.623 150.729C673.165 150.729 675.523 150.214 678.694 149.186C679.037 149.614 679.251 150.086 679.337 150.6C679.508 151.114 679.637 151.586 679.723 152.014C677.58 154.329 675.308 156 672.908 157.029C670.594 158.057 668.237 158.571 665.837 158.571ZM655.165 146.614L655.423 127.329C647.537 128.357 642.094 130.029 639.094 132.343C636.18 134.657 634.723 137.614 634.723 141.214C634.723 144.214 635.494 146.529 637.037 148.157C638.665 149.7 640.68 150.471 643.08 150.471C644.623 150.471 646.337 150.129 648.223 149.443C650.194 148.757 652.508 147.814 655.165 146.614Z" fill="currentColor"></path><rect x="715" y="65" width="195" height="105" rx="52.5" fill="currentColor" fill-opacity="0.05"></rect><path d="M767.529 142.875L754.049 107.938H762.552L769.309 127.582C769.705 128.812 770.078 130.032 770.43 131.24C770.781 132.449 771.078 133.559 771.32 134.569H771.616C771.858 133.559 772.144 132.449 772.473 131.24C772.825 130.032 773.198 128.812 773.594 127.582L780.186 107.938H788.689L775.472 142.875H767.529ZM810.856 143.633C806.901 143.633 803.528 142.71 800.737 140.865C797.969 138.997 795.871 136.305 794.442 132.79C793.014 129.252 792.3 124.989 792.3 120.001V118.255C792.3 113.245 793.014 108.982 794.442 105.467C795.871 101.929 797.969 99.2373 800.737 97.3916C803.528 95.5239 806.901 94.5901 810.856 94.5901C814.789 94.5901 818.129 95.5129 820.875 97.3586C823.644 99.2043 825.731 101.907 827.138 105.467C828.566 109.004 829.28 113.267 829.28 118.255V120.001C829.28 124.989 828.577 129.252 827.171 132.79C825.764 136.327 823.677 139.019 820.908 140.865C818.162 142.71 814.811 143.633 810.856 143.633ZM810.889 136.382C813.064 136.382 814.877 135.789 816.327 134.602C817.799 133.416 818.898 131.658 819.623 129.329C820.348 126.978 820.711 124.066 820.711 120.595V117.694C820.711 114.223 820.337 111.311 819.59 108.96C818.865 106.609 817.777 104.84 816.327 103.654C814.877 102.445 813.064 101.841 810.889 101.841C808.714 101.841 806.879 102.434 805.385 103.621C803.912 104.785 802.792 106.554 802.023 108.927C801.276 111.278 800.902 114.201 800.902 117.694V120.595C800.902 124.044 801.287 126.945 802.056 129.296C802.825 131.647 803.945 133.416 805.418 134.602C806.89 135.789 808.714 136.382 810.889 136.382ZM838.988 143.205C838 143.205 837.099 142.985 836.286 142.545C835.495 142.106 834.879 141.491 834.44 140.7C834.001 139.909 833.781 139.019 833.781 138.03C833.781 137.019 834.001 136.118 834.44 135.327C834.879 134.536 835.495 133.921 836.286 133.482C837.099 133.042 838 132.823 838.988 132.823C839.977 132.823 840.867 133.042 841.658 133.482C842.449 133.921 843.064 134.536 843.504 135.327C843.943 136.118 844.163 137.019 844.163 138.03C844.163 139.019 843.943 139.909 843.504 140.7C843.064 141.491 842.449 142.106 841.658 142.545C840.867 142.985 839.977 143.205 838.988 143.205ZM857.365 142.875V104.511L846.39 111.663V103.357L858.453 95.3481H865.802V142.875H857.365Z" fill="currentColor"></path></svg></a></div><div class="mx-auto flex w-full"><button class="focus-visible:ring-ring inline-flex items-center justify-center gap-x-2 whitespace-nowrap text-sm font-medium transition-colors focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 border-input text-primary hover:border-primary/15 border hover:bg-overlay-hover py-2 max-w-full px-3 shadow-none sm:w-80 focus-visible:z-1 mx-auto h-full w-full rounded-full bg-surface-l1" type="button"><div class="flex items-center justify-between sm:w-full gap-4"><div class="flex items-center justify-start gap-2"><span class="inline-flex items-center justify-center p-0 m-0 w-4 h-4 text-muted" data-namespace="@xai/icons" data-slot="icon"><svg xmlns="http://www.w3.org/2000/svg" fill="currentColor" viewBox="0 0 24 24" aria-hidden="true" class="w-4 h-4" focusable="false" style="fill:currentColor"><path d="m18.031 16.617 4.283 4.282-1.415 1.415-4.282-4.283A8.96 8.96 0 0 1 11 20c-4.968 0-9-4.032-9-9s4.032-9 9-9 9 4.032 9 9a8.96 8.96 0 0 1-1.969 5.617m-2.006-.742A6.98 6.98 0 0 0 18 11c0-3.867-3.133-7-7-7s-7 3.133-7 7 3.133 7 7 7a6.98 6.98 0 0 0 4.875-1.975z"></path></svg></span><p class="text-sm text-muted hidden sm:block">Search</p></div><span class="hidden sm:block"><div class="bg-foreground/10 text-muted inline-flex items-center rounded-md px-1 py-0.5 text-center font-sans text-xs font-normal tracking-widest rtl:space-x-reverse"><span>âŒ˜</span><span class="text-xs">K</span></div></span></div></button></div><div class="flex items-center gap-2 justify-self-end"><button class="focus-visible:ring-ring inline-flex items-center justify-center gap-x-2 whitespace-nowrap rounded-full text-sm font-medium transition-colors focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary hover:bg-overlay-hover px-4 py-2 w-9 h-9 flex-shrink-0" type="button" id="radix-_R_7apfiumdb_" aria-haspopup="menu" aria-expanded="false" data-state="closed"><span class="inline-flex items-center justify-center p-0 m-0 w-6 h-6 rotate-0 scale-100 transition-all dark:-rotate-90 dark:scale-0" data-namespace="@xai/icons" data-slot="icon"><svg xmlns="http://www.w3.org/2000/svg" fill="currentColor" viewBox="0 0 24 24" aria-hidden="true" class="w-6 h-6" focusable="false" style="fill:currentColor"><path d="M12 18a6 6 0 1 1 0-12 6 6 0 0 1 0 12m0-2a4 4 0 1 0 0-8 4 4 0 0 0 0 8M11 1h2v3h-2zm0 19h2v3h-2zM3.515 4.929l1.414-1.414L7.05 5.636 5.636 7.05zM16.95 18.364l1.414-1.414 2.121 2.121-1.414 1.414zm2.121-14.85 1.414 1.415-2.121 2.121-1.414-1.414zM5.636 16.95l1.414 1.414-2.121 2.121-1.414-1.414zM23 11v2h-3v-2zM4 11v2H1v-2z"></path></svg></span><span class="inline-flex items-center justify-center p-0 m-0 w-6 h-6 absolute rotate-90 scale-0 transition-all dark:rotate-0 dark:scale-100" data-namespace="@xai/icons" data-slot="icon"><svg xmlns="http://www.w3.org/2000/svg" fill="currentColor" viewBox="0 0 24 24" aria-hidden="true" class="w-6 h-6" focusable="false" style="fill:currentColor"><path d="M10 7a7 7 0 0 0 12 4.9v.1c0 5.523-4.477 10-10 10S2 17.523 2 12 6.477 2 12 2h.1A6.98 6.98 0 0 0 10 7m-6 5a8 8 0 0 0 15.062 3.762A9 9 0 0 1 8.238 4.938 8 8 0 0 0 4 12"></path></svg></span><span class="sr-only">Toggle theme</span></button></div></div><div class="flex h-full items-center md:hidden justify-between max-w-full py-6 px-4 w-full mx-auto pt-8"><div class="flex items-center"><div class="-ml-2"><button class="focus-visible:ring-ring inline-flex items-center justify-center gap-x-2 whitespace-nowrap rounded-full text-sm font-medium transition-colors focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary hover:bg-overlay-hover h-9 w-9" type="button" aria-label="Toggle table of contents"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-list h-6 w-6"><path d="M3 12h.01"></path><path d="M3 18h.01"></path><path d="M3 6h.01"></path><path d="M8 12h13"></path><path d="M8 18h13"></path><path d="M8 6h13"></path></svg></button></div><a class="cursor-pointer" href="/"><svg width="160" height="auto" viewBox="0 0 955 225" fill="none" xmlns="http://www.w3.org/2000/svg"><path d="M99.6937 159.214C90.008 159.214 81.5652 157.414 74.3652 153.814C67.1652 150.214 61.5509 144.986 57.5223 138.129C53.5794 131.271 51.608 123.043 51.608 113.443C51.608 103.843 53.5794 95.4857 57.5223 88.3714C61.5509 81.2572 67.1652 75.7286 74.3652 71.7857C81.6509 67.8429 90.1794 65.8714 99.9509 65.8714C103.208 65.8714 106.679 66.1286 110.365 66.6429C114.051 67.0714 117.222 67.6714 119.879 68.4429C121.508 68.8714 123.008 69.2572 124.379 69.6C125.751 69.9429 127.122 70.1143 128.494 70.1143C129.522 70.1143 130.551 69.9857 131.579 69.7286C131.751 73.5 131.922 77.4 132.094 81.4286C132.265 85.4572 132.522 89.6572 132.865 94.0286C131.065 94.2857 129.565 94.3714 128.365 94.2857C126.651 86.4 123.522 80.5714 118.979 76.8C114.437 72.9429 108.394 71.0143 100.851 71.0143C94.8509 71.0143 89.708 72.1286 85.4223 74.3572C81.2223 76.5 77.7937 79.4572 75.1366 83.2286C72.5652 87 70.6794 91.3714 69.4794 96.3429C68.2794 101.229 67.6794 106.457 67.6794 112.029C67.6794 120.171 68.9223 127.371 71.408 133.629C73.8937 139.886 77.6652 144.814 82.7223 148.414C87.8652 151.929 94.2937 153.686 102.008 153.686C104.408 153.686 107.065 153.471 109.979 153.043C112.894 152.529 115.679 151.757 118.337 150.729V134.529C118.337 131.871 118.208 129.814 117.951 128.357C117.779 126.814 117.222 125.7 116.279 125.014C115.422 124.329 114.008 123.857 112.037 123.6C110.151 123.257 107.537 122.957 104.194 122.7C103.937 121.329 103.937 119.957 104.194 118.586C105.994 118.586 108.179 118.629 110.751 118.714C113.322 118.714 115.894 118.757 118.465 118.843C121.122 118.843 123.308 118.843 125.022 118.843C127.679 118.843 130.722 118.8 134.151 118.714C137.665 118.629 140.665 118.586 143.151 118.586C143.322 119.871 143.322 121.2 143.151 122.571C139.637 123 137.108 123.429 135.565 123.857C134.022 124.286 133.079 125.143 132.737 126.429C132.394 127.714 132.222 129.9 132.222 132.986V137.1C132.222 141.129 132.308 144.514 132.479 147.257C132.737 150 132.951 151.971 133.122 153.171C121.208 157.2 110.065 159.214 99.6937 159.214ZM148.19 157.414C147.933 156.043 147.933 154.714 148.19 153.429C151.105 153.257 153.248 153 154.619 152.657C155.99 152.229 156.89 151.371 157.319 150.086C157.748 148.8 157.962 146.743 157.962 143.914V115.114C157.962 111.771 157.79 109.286 157.448 107.657C157.19 106.029 156.376 104.914 155.005 104.314C153.719 103.629 151.49 103.071 148.319 102.643C148.062 101.443 148.062 100.329 148.319 99.3C151.748 98.6143 155.09 97.8429 158.348 96.9857C161.605 96.0429 165.033 94.8429 168.633 93.3857L170.819 94.1572V105.471C176.819 97.8429 182.948 94.0286 189.205 94.0286C192.205 94.0286 194.433 94.8429 195.89 96.4714C197.348 98.0143 198.076 99.7714 198.076 101.743C198.076 104.057 197.305 105.857 195.762 107.143C194.219 108.343 192.462 108.943 190.49 108.943C188.862 108.943 187.233 108.514 185.605 107.657C184.062 106.8 182.905 105.471 182.133 103.671C179.219 103.671 176.605 104.829 174.29 107.143C172.062 109.371 170.948 111.986 170.948 114.986V142.629C170.948 145.971 171.119 148.371 171.462 149.829C171.89 151.286 172.919 152.229 174.548 152.657C176.262 153 179.005 153.257 182.776 153.429C182.948 154.629 182.948 155.957 182.776 157.414C179.862 157.414 176.862 157.371 173.776 157.286C170.69 157.2 167.519 157.157 164.262 157.157C161.09 157.157 158.262 157.2 155.776 157.286C153.376 157.371 150.848 157.414 148.19 157.414ZM229.285 158.829C223.028 158.829 217.542 157.5 212.828 154.843C208.199 152.1 204.599 148.371 202.028 143.657C199.457 138.857 198.171 133.371 198.171 127.2C198.171 120.514 199.499 114.686 202.157 109.714C204.899 104.743 208.714 100.886 213.599 98.1429C218.485 95.4 224.099 94.0286 230.442 94.0286C236.699 94.0286 242.142 95.4 246.771 98.1429C251.399 100.886 254.999 104.657 257.571 109.457C260.142 114.257 261.428 119.7 261.428 125.786C261.428 132.043 260.057 137.7 257.314 142.757C254.657 147.729 250.928 151.671 246.128 154.586C241.328 157.414 235.714 158.829 229.285 158.829ZM212.699 125.657C212.699 134.4 214.114 141.343 216.942 146.486C219.857 151.543 224.185 154.071 229.928 154.071C235.414 154.071 239.614 151.671 242.528 146.871C245.442 141.986 246.899 135.471 246.899 127.329C246.899 118.671 245.442 111.771 242.528 106.629C239.614 101.486 235.371 98.9143 229.799 98.9143C224.314 98.9143 220.071 101.271 217.071 105.986C214.157 110.7 212.699 117.257 212.699 125.657ZM267.394 157.414C267.308 157.071 267.265 156.729 267.265 156.386C267.265 156.043 267.265 155.7 267.265 155.357C267.265 155.014 267.265 154.714 267.265 154.457C267.265 154.114 267.308 153.771 267.394 153.429C270.308 153.257 272.451 153 273.822 152.657C275.194 152.229 276.094 151.371 276.522 150.086C276.951 148.8 277.165 146.743 277.165 143.914V79.5C277.165 76.8429 276.908 74.8714 276.394 73.5857C275.965 72.2143 274.979 71.2714 273.437 70.7572C271.979 70.1572 269.751 69.7286 266.751 69.4714C266.665 69.1286 266.622 68.8286 266.622 68.5714C266.622 68.3143 266.622 68.0572 266.622 67.8C266.622 67.4572 266.622 67.1572 266.622 66.9C266.622 66.6429 266.665 66.3429 266.751 66C270.179 65.5714 273.694 64.9286 277.294 64.0714C280.894 63.1286 284.579 61.8429 288.351 60.2143L290.537 60.9857C290.451 62.8714 290.365 65.0143 290.279 67.4143C290.279 69.8143 290.279 72.4286 290.279 75.2572V122.957C291.308 122.957 292.165 122.786 292.851 122.443C293.537 122.1 294.094 121.757 294.522 121.414C294.694 121.243 295.037 120.943 295.551 120.514C296.065 120 296.965 119.1 298.251 117.814C299.537 116.529 301.379 114.6 303.779 112.029C306.008 109.543 307.765 107.614 309.051 106.243C310.422 104.786 311.108 103.586 311.108 102.643C311.108 101.957 310.508 101.4 309.308 100.971C308.194 100.457 306.651 100.157 304.679 100.071C304.594 99.7286 304.551 99.3857 304.551 99.0429C304.551 98.7 304.551 98.3572 304.551 98.0143C304.551 97.6714 304.551 97.3286 304.551 96.9857C304.551 96.6429 304.594 96.3 304.679 95.9572C306.394 95.9572 308.537 96 311.108 96.0857C313.765 96.1714 316.122 96.2143 318.179 96.2143C319.208 96.2143 320.665 96.2143 322.551 96.2143C324.522 96.1286 326.494 96.0857 328.465 96.0857C330.437 96.0857 331.894 96.0857 332.837 96.0857C332.922 96.4286 332.965 96.7714 332.965 97.1143C333.051 97.4572 333.094 97.8 333.094 98.1429C333.094 98.4857 333.051 98.8286 332.965 99.1714C332.965 99.4286 332.922 99.7286 332.837 100.071C328.379 100.157 324.608 101.271 321.522 103.414C318.437 105.471 315.479 107.914 312.651 110.743L303.394 120L321.137 143.4C323.022 145.886 324.565 147.857 325.765 149.314C327.051 150.686 328.422 151.671 329.879 152.271C331.337 152.871 333.351 153.257 335.922 153.429C336.094 154.629 336.094 155.957 335.922 157.414C334.808 157.414 333.137 157.371 330.908 157.286C328.765 157.2 325.379 157.157 320.751 157.157C320.065 157.157 319.037 157.157 317.665 157.157C316.294 157.157 315.008 157.243 313.808 157.414C313.808 156.471 313.294 155.186 312.265 153.557C311.237 151.843 310.422 150.6 309.822 149.829C309.565 149.4 308.922 148.5 307.894 147.129C306.865 145.671 305.622 144 304.165 142.114C302.794 140.143 301.379 138.171 299.922 136.2C298.465 134.143 297.137 132.343 295.937 130.8C294.994 129.514 294.094 128.529 293.237 127.843C292.465 127.071 291.479 126.686 290.279 126.686V142.629C290.279 145.971 290.408 148.371 290.665 149.829C291.008 151.286 291.737 152.229 292.851 152.657C294.051 153 295.851 153.257 298.251 153.429C298.422 154.714 298.422 156.043 298.251 157.414C296.022 157.414 293.665 157.371 291.179 157.286C288.779 157.2 286.165 157.157 283.337 157.157C280.594 157.157 277.894 157.2 275.237 157.286C272.579 157.371 269.965 157.414 267.394 157.414ZM369.34 157.414C366.94 157.414 364.454 157.371 361.883 157.286C359.311 157.2 356.526 157.157 353.526 157.157C350.783 157.157 347.997 157.2 345.169 157.286C342.426 157.371 339.769 157.414 337.197 157.414C336.94 156.043 336.94 154.714 337.197 153.429C340.111 153.257 342.254 153 343.626 152.657C344.997 152.229 345.897 151.371 346.326 150.086C346.754 148.8 346.969 146.743 346.969 143.914V115.114C346.969 111.771 346.84 109.286 346.583 107.657C346.326 106.029 345.511 104.914 344.14 104.314C342.854 103.629 340.583 103.071 337.326 102.643C337.069 101.443 337.069 100.329 337.326 99.3C341.097 98.6143 344.697 97.7572 348.126 96.7286C351.554 95.7 354.854 94.5857 358.026 93.3857L360.211 94.1572C360.126 96.8143 360.04 99.3 359.954 101.614C359.954 103.929 359.954 106.114 359.954 108.171V142.629C359.954 145.971 360.126 148.371 360.469 149.829C360.897 151.286 361.754 152.229 363.04 152.657C364.411 153 366.511 153.257 369.34 153.429C369.597 154.714 369.597 156.043 369.34 157.414ZM343.626 71.5286C343.626 69.0429 344.483 66.9429 346.197 65.2286C347.997 63.5143 350.14 62.6572 352.626 62.6572C355.026 62.6572 357.083 63.5143 358.797 65.2286C360.597 66.9429 361.497 69 361.497 71.4C361.497 73.6286 360.64 75.6857 358.926 77.5715C357.211 79.3714 355.026 80.2714 352.369 80.2714C349.969 80.2714 347.911 79.4143 346.197 77.7C344.483 75.9857 343.626 73.9286 343.626 71.5286ZM372.678 188.914C372.592 187.543 372.592 186.214 372.678 184.929C375.678 184.757 377.864 184.457 379.235 184.029C380.607 183.6 381.464 182.743 381.807 181.457C382.235 180.257 382.45 178.286 382.45 175.543V115.114C382.45 111.771 382.278 109.286 381.935 107.657C381.678 106.029 380.864 104.914 379.492 104.314C378.207 103.629 375.978 103.071 372.807 102.643C372.635 101.443 372.635 100.329 372.807 99.3C376.321 98.6143 379.75 97.8 383.092 96.8572C386.435 95.9143 389.907 94.7572 393.507 93.3857L395.307 94.2857C395.221 96.4286 395.178 98.2714 395.178 99.8143C395.178 101.271 395.178 102.686 395.178 104.057C398.521 100.543 401.821 98.0143 405.078 96.4714C408.335 94.8429 411.807 94.0286 415.492 94.0286C420.892 94.0286 425.435 95.4429 429.121 98.2714C432.892 101.1 435.764 104.786 437.735 109.329C439.707 113.871 440.692 118.8 440.692 124.114C440.692 130.371 439.321 136.157 436.578 141.471C433.921 146.7 430.192 150.9 425.392 154.071C420.592 157.243 415.021 158.829 408.678 158.829C406.192 158.829 403.835 158.614 401.607 158.186C399.378 157.843 397.278 157.329 395.307 156.643V174C395.307 177.343 395.564 179.743 396.078 181.2C396.592 182.657 397.707 183.557 399.421 183.9C401.135 184.329 403.835 184.629 407.521 184.8C407.607 186.171 407.607 187.543 407.521 188.914C404.607 188.914 401.65 188.871 398.65 188.786C395.735 188.7 392.521 188.657 389.007 188.657C385.664 188.657 382.792 188.7 380.392 188.786C377.992 188.871 375.421 188.914 372.678 188.914ZM395.178 146.1C398.864 151.414 403.75 154.071 409.835 154.071C414.121 154.071 417.507 152.871 419.992 150.471C422.564 148.071 424.407 144.943 425.521 141.086C426.721 137.229 427.321 133.157 427.321 128.871C427.321 124.586 426.764 120.386 425.65 116.271C424.535 112.157 422.692 108.771 420.121 106.114C417.635 103.371 414.207 102 409.835 102C404.607 102 399.721 104.529 395.178 109.586V146.1ZM477.335 158.829C471.25 158.829 466.107 157.414 461.907 154.586C457.707 151.757 454.493 147.986 452.264 143.271C450.121 138.471 449.05 133.2 449.05 127.457C449.05 121.543 450.164 116.057 452.393 111C454.707 105.943 458.05 101.871 462.421 98.7857C466.793 95.6143 472.107 94.0286 478.364 94.0286C485.907 94.0286 491.778 96.3 495.978 100.843C500.264 105.3 502.407 111.086 502.407 118.2C502.407 119.057 502.364 119.829 502.278 120.514C502.278 121.114 502.235 121.629 502.15 122.057L461.65 121.671C461.65 122.014 461.65 122.314 461.65 122.571C461.65 130.971 463.578 137.571 467.435 142.371C471.293 147.171 476.693 149.571 483.635 149.571C489.464 149.571 495.207 147.686 500.864 143.914C501.721 144.943 502.364 145.929 502.793 146.871C495.507 154.843 487.021 158.829 477.335 158.829ZM462.035 116.914L488.65 116.4C488.735 116.229 488.778 116.014 488.778 115.757C488.778 115.414 488.778 115.2 488.778 115.114C488.778 110.486 487.75 106.629 485.693 103.543C483.721 100.457 480.764 98.9143 476.821 98.9143C473.135 98.9143 469.921 100.414 467.178 103.414C464.435 106.414 462.721 110.914 462.035 116.914ZM559.644 158.957L557.587 158.057L557.073 149.186C554.073 152.443 550.987 154.886 547.816 156.514C544.73 158.057 541.302 158.829 537.53 158.829C532.216 158.829 527.544 157.414 523.516 154.586C519.573 151.671 516.53 147.9 514.387 143.271C512.244 138.643 511.173 133.629 511.173 128.229C511.173 121.971 512.502 116.271 515.159 111.129C517.902 105.986 521.716 101.871 526.602 98.7857C531.573 95.6143 537.359 94.0286 543.959 94.0286C545.93 94.0286 547.987 94.2 550.13 94.5429C552.273 94.8 554.502 95.2714 556.816 95.9572V79.5C556.816 76.8429 556.559 74.8714 556.044 73.5857C555.53 72.2143 554.502 71.2714 552.959 70.7572C551.502 70.1572 549.273 69.7286 546.273 69.4714C546.016 68.3572 546.016 67.2 546.273 66C549.702 65.5714 553.216 64.9286 556.816 64.0714C560.416 63.1286 564.102 61.8429 567.873 60.2143L570.059 60.9857C569.973 62.8714 569.887 65.0143 569.802 67.4143C569.802 69.8143 569.802 72.4286 569.802 75.2572V139.029C569.802 142.286 569.93 144.729 570.187 146.357C570.445 147.986 571.216 149.143 572.502 149.829C573.787 150.429 575.973 150.986 579.059 151.5C579.316 152.614 579.316 153.771 579.059 154.971C575.63 155.486 572.287 156.043 569.03 156.643C565.773 157.243 562.644 158.014 559.644 158.957ZM556.944 106.886C553.259 101.829 548.416 99.3 542.416 99.3C536.502 99.3 532.044 101.486 529.044 105.857C526.044 110.143 524.544 116.1 524.544 123.729C524.544 128.186 525.144 132.471 526.344 136.586C527.544 140.7 529.516 144.086 532.259 146.743C535.002 149.4 538.644 150.729 543.187 150.729C548.93 150.729 553.516 148.243 556.944 143.271V106.886ZM615.699 157.414C613.299 157.414 610.813 157.371 608.242 157.286C605.67 157.2 602.885 157.157 599.885 157.157C597.142 157.157 594.356 157.2 591.527 157.286C588.785 157.371 586.127 157.414 583.556 157.414C583.299 156.043 583.299 154.714 583.556 153.429C586.47 153.257 588.613 153 589.985 152.657C591.356 152.229 592.256 151.371 592.685 150.086C593.113 148.8 593.327 146.743 593.327 143.914V115.114C593.327 111.771 593.199 109.286 592.942 107.657C592.685 106.029 591.87 104.914 590.499 104.314C589.213 103.629 586.942 103.071 583.685 102.643C583.427 101.443 583.427 100.329 583.685 99.3C587.456 98.6143 591.056 97.7572 594.485 96.7286C597.913 95.7 601.213 94.5857 604.385 93.3857L606.57 94.1572C606.485 96.8143 606.399 99.3 606.313 101.614C606.313 103.929 606.313 106.114 606.313 108.171V142.629C606.313 145.971 606.485 148.371 606.827 149.829C607.256 151.286 608.113 152.229 609.399 152.657C610.77 153 612.87 153.257 615.699 153.429C615.956 154.714 615.956 156.043 615.699 157.414ZM589.985 71.5286C589.985 69.0429 590.842 66.9429 592.556 65.2286C594.356 63.5143 596.499 62.6572 598.985 62.6572C601.385 62.6572 603.442 63.5143 605.156 65.2286C606.956 66.9429 607.856 69 607.856 71.4C607.856 73.6286 606.999 75.6857 605.285 77.5715C603.57 79.3714 601.385 80.2714 598.727 80.2714C596.327 80.2714 594.27 79.4143 592.556 77.7C590.842 75.9857 589.985 73.9286 589.985 71.5286ZM665.837 158.571C660.18 158.571 656.623 155.743 655.165 150.086C649.08 155.914 642.865 158.829 636.523 158.829C632.151 158.829 628.423 157.543 625.337 154.971C622.337 152.314 620.837 148.671 620.837 144.043C620.837 132.729 632.365 125.614 655.423 122.7C655.423 120.643 655.423 118.543 655.423 116.4C655.508 114.257 655.551 111.986 655.551 109.586C655.551 106.586 654.437 104.271 652.208 102.643C650.065 100.929 647.451 100.071 644.365 100.071C642.137 100.071 640.251 100.414 638.708 101.1C638.708 103.071 638.28 105.086 637.423 107.143C636.565 109.2 635.365 110.957 633.823 112.414C632.365 113.786 630.565 114.471 628.423 114.471C626.537 114.471 625.037 113.957 623.923 112.929C622.894 111.814 622.38 110.486 622.38 108.943C622.38 106.886 623.323 104.957 625.208 103.157C627.18 101.271 629.665 99.6857 632.665 98.4C635.665 97.0286 638.794 95.9572 642.051 95.1857C645.308 94.4143 648.223 94.0286 650.794 94.0286C653.965 94.0286 656.88 94.6286 659.537 95.8286C662.28 96.9429 664.465 98.6572 666.094 100.971C667.808 103.2 668.665 105.986 668.665 109.329C668.665 111.386 668.623 114.086 668.537 117.429C668.451 120.686 668.365 124.2 668.28 127.971C668.28 131.657 668.237 135.171 668.151 138.514C668.065 141.857 668.023 144.557 668.023 146.614C668.023 149.357 669.223 150.729 671.623 150.729C673.165 150.729 675.523 150.214 678.694 149.186C679.037 149.614 679.251 150.086 679.337 150.6C679.508 151.114 679.637 151.586 679.723 152.014C677.58 154.329 675.308 156 672.908 157.029C670.594 158.057 668.237 158.571 665.837 158.571ZM655.165 146.614L655.423 127.329C647.537 128.357 642.094 130.029 639.094 132.343C636.18 134.657 634.723 137.614 634.723 141.214C634.723 144.214 635.494 146.529 637.037 148.157C638.665 149.7 640.68 150.471 643.08 150.471C644.623 150.471 646.337 150.129 648.223 149.443C650.194 148.757 652.508 147.814 655.165 146.614Z" fill="currentColor"></path><rect x="715" y="65" width="195" height="105" rx="52.5" fill="currentColor" fill-opacity="0.05"></rect><path d="M767.529 142.875L754.049 107.938H762.552L769.309 127.582C769.705 128.812 770.078 130.032 770.43 131.24C770.781 132.449 771.078 133.559 771.32 134.569H771.616C771.858 133.559 772.144 132.449 772.473 131.24C772.825 130.032 773.198 128.812 773.594 127.582L780.186 107.938H788.689L775.472 142.875H767.529ZM810.856 143.633C806.901 143.633 803.528 142.71 800.737 140.865C797.969 138.997 795.871 136.305 794.442 132.79C793.014 129.252 792.3 124.989 792.3 120.001V118.255C792.3 113.245 793.014 108.982 794.442 105.467C795.871 101.929 797.969 99.2373 800.737 97.3916C803.528 95.5239 806.901 94.5901 810.856 94.5901C814.789 94.5901 818.129 95.5129 820.875 97.3586C823.644 99.2043 825.731 101.907 827.138 105.467C828.566 109.004 829.28 113.267 829.28 118.255V120.001C829.28 124.989 828.577 129.252 827.171 132.79C825.764 136.327 823.677 139.019 820.908 140.865C818.162 142.71 814.811 143.633 810.856 143.633ZM810.889 136.382C813.064 136.382 814.877 135.789 816.327 134.602C817.799 133.416 818.898 131.658 819.623 129.329C820.348 126.978 820.711 124.066 820.711 120.595V117.694C820.711 114.223 820.337 111.311 819.59 108.96C818.865 106.609 817.777 104.84 816.327 103.654C814.877 102.445 813.064 101.841 810.889 101.841C808.714 101.841 806.879 102.434 805.385 103.621C803.912 104.785 802.792 106.554 802.023 108.927C801.276 111.278 800.902 114.201 800.902 117.694V120.595C800.902 124.044 801.287 126.945 802.056 129.296C802.825 131.647 803.945 133.416 805.418 134.602C806.89 135.789 808.714 136.382 810.889 136.382ZM838.988 143.205C838 143.205 837.099 142.985 836.286 142.545C835.495 142.106 834.879 141.491 834.44 140.7C834.001 139.909 833.781 139.019 833.781 138.03C833.781 137.019 834.001 136.118 834.44 135.327C834.879 134.536 835.495 133.921 836.286 133.482C837.099 133.042 838 132.823 838.988 132.823C839.977 132.823 840.867 133.042 841.658 133.482C842.449 133.921 843.064 134.536 843.504 135.327C843.943 136.118 844.163 137.019 844.163 138.03C844.163 139.019 843.943 139.909 843.504 140.7C843.064 141.491 842.449 142.106 841.658 142.545C840.867 142.985 839.977 143.205 838.988 143.205ZM857.365 142.875V104.511L846.39 111.663V103.357L858.453 95.3481H865.802V142.875H857.365Z" fill="currentColor"></path></svg></a></div><div class="flex items-center gap-1"><button class="focus-visible:ring-ring inline-flex items-center justify-center gap-x-2 whitespace-nowrap rounded-full text-sm font-medium transition-colors focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary hover:bg-overlay-hover px-4 py-2 w-9 h-9 flex-shrink-0 [&amp;_svg]:!w-5" type="button" id="radix-_R_aipfiumdb_" aria-haspopup="menu" aria-expanded="false" data-state="closed"><span class="inline-flex items-center justify-center p-0 m-0 w-6 h-6 rotate-0 scale-100 transition-all dark:-rotate-90 dark:scale-0" data-namespace="@xai/icons" data-slot="icon"><svg xmlns="http://www.w3.org/2000/svg" fill="currentColor" viewBox="0 0 24 24" aria-hidden="true" class="w-6 h-6" focusable="false" style="fill:currentColor"><path d="M12 18a6 6 0 1 1 0-12 6 6 0 0 1 0 12m0-2a4 4 0 1 0 0-8 4 4 0 0 0 0 8M11 1h2v3h-2zm0 19h2v3h-2zM3.515 4.929l1.414-1.414L7.05 5.636 5.636 7.05zM16.95 18.364l1.414-1.414 2.121 2.121-1.414 1.414zm2.121-14.85 1.414 1.415-2.121 2.121-1.414-1.414zM5.636 16.95l1.414 1.414-2.121 2.121-1.414-1.414zM23 11v2h-3v-2zM4 11v2H1v-2z"></path></svg></span><span class="inline-flex items-center justify-center p-0 m-0 w-6 h-6 absolute rotate-90 scale-0 transition-all dark:rotate-0 dark:scale-100" data-namespace="@xai/icons" data-slot="icon"><svg xmlns="http://www.w3.org/2000/svg" fill="currentColor" viewBox="0 0 24 24" aria-hidden="true" class="w-6 h-6" focusable="false" style="fill:currentColor"><path d="M10 7a7 7 0 0 0 12 4.9v.1c0 5.523-4.477 10-10 10S2 17.523 2 12 6.477 2 12 2h.1A6.98 6.98 0 0 0 10 7m-6 5a8 8 0 0 0 15.062 3.762A9 9 0 0 1 8.238 4.938 8 8 0 0 0 4 12"></path></svg></span><span class="sr-only">Toggle theme</span></button><button class="focus-visible:ring-ring inline-flex items-center justify-center gap-x-2 whitespace-nowrap rounded-full text-sm font-medium transition-colors focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary hover:bg-overlay-hover h-9 w-9" type="button"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-search h-5 w-5"><circle cx="11" cy="11" r="8"></circle><path d="m21 21-4.3-4.3"></path></svg></button></div></div></header><div class="bg-surface-base fixed right-0 top-16 z-50 h-[calc(100vh-4rem)] w-full transform border-l transition-transform duration-300 ease-in-out sm:w-1/2 md:hidden translate-x-full"><div class="flex flex-col gap-4 p-4"><div class="flex flex-row gap-2"><button class="focus-visible:ring-ring inline-flex items-center gap-x-2 whitespace-nowrap text-sm font-medium transition-colors focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 border-input text-primary hover:border-primary/15 border hover:bg-overlay-hover py-2 max-w-full shadow-none sm:w-80 h-10 w-full justify-start rounded-full bg-surface-l1 px-4" type="button"><div class="flex items-center justify-between sm:w-full gap-4"><div class="flex items-center justify-start gap-2"><span class="inline-flex items-center justify-center p-0 m-0 w-4 h-4 text-muted" data-namespace="@xai/icons" data-slot="icon"><svg xmlns="http://www.w3.org/2000/svg" fill="currentColor" viewBox="0 0 24 24" aria-hidden="true" class="w-4 h-4" focusable="false" style="fill:currentColor"><path d="m18.031 16.617 4.283 4.282-1.415 1.415-4.282-4.283A8.96 8.96 0 0 1 11 20c-4.968 0-9-4.032-9-9s4.032-9 9-9 9 4.032 9 9a8.96 8.96 0 0 1-1.969 5.617m-2.006-.742A6.98 6.98 0 0 0 18 11c0-3.867-3.133-7-7-7s-7 3.133-7 7 3.133 7 7 7a6.98 6.98 0 0 0 4.875-1.975z"></path></svg></span><p class="text-sm text-muted hidden sm:block">Search</p></div><span class="hidden sm:block"><div class="bg-foreground/10 text-muted inline-flex items-center rounded-md px-1 py-0.5 text-center font-sans text-xs font-normal tracking-widest rtl:space-x-reverse"><span>âŒ˜</span><span class="text-xs">K</span></div></span></div></button></div></div></div><div><div class="min-[1350px]:grid min-[1350px]:grid-cols-[1fr_3fr_1fr]"><nav class="bg-surface-base hidden h-[calc(100vh-4rem)] overflow-y-auto px-6 pb-32 min-[1350px]:sticky min-[1350px]:top-16 min-[1350px]:block scrollbar-none [-ms-overflow-style:none] [scrollbar-width:none] [&amp;::-webkit-scrollbar]:hidden [overscroll-behavior:contain] pt-8"><ul class="space-y-2 text-sm"><li style="padding-left:0rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#kidney-cancer" class="transition-opacity hover:opacity-100 opacity-50">Kidney cancer</a></li><li style="padding-left:0rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#kidney-cancer-signs-and-symptoms" class="transition-opacity hover:opacity-100 opacity-50">Kidney Cancer Signs and Symptoms</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#signs-and-symptoms" class="transition-opacity hover:opacity-100 opacity-50">Signs and symptoms</a></li><li style="padding-left:0rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#kidney-cancer-causes" class="transition-opacity hover:opacity-100 opacity-50">Kidney Cancer Causes</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#causes" class="transition-opacity hover:opacity-100 opacity-50">Causes</a></li><li style="padding-left:0rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#diagnosis" class="transition-opacity hover:opacity-100 opacity-50">Diagnosis</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#medical-imaging" class="transition-opacity hover:opacity-100 opacity-50">Medical imaging</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#histopathologic-classification" class="transition-opacity hover:opacity-100 opacity-50">Histopathologic classification</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#immunohistochemistry" class="transition-opacity hover:opacity-100 opacity-50">Immunohistochemistry</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#laboratory-studies" class="transition-opacity hover:opacity-100 opacity-50">Laboratory studies</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#biopsy" class="transition-opacity hover:opacity-100 opacity-50">Biopsy</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#staging" class="transition-opacity hover:opacity-100 opacity-50">Staging</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#treatment" class="transition-opacity hover:opacity-100 opacity-50">Treatment</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#children" class="transition-opacity hover:opacity-100 opacity-50">Children</a></li><li style="padding-left:0rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#epidemiology" class="transition-opacity hover:opacity-100 opacity-50">Epidemiology</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#age" class="transition-opacity hover:opacity-100 opacity-50">Age</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#sex" class="transition-opacity hover:opacity-100 opacity-50">Sex</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#international-variations" class="transition-opacity hover:opacity-100 opacity-50">International variations</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#race" class="transition-opacity hover:opacity-100 opacity-50">Race</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#screening" class="transition-opacity hover:opacity-100 opacity-50">Screening</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#united-states" class="transition-opacity hover:opacity-100 opacity-50">United States</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#europe" class="transition-opacity hover:opacity-100 opacity-50">Europe</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#references" class="transition-opacity hover:opacity-100 opacity-50">References</a></li></ul></nav><div class="relative top-16 pb-32 pt-8 px-4 md:px-8"><div class="mx-auto max-w-[850px]"><button data-state="closed" type="button" class="flex items-center"><div class="text-fg-tertiary mb-2 flex cursor-help items-center gap-2 text-sm"><span class="inline-flex items-center justify-center p-0 m-0" data-namespace="@xai/icons" data-slot="icon" style="height:16px;width:16px"><svg xmlns="http://www.w3.org/2000/svg" fill="none" viewBox="0 0 33 33" aria-hidden="true" class="" focusable="false" style="fill:currentColor;height:16px;width:16px"><path fill="currentColor" d="m13.237 21.04 11.082-8.19c.543-.4 1.32-.244 1.578.38 1.363 3.288.754 7.241-1.957 9.955-2.71 2.714-6.482 3.31-9.93 1.954l-3.765 1.745c5.401 3.697 11.96 2.782 16.059-1.324 3.251-3.255 4.258-7.692 3.317-11.693l.008.009c-1.365-5.878.336-8.227 3.82-13.031q.123-.17.247-.345l-4.585 4.59v-.014L13.234 21.044M10.95 23.031c-3.877-3.707-3.208-9.446.1-12.755 2.446-2.449 6.454-3.448 9.952-1.979L24.76 6.56c-.677-.49-1.545-1.017-2.54-1.387A12.465 12.465 0 0 0 8.675 7.901c-3.519 3.523-4.625 8.94-2.725 13.561 1.42 3.454-.907 5.898-3.251 8.364-.83.874-1.664 1.749-2.335 2.674l10.583-9.466"></path></svg></span><span>Fact-checked by Grok<!-- --> <!-- -->4 days ago</span></div></button><article class="text-[16px]"><h1 id="kidney-cancer" class="group relative mb-2 scroll-mt-24 font-serif text-[2.125em] font-semibold tracking-[-1px] [&amp;:not(:first-child)]:mt-14" node="[object Object]">Kidney cancer<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h1>





















































<!-- -->
<span class="mb-4 block break-words text-[1em] leading-7"><strong>Kidney cancer</strong> , also known as <strong>renal cancer</strong> , is a group of cancers that starts in the kidney.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_a1abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[4]</sup> Symptoms may include blood in the urine, a lump in the abdomen, or back pain.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_e1abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_g1abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[2]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_i1abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[3]</sup> Fever, weight loss, and tiredness may also occur.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_m1abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_o1abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[2]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_q1abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[3]</sup> Complications can include spread to the lungs or brain.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_u1abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[5]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">The main types of kidney cancer are renal cell cancer (RCC), transitional cell cancer (TCC), and Wilms&#x27; tumor.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_41qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[6]</sup> RCC makes up approximately 80% of kidney cancers, and TCC accounts for most of the rest.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_81qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[7]</sup> Risk factors for RCC and TCC include smoking, certain pain medications, previous bladder cancer, being overweight, high blood pressure, certain chemicals, and a family history.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_c1qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_e1qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[2]</sup> Risk factors for Wilms&#x27; tumor include a family history and certain genetic disorders such as WAGR syndrome.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_i1qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[3]</sup> Diagnosis may be suspected based on symptoms, urine testing, and medical imaging.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_m1qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_o1qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[2]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_q1qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[3]</sup> It is confirmed by tissue biopsy.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_u1qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_101qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[2]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_121qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[3]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Treatment may include surgery, radiation therapy, chemotherapy, immunotherapy, and targeted therapy.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_42abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_62abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[2]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_82abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[3]</sup> Kidney cancer newly affected about 434,800 people and resulted in 156,000 deaths globally in 2022. Onset is usually after the age of 45.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_c2abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[4]</sup> Males are affected more often than females.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_g2abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[4]</sup> The overall five-year survival rate is 78% in the United States, 73% in Canada, 70% in China, and 66% in Europe (as of 2024).<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_k2abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[8]</sup> For cancers that are confined to the kidney, the five-year survival rate is 93%, if it has spread to the surrounding lymph nodes it is 72%, and if it has spread widely, it is 16%. Kidney cancer has been identified as the 14th most common form of cancer,<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_o2abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[9]</sup> and is responsible for about 2% of the world&#x27;s cancer cases and 2% of deaths. The incidence of kidney cancer has continued to increase since 1930 and is projected to double by 2050. Renal cancer is more commonly found in populations of urban areas than rural areas.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_s2abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[10]</sup></span>
<h1 id="kidney-cancer-signs-and-symptoms" class="group relative mb-2 scroll-mt-24 font-serif text-[2.125em] font-semibold tracking-[-1px] [&amp;:not(:first-child)]:mt-14" node="[object Object]">Kidney Cancer Signs and Symptoms<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h1>
<h2 id="signs-and-symptoms" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">Signs and symptoms<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<span class="mb-4 block break-words text-[1em] leading-7">Due to increased use of abdominal imaging for other conditions, the majority of kidney cancers (over 50%) are now detected incidentally before symptoms develop. Early on, kidney masses do not typically cause any symptoms and are undetectable on physical examination.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_43qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[11]</sup> As kidney cancer becomes more advanced it classically results in blood in the urine, flank or back pain, and a mass.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_83qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[11]</sup> Other symptoms that are consistent with advanced disease include weight loss, fever, night sweats, palpable swollen lymph nodes in the neck, non-reducing varicocele, bone pain, continuous cough, and bilateral lower leg swelling.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_c3qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[11]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">The classic triad of visible blood in the urine (hematuria), flank pain and palpable abdominal mass occurs in approximately 5-10% of the cases. RCC may present with signs and symptoms caused by the substances the cancer cells produce (i.e. paraneoplastic syndromes).</span>
<span class="mb-4 block break-words text-[1em] leading-7">Paraneoplastic syndromes caused by kidney cancer can be broadly classified as endocrine and non-endocrine. Endocrine dysfunctions include increase in blood calcium levels (hypercalcemia), high blood pressure (hypertension), increased red blood cells (polycythemia), liver dysfunction, milky nipple discharge unrelated to normal breast-feeding (galactorrhea), and Cushing&#x27;s syndrome. Non-endocrine dysfunctions include deposition of protein in tissue (amyloidosis), decrease in hemoglobin or red blood cells (anemia), disorders of nerves, muscles (neuromyopathies), blood vessels (vasculopathy) and blood clotting mechanisms (coagulopathy).<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_44qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[12]</sup></span>
<h1 id="kidney-cancer-causes" class="group relative mb-2 scroll-mt-24 font-serif text-[2.125em] font-semibold tracking-[-1px] [&amp;:not(:first-child)]:mt-14" node="[object Object]">Kidney Cancer Causes<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h1>
<h2 id="causes" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">Causes<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<span class="mb-4 block break-words text-[1em] leading-7">Factors that increase the risk of kidney cancer include smoking, high blood pressure, obesity, inherited genetic conditions, and a family history of kidney cancer in first-degree relatives.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_46abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[13]</sup> Long-term dialysis for advanced kidney disease is also a risk factor.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_86abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[14]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_a6abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[15]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Other possible risk factors, such as kidney stones, are under investigation.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_46qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[16]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_66qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[17]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Approximately 20% of kidney cancer cases are attributable to smoking.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_47abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[15]</sup> Smokers have a 1.3 times higher risk of developing kidney cancer compared to non-smokers. Moreover, there is a dose-dependent increased risk of cancer development. Men who smoke more than 20 cigarettes per day have twice the risk. Likewise, women who smoke more than 20 cigarettes per day have 1.5 times the risk of non-smokers. After 10 years of smoking cessation, a substantial reduction is seen in the risk of developing kidney cancer.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_87abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[18]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Other modifiable risk factors include type 2 diabetes and chronic kidney disease. The incidence of kidney cancer is projected to double globally by 2050, largely due to rising obesity rates.</span>
<h1 id="diagnosis" class="group relative mb-2 scroll-mt-24 font-serif text-[2.125em] font-semibold tracking-[-1px] [&amp;:not(:first-child)]:mt-14" node="[object Object]">Diagnosis<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h1>
<span class="mb-4 block break-words text-[1em] leading-7">Due to the increase in ultrasound and <span class="inline text-[1em] leading-7">CT imaging</span> for nonspecific abdominal complaints, kidney masses are frequently incidentally diagnosed on medical imaging.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_88qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[11]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_a8qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[19]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_c8qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[20]</sup> Approximately 50% (37â€“61%) of renal cell carcinoma (the most common type of kidney cancer) are diagnosed incidentally by abdominal imaging for nonspecific abdominal complaints.</span>
<span class="mb-4 block break-words text-[1em] leading-7">Kidney masses can be classified by the nature of the cells in the growth, or by its appearance on <span class="inline text-[1em] leading-7">radiography</span>.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_89abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[11]</sup> The term cancer refers to a <span class="inline text-[1em] leading-7">malignant tumor</span>, which is an uncontrolled growth of abnormal cells.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_g9abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[21]</sup> However, kidney masses can be due to growth of normal tissue (benign), inflammatory (a reaction of the immune system), or vascular (cells of the blood vessels).</span>
<h2 id="medical-imaging" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">Medical imaging<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<span class="mb-4 block break-words text-[1em] leading-7">Since there is a large differential diagnosis for a kidney tumor, the first step is to characterize the mass with medical imaging to assess its likelihood of being benign or malignant. <span class="inline text-[1em] leading-7">Ultrasonography</span> is sometimes used to evaluate a suspected kidney mass, as it can characterize cystic and solid kidney masses without radiation exposure and at relatively low cost.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8aabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[11]</sup> Radiologically tumors are grouped based on appearance into simple cystic, complex cystic, or solid.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_caabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[11]</sup> The most important differentiating feature of a cancerous and non-cancerous tumor on imaging is enhancement.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_gaabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[22]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_iaabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[23]</sup> Simple cysts, which are defined by strict criteria<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_maabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[24]</sup> are safe to be monitored if the person does not have any symptoms.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_qaabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[11]</sup> However, all masses that are not clearly simple cysts should be further evaluated and confirmed by alternate imaging techniques.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_uaabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[25]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_10aabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[11]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Computed tomography (CT) of the abdomen administered with and without IV contrast is the ideal imaging to diagnose and determine the stage of kidney cancer.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4aqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[26]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_6aqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[25]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8aqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[11]</sup> There is tentative evidence that iodinated contrast agents may cause worsening of kidney function in people with chronic kidney disease (CKD) with a <span class="inline text-[1em] leading-7">glomerular filtration rate</span> (GFR) less than 45ml/min/1.73m2 and should therefore be given cautiously to such persons.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_gaqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[27]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Abdominal <span class="inline text-[1em] leading-7">magnetic resonance imaging</span> (MRI) is an alternative imaging method that can be used to characterize and stage a kidney mass.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8babav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[26]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_ababav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[25]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_cbabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[11]</sup> It may be suggested if contrast material cannot be given.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_gbabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[26]</sup> MRI can also evaluate the <span class="inline text-[1em] leading-7">inferior vena cava</span> if the mass is suspected to extend outside the kidney.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_obabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[26]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Since the lungs are the most common organ for kidney cancer to spread to, a <span class="inline text-[1em] leading-7">chest X-ray</span> or CT scan may be ordered based on the person&#x27;s risk for metastatic disease.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8bqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[11]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_abqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[25]</sup></span>
<h2 id="histopathologic-classification" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">Histopathologic classification<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<span class="mb-4 block break-words text-[1em] leading-7">The most common type of kidney malignancy is <span class="inline text-[1em] leading-7">renal cell carcinoma</span>,<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8cqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[28]</sup> which is thought to originate from cells in the <span class="inline text-[1em] leading-7">proximal convoluted tubule</span> of the <span class="inline text-[1em] leading-7">nephron</span>.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_kcqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[11]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_mcqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[29]</sup> Another type of kidney cancer although less common, is <span class="inline text-[1em] leading-7">transitional cell cancer</span> (TCC) or urothelial carcinoma of the <span class="inline text-[1em] leading-7">renal pelvis</span>.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_12cqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[30]</sup> The renal pelvis is the part of the kidney that collects urine and drains it into a tube called the <span class="inline text-[1em] leading-7">ureter</span>.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_1acqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[30]</sup> The cells that line the renal pelvis are called <span class="inline text-[1em] leading-7">transitional cells</span>, and are also sometimes called urothelial cells. The transitional/urothelial cells in the renal pelvis are the same type of cells that line the ureter and <span class="inline text-[1em] leading-7">bladder</span>. For this reason TCC of the renal pelvis is distinct from RCC and is thought to behave more like <span class="inline text-[1em] leading-7">bladder cancer</span>.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_1qcqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[30]</sup> Other rare types of kidney cancers that can arise from the urothelial cells of the renal pelvis are <span class="inline text-[1em] leading-7">squamous cell carcinoma</span> and <span class="inline text-[1em] leading-7">adenocarcinoma</span>.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_26cqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[11]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Other causes of kidney cancer include the following:<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4dabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[11]</sup></span>
<ul class="marker:text-primary my-4 ml-6 list-disc space-y-2 text-[1em]">
<li class="text-[1em]"><span class="inline text-[1em] leading-7">Sarcoma</span> â€“ for example <span class="inline text-[1em] leading-7">leiomyosarcoma</span>, <span class="inline text-[1em] leading-7">liposarcoma</span>, <span class="inline text-[1em] leading-7">angiosarcoma</span>, <span class="inline text-[1em] leading-7">clear-cell sarcoma</span> and <span class="inline text-[1em] leading-7">rhabdomyosarcoma</span> are types of sarcomas that have occurred in the kidney</li>
<li class="text-[1em]">Metastatic tumor from distant organ</li>
<li class="text-[1em]"><span class="inline text-[1em] leading-7">Lymphoma</span></li>
<li class="text-[1em]"><span class="inline text-[1em] leading-7">Wilms tumor</span> â€“ an embryonic tumor that is the most common type of kidney cancer in children</li>
<li class="text-[1em]"><span class="inline text-[1em] leading-7">Carcinoid tumor</span> of the renal pelvis<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_3kdqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[31]</sup></li>
<li class="text-[1em]"><span class="inline text-[1em] leading-7">Carcinosarcoma</span><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_2odqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[32]</sup></li>
</ul>
<span class="mb-4 block break-words text-[1em] leading-7">In children, <span class="inline text-[1em] leading-7">Wilms tumor</span> is the most common type of kidney cancer.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8eabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[11]</sup> <span class="inline text-[1em] leading-7">Mesoblastic nephroma</span>, although rare, also typically presents in childhood.</span>
<span class="mb-4 block break-words text-[1em] leading-7">Renal cell carcinoma has been further divided into sub-types based on histological features and genetic abnormalities. The 2022 <span class="inline text-[1em] leading-7">WHO</span> Classification of Tumours of the Urinary and Male Genital Systems (5th edition) describes these categories, incorporating molecular and genetic features:</span>
<ul class="marker:text-primary my-4 ml-6 list-disc space-y-2 text-[1em]">
<li class="text-[1em]">Clear cell renal cell carcinoma</li>
<li class="text-[1em]">Papillary renal cell carcinoma (type 1, type 2)</li>
<li class="text-[1em]">Chromophobe renal cell carcinoma</li>
<li class="text-[1em]">Collecting duct carcinoma</li>
<li class="text-[1em]">Renal medullary carcinoma</li>
<li class="text-[1em]">MiT family translocation renal cell carcinoma</li>
<li class="text-[1em]">Succinate dehydrogenase (SDH)-deficient renal cell carcinoma</li>
<li class="text-[1em]">FKHR (FOXG1)-altered renal cell carcinoma</li>
<li class="text-[1em]">Eosinophilic solid and cystic renal cell carcinoma</li>
<li class="text-[1em]">Other molecularly defined renal carcinomas (e.g., EWSR1::PATZ1, etc.)</li>
<li class="text-[1em]">Clear cell papillary renal cell tumor (formerly carcinoma; low malignant potential)</li>
</ul>
<span class="mb-4 block break-words text-[1em] leading-7">Tumors that are considered benign include <span class="inline text-[1em] leading-7">angiomyolipoma</span>, <span class="inline text-[1em] leading-7">oncocytoma</span>, <span class="inline text-[1em] leading-7">reninoma (juxtaglomerular cell tumor)</span>, and renal adenoma.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_gfqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[11]</sup></span>
<h2 id="immunohistochemistry" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">Immunohistochemistry<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<span class="mb-4 block break-words text-[1em] leading-7">Typical <span class="inline text-[1em] leading-7">immunohistochemistry</span> for various kidney cancer types.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8gqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[33]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_agqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[34]</sup></span>































































































































































<div class="border-border-l1 overflow-x-auto rounded-lg border my-6 w-full"><table node="[object Object]" class="w-full border-collapse text-sm"><thead node="[object Object]" class="border-border-l1 border-b bg-surface-l1"><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><th node="[object Object]" class="dark:text-fg-primary bg-gray-100 px-2 py-1 text-left align-top font-bold dark:bg-black"><span class="text-[1em] leading-7">Type</span></th><th node="[object Object]" class="dark:text-fg-primary bg-gray-100 px-2 py-1 text-left align-top font-bold dark:bg-black"><span class="text-[1em] leading-7">PAX8</span></th><th node="[object Object]" class="dark:text-fg-primary bg-gray-100 px-2 py-1 text-left align-top font-bold dark:bg-black"><span class="text-[1em] leading-7">CD10</span></th><th node="[object Object]" class="dark:text-fg-primary bg-gray-100 px-2 py-1 text-left align-top font-bold dark:bg-black"><span class="text-[1em] leading-7">CAIX</span></th><th node="[object Object]" class="dark:text-fg-primary bg-gray-100 px-2 py-1 text-left align-top font-bold dark:bg-black"><span class="text-[1em] leading-7">RCC</span></th><th node="[object Object]" class="dark:text-fg-primary bg-gray-100 px-2 py-1 text-left align-top font-bold dark:bg-black"><span class="text-[1em] leading-7">Melanocytic markers</span></th><th node="[object Object]" class="dark:text-fg-primary bg-gray-100 px-2 py-1 text-left align-top font-bold dark:bg-black"><span class="text-[1em] leading-7">Vimentin</span></th><th node="[object Object]" class="dark:text-fg-primary bg-gray-100 px-2 py-1 text-left align-top font-bold dark:bg-black"><span class="text-[1em] leading-7">CK7</span></th><th node="[object Object]" class="dark:text-fg-primary bg-gray-100 px-2 py-1 text-left align-top font-bold dark:bg-black"><span class="text-[1em] leading-7">HMWCK</span></th><th node="[object Object]" class="dark:text-fg-primary bg-gray-100 px-2 py-1 text-left align-top font-bold dark:bg-black"><span class="text-[1em] leading-7">CD117 / KIT</span></th><th node="[object Object]" class="dark:text-fg-primary bg-gray-100 px-2 py-1 text-left align-top font-bold dark:bg-black"><span class="text-[1em] leading-7">AMACR</span></th><th node="[object Object]" class="dark:text-fg-primary bg-gray-100 px-2 py-1 text-left align-top font-bold dark:bg-black"><span class="text-[1em] leading-7">GATA3</span></th></tr></thead><tbody node="[object Object]" class="divide-border-l1 divide-y"><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Clear cell RCC</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">+</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">+</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">+ (box-like)</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">+</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">-</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">+</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">-</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">-</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">-</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">-/+</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">-</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Papillary RCC</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">+</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">+</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">+/-</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">+</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">-</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">+</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">+</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">-</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">-</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">+</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">-</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Clear cell papillary RCC</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">+</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">-</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">+ (cup-like)</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">+/-</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">-</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">+</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">+</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">+/-</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">-</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">-</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">+/-</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Chromophobe RCC</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">+</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">-/+</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">-</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">+/-</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">-</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">-</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">+</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">-</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">+</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">-</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">+/-</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Oncocytoma</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">+</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">-/+</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">-</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">-</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">-</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">-</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Focal</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">-</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">+</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">-/+</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">-</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Angiomyolipoma</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">-</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">-</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">-/+</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">-</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">+</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">-/+</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">-</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">-</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">-</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">-</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">-</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Collecting duct carcinoma</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">+</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">-</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">-/+</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">-</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">-</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">+</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">+/-</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">+</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">-</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">-</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">-</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Tubulocystic carcinoma</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">+</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">+</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">+/-</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">+</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">-</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">+/-</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">-/+</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">-</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">-</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">+/-</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">-</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Translocation RCC</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">+</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">+/-</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">-/+</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">+/-</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">+/-</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">+</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">-</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">-</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">-</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">+/-</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">-</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">MTSCC</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">+</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">-/+</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">-/+</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">+/-</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">-</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">+</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">+</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">-/+</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">-</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">+/-</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">-</span></td></tr></tbody></table></div>
<span class="mb-4 block break-words text-[1em] leading-7">Legend:</span>
<ul class="marker:text-primary my-4 ml-6 list-disc space-y-2 text-[1em]">
<li class="text-[1em]">
<ul class="marker:text-primary my-4 ml-6 list-disc space-y-2 text-[1em]">
<li class="text-[1em]">= usually positive</li>
</ul>
</li>
<li class="text-[1em]">+/- = frequently positive</li>
<li class="text-[1em]">-/+ = occasionally positive</li>
<li class="text-[1em]">
<ul class="marker:text-primary my-4 ml-6 list-disc space-y-2 text-[1em]">
<li class="text-[1em]">= usually negative</li>
</ul>
</li>
</ul>
<h2 id="laboratory-studies" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">Laboratory studies<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<span class="mb-4 block break-words text-[1em] leading-7">People with suspected kidney cancer should also have their kidney function evaluated to help determine treatment options. Blood tests to determine kidney function include a <span class="inline text-[1em] leading-7">comprehensive metabolic panel</span> (CMP) and a <span class="inline text-[1em] leading-7">complete blood count</span> (CBC).<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_cjabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[35]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_ejabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[25]</sup> In addition, these tests help understand the overall health of the person, which can be affected by <span class="inline text-[1em] leading-7">metastatic disease</span> (disease that is outside of the kidney). For example, liver or bone involvement could result in abnormal liver enzymes, electrolyte abnormalities, or <span class="inline text-[1em] leading-7">anemia</span>. A urine sample should also be collected for <span class="inline text-[1em] leading-7">urinalysis</span>.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_ujabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[25]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_10jabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[11]</sup></span>
<h2 id="biopsy" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">Biopsy<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<span class="mb-4 block break-words text-[1em] leading-7">The utility of renal mass biopsy (RMB) lies in that it can confirm malignancy with reliability, can direct therapy based on diagnosis, and can provide drainage.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4kabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[25]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Once imaging has been completed, renal mass biopsy should be considered if there is a high likelihood that the mass is hematologic, metastatic, inflammatory, or infectious.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4kqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[25]</sup> These types of lesions would not be managed surgically, differing from cancer originating from the kidney. Cancer originating outside the kidney and lymphoma are managed systemically.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8kqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[11]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_akqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[25]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">RMB can accurately diagnose malignancy, however, it cannot reliably diagnose benign disease. In other words, if the biopsy shows cancer, there is a 99.8% chance that kidney cancer is present (Positive Predictive Value= 99.8%). A negative biopsy does not rule out a diagnosis of cancer.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4labav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[36]</sup></span>
<h2 id="staging" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">Staging<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<span class="mb-4 block break-words text-[1em] leading-7">The TNM staging system is commonly used for renal cell carcinoma; other types of kidney cancer, such as transitional cell carcinoma and Wilms tumor, use different staging systems.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4mabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[37]</sup> The first step of staging follows the <span class="inline text-[1em] leading-7">TNM staging system</span> proposed by the Union International Contre le Cancer that is widely used among cancers in other organs.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_cmabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[11]</sup> The TNM staging system classifies the primary tumor (T), lymph nodes (N) and distant metastasis (M) of the disease. The <span class="inline text-[1em] leading-7">American Joint Committee on Cancer</span> (AJCC) published a Cancer Staging Manual revision in 2010 that describes the values of TMN for renal cell carcinoma.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_kmabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[38]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_mmabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[11]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Lymph node involvement is classified as either regional lymph node metastasis (N1), or no involvement (N0).<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4mqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[38]</sup> Similarly, M1 describes distant metastasis, while M0 describes no distant metastasis.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8mqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[38]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">The primary tumor of renal cell carcinoma is categorized in the table below, as according to the AJCC 8th Edition Cancer Staging Manual:<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4nabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[39]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_6nabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[40]</sup></span>





















































































<div class="border-border-l1 overflow-x-auto rounded-lg border my-6 w-full"><table node="[object Object]" class="w-full border-collapse text-sm"><thead node="[object Object]" class="border-border-l1 border-b bg-surface-l1"><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><th node="[object Object]" class="dark:text-fg-primary bg-gray-100 px-2 py-1 text-left align-top font-bold dark:bg-black"><span class="text-[1em] leading-7">Stage</span></th><th node="[object Object]" class="dark:text-fg-primary bg-gray-100 px-2 py-1 text-left align-top font-bold dark:bg-black"><span class="text-[1em] leading-7">TNM</span></th><th node="[object Object]" class="dark:text-fg-primary bg-gray-100 px-2 py-1 text-left align-top font-bold dark:bg-black"><span class="text-[1em] leading-7">Description</span></th></tr></thead><tbody node="[object Object]" class="divide-border-l1 divide-y"><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><strong>Tx</strong><span class="text-[1em] leading-7">, N0, M0</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Tumor cannot be assessed</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><strong>T0</strong><span class="text-[1em] leading-7">, N0, M0</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">No evidence of primary tumor</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">I</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><strong>T1</strong><span class="text-[1em] leading-7">, N0, M0</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Tumor â‰¤7 cm; limited to kidney</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><strong>T1a</strong><span class="text-[1em] leading-7">, N0, M0</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Tumor â‰¤4 cm; limited to kidney</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><strong>T1b</strong><span class="text-[1em] leading-7">, N0, M0</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Tumor 4-â‰¤7 cm; limited to kidney</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">II</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><strong>T2</strong><span class="text-[1em] leading-7">, N0, M0</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Tumor &gt;7 cm; limited to kidney</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><strong>T2a</strong><span class="text-[1em] leading-7">, N0, M0</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Tumor 7-â‰¤10 cm; limited to kidney</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><strong>T2b</strong><span class="text-[1em] leading-7">, N0, M0</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Tumor &gt;10 cm; limited to kidney</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">III</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><strong>T3</strong><span class="text-[1em] leading-7">, N0, M0</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Tumor extends to major veins or perinephric tissue but not into ipsilateral adrenal gland nor beyond Gerota&#x27;s fascia</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><strong>T3a</strong><span class="text-[1em] leading-7">, N0, M0</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Tumor grossly extends into renal vein or its segmental branches, or tumor invades the pelvicalyceal system, or tumor invades perirenal and/or renal sinus fat but not beyond Gerota&#x27;s fascia</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><strong>T3b</strong><span class="text-[1em] leading-7">, N0, M0</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Tumor grossly extends into vena cava below the diaphragm</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><strong>T3c</strong><span class="text-[1em] leading-7">, N0, M0</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Tumor grossly extends into vena cava above the diaphragm or invades the wall of the vena cava</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><strong>T1-T3, N1</strong><span class="text-[1em] leading-7">, M0</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">The main tumor can be any size and may be outside the kidney, but it has not spread beyond Gerota&#x27;s fascia. The cancer has spread to regional lymph nodes (N1) but has not spread to distant lymph nodes or other organs (M0).</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">IV</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><strong>T4</strong><span class="text-[1em] leading-7">, any N, M0</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Tumor invades beyond Gerota&#x27;s fascia</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Any T, any N, </span><strong>M1</strong></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Tumor has spread to distant lymph nodes and/or other organs.</span></td></tr></tbody></table></div>
<span class="mb-4 block break-words text-[1em] leading-7">The lungs are the most common site for metastasis,<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4oabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[25]</sup> with other common sites including bone, brain, liver, <span class="inline text-[1em] leading-7">adrenal gland</span> and distant lymph nodes.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_coabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[35]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_eoabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[41]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_goabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[38]</sup></span>
<h2 id="treatment" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">Treatment<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<span class="mb-4 block break-words text-[1em] leading-7">Treatment for kidney cancer depends on the type and stage of the disease. Surgery is the most common treatment as kidney cancer does not often respond to <span class="inline text-[1em] leading-7">chemotherapy</span> and <span class="inline text-[1em] leading-7">radiotherapy</span>. Surgical complexity can be estimated by the <span class="inline text-[1em] leading-7">RENAL Nephrometry Scoring System</span>. If the cancer has not spread it will usually be removed by surgery. In some cases this involves <span class="inline text-[1em] leading-7">removing the whole kidney</span> however most tumors are amenable to <span class="inline text-[1em] leading-7">partial removal</span> to eradicate the tumor and preserve the remaining normal portion of the kidney. Surgery is not always possible â€“ for example, the patient may have other medical conditions that prevent it, or the cancer may have spread around the body and doctors may not be able to remove it.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_opabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[42]</sup> If the cancer cannot be treated with surgery, other techniques such as <span class="inline text-[1em] leading-7">freezing the tumour</span> or <span class="inline text-[1em] leading-7">treating it with high temperatures</span> may be used. However, these are not yet used as standard treatments for kidney cancer.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_14pabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[43]</sup> Evidence from the KEYNOTE-564 study supports the use of adjuvant pembrolizumab for high-risk clear cell renal cell carcinoma (RCC) following surgery, with long-term follow-up confirming improvements in disease-free and overall survival (48-month OS: 91.2% vs. 86.0% placebo; HR 0.62).</span>
<span class="mb-4 block break-words text-[1em] leading-7">Other treatment options include targeted therapies such as <span class="inline text-[1em] leading-7">everolimus</span>, <span class="inline text-[1em] leading-7">temsirolimus</span>, <span class="inline text-[1em] leading-7">sorafenib</span>, <span class="inline text-[1em] leading-7">sunitinib</span>, <span class="inline text-[1em] leading-7">pazopanib</span>, and <span class="inline text-[1em] leading-7">axitinib</span>, as well as <span class="inline text-[1em] leading-7">immunotherapy</span> including <span class="inline text-[1em] leading-7">interferon</span> and <span class="inline text-[1em] leading-7">interleukin-2</span>.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_18pqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[44]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_1apqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[45]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_1cpqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[46]</sup> For advanced clear cell RCC, preferred first-line systemic therapies include combinations of immune checkpoint inhibitors with tyrosine kinase inhibitors, such as pembrolizumab + axitinib, nivolumab + cabozantinib, or lenvatinib + pembrolizumab, or immune checkpoint inhibitor monotherapy like nivolumab + ipilimumab for intermediate/poor-risk patients. Adjuvant pembrolizumab is recommended for patients with high-risk clear cell RCC following nephrectomy. Subsequent-line therapies depend on prior treatments and may include cabozantinib, axitinib, or belzutifan. In the second-line setting, <span class="inline text-[1em] leading-7">nivolumab</span> and <span class="inline text-[1em] leading-7">cabozantinib</span> remain options following certain prior therapies.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_1opqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[47]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_1qpqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[48]</sup> <span class="inline text-[1em] leading-7">Lenvatinib</span> + pembrolizumab is approved for first-line use in advanced RCC (as of 2021).</span>
<span class="mb-4 block break-words text-[1em] leading-7">In <span class="inline text-[1em] leading-7">Wilms&#x27; tumor</span>, chemotherapy, radiotherapy and surgery are the accepted treatments, depending on the stage of the disease when it is diagnosed.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8qabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[49]</sup></span>
<h3 id="children" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Children<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">The majority of kidney cancers in children are Wilms&#x27; tumors, treated with a multimodal approach including surgery (nephrectomy), chemotherapy (e.g., vincristine, dactinomycin, doxorubicin based on stage), and radiation therapy for higher-risk cases. Treatment is guided by risk stratification from protocols like those from the Children&#x27;s Oncology Group, with overall survival exceeding 90% for most patients.</span>
<h1 id="epidemiology" class="group relative mb-2 scroll-mt-24 font-serif text-[2.125em] font-semibold tracking-[-1px] [&amp;:not(:first-child)]:mt-14" node="[object Object]">Epidemiology<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h1>
<span class="mb-4 block break-words text-[1em] leading-7">In 2022, kidney cancer accounted for 434,840 new cases worldwide (about 2.2% of all cancers), with 155,953 deaths (1.7% of cancer deaths). Incidence rates are highest in Europe and Northern America (ASR 15-20/100,000) and lowest in Africa and parts of Asia (&lt;5/100,000).</span>
<h2 id="age" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">Age<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<span class="mb-4 block break-words text-[1em] leading-7">Kidney cancer incidence increases with age, with a median diagnosis age of 65 years and peak in the 65-74 age group (30% of cases). Nearly half of cases occur before age 65. Pediatric renal tumors (primarily Wilms tumor) represent about 1-2% of all kidney cancer cases.</span>
<h2 id="sex" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">Sex<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<span class="mb-4 block break-words text-[1em] leading-7">Incidence is about twice as high in men (23.8/100,000) as in women (12.0/100,000), possibly due to hormonal or behavioral differences. Mortality declines have been similar across sexes in recent years.</span>
<h2 id="international-variations" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">International variations<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<span class="mb-4 block break-words text-[1em] leading-7">Age-standardized incidence rates vary widely. In 2022, Belarus had the highest rate (22.9/100,000 in males), followed by Latvia and Czechia; low-risk countries like China, Thailand, and many in Africa have rates under 2/100,000. Since the 2000s, incidence has stabilized or increased in most countries, with decreases reported in a few (e.g., Austria, Poland). Variations partly reflect healthcare access and screening/diagnostic practices, leading to underreporting in low-income regions.</span>
<span class="mb-4 block break-words text-[1em] leading-7">Global incidence is projected to nearly double by 2050 (to ~800,000 cases annually), driven by aging populations, obesity, and improved detection.</span>
<h2 id="race" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">Race<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<span class="mb-4 block break-words text-[1em] leading-7">In the US, overall incidence is highest among non-Hispanic Whites (18.3/100,000), followed by non-Hispanic Blacks (16.5/100,000) and Hispanics (14.0/100,000); rates are lowest in Asians/Pacific Islanders (~10/100,000). Among men, non-Hispanic American Indian/Alaska Native have the highest (39.2/100,000), followed closely by non-Hispanic Black, Hispanic, and non-Hispanic White (all ~24-26/100,000). Mortality is higher among non-Hispanic Blacks (4.0/100,000) and American Indian/Alaska Native (~4.5/100,000) than non-Hispanic Whites (3.6/100,000).</span>
<h2 id="screening" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">Screening<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<span class="mb-4 block break-words text-[1em] leading-7">Routine screening for kidney cancer is not recommended due to low prevalence and lack of cost-effective tests; most cases are detected incidentally via imaging. Improving registries and access in low-resource settings could better track and reduce disparities.</span>
<h2 id="united-states" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">United States<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<span class="mb-4 block break-words text-[1em] leading-7">The American Cancer Society estimates 80,980 new kidney cancer cases and 14,510 deaths in the US for 2025. Incidence has been stable since 2013 (17.5/100,000 overall), reflecting a true increase offset by earlier detection of indolent tumors.</span>
<h2 id="europe" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">Europe<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<span class="mb-4 block break-words text-[1em] leading-7">GLOBOCAN 2022 estimates 145,721 new kidney cancer cases in Europe, accounting for ~3% of all cancers. Incidence rates are among the world&#x27;s highest (ASR ~15/100,000 overall). In the UK, ~13,900 cases occur annually (2017-2019 average), projected to rise 15% to ~21,900 by 2038-2040; it ranks as the 8th most common cancer.</span></article><div id="references" class="min-w-0 scroll-mt-8 overflow-hidden"><div class="text-[16px]"><h2 id="references" node="[object Object]" class="mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden">References</h2></div><ol class="columns-1 gap-x-12 [counter-reset:item] md:columns-2"><li id="1" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.cancer.gov/types/kidney/patient/kidney-treatment-pdq" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Renal Cell Cancer Treatment&quot;</a>. <em>National Cancer Institute</em>. 2019. <a href="https://web.archive.org/web/20190410020031/https://www.cancer.gov/types/kidney/patient/kidney-treatment-pdq" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">Archived</a> from the original on 10 April 2019. Retrieved 8 June 2019.</span></div></li><li id="2" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.cancer.gov/types/kidney/patient/transitional-cell-treatment-pdq" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Transitional Cell Cancer (Kidney/Ureter) Treatment&quot;</a>. <em>National Cancer Institute</em>. 2019. <a href="https://web.archive.org/web/20190608225352/https://www.cancer.gov/types/kidney/patient/transitional-cell-treatment-pdq" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">Archived</a> from the original on 8 June 2019. Retrieved 8 June 2019.</span></div></li><li id="3" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.cancer.gov/types/kidney/patient/wilms-treatment-pdq" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Wilms Tumor and Other Childhood Kidney Tumors Treatment&quot;</a>. <em>National Cancer Institute</em>. 2019. <a href="https://web.archive.org/web/20190410020021/https://www.cancer.gov/types/kidney/patient/wilms-treatment-pdq" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">Archived</a> from the original on 10 April 2019. Retrieved 8 June 2019.</span></div></li><li id="4" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://seer.cancer.gov/statfacts/html/kidrp.html" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Cancer of the Kidney and Renal Pelvis - Cancer Stat Facts&quot;</a>. <em>SEER</em>. <a href="https://web.archive.org/web/20190611034844/https://seer.cancer.gov/statfacts/html/kidrp.html" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">Archived</a> from the original on 11 June 2019. Retrieved 30 May 2019.</span></div></li><li id="6" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Sommers MS, Fannin E (2014). <a href="https://books.google.com/books?id=pIEsBQAAQBAJ&amp;pg=PA657" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300"><em>Diseases and Disorders: A Nursing Therapeutics Manual</em></a>. F.A. Davis. p. 657. <span class="inline text-[1em] leading-7">ISBN</span> 9780803644878.</span></div></li><li id="7" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.cancer.gov/types/kidney?redirect=true" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Kidney Cancer&quot;</a>. <em>National Cancer Institute</em>. 2019. <a href="https://web.archive.org/web/20200815203015/https://www.cancer.gov/types/kidney?redirect=true" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">Archived</a> from the original on 15 August 2020. Retrieved 8 June 2019.</span></div></li><li id="8" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Mulders PF, Brouwers AH, Hulsbergen-van der Kaa CA, van Lin EN, Osanto S, de Mulder PH (February 2008). &quot;[Guideline &#x27;Renal cell carcinoma&#x27;]&quot;. <em>Ned Tijdschr Geneeskd</em> (in Dutch). <strong>152</strong> (7): 376â€“80. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/18380384" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">18380384</a>.</span></div></li><li id="11" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Zeng H, Chen W, Zheng R, Zhang S, Ji JS, Zou X, Xia C, Sun K, Yang Z, Li H, Wang N (2018). <a href="https://doi.org/10.1016%2FS2214-109X%2818%2930127-X" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Changing cancer survival in China during 2003â€“15: a pooled analysis of 17 population-based cancer registries&quot;</a>. <em>The Lancet Global Health</em>. <strong>6</strong> (5): e555 â€“ e567. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1016%2FS2214-109X%2818%2930127-X" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1016/S2214-109X(18)30127-X</a>. <span class="inline text-[1em] leading-7">hdl</span>:<a href="https://hdl.handle.net/10072%2F386179" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10072/386179</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/29653628" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">29653628</a>.</span></div></li><li id="13" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Padala SA, Barsouk A, Thandra KC, Saginala K, Mohammed A, Vakiti A, Rawla P, Barsouk A (June 2020). <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7239575" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Epidemiology of Renal Cell Carcinoma&quot;</a>. <em>World Journal of Oncology</em>. <strong>11</strong> (3): 79â€“87. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.14740%2Fwjon1279" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.14740/wjon1279</a>. <span class="inline text-[1em] leading-7">ISSN</span> <a href="https://search.worldcat.org/issn/1920-4531" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">1920-4531</a>. <span class="inline text-[1em] leading-7">PMC</span> <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7239575" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">7239575</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/32494314" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">32494314</a>.</span></div></li><li id="14" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Pascual D, Borque A (2008-11-04). <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2581742" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Epidemiology of Kidney Cancer&quot;</a>. <em>Advances in Urology</em>. <strong>2008</strong> : e782381. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1155%2F2008%2F782381" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1155/2008/782381</a>. <span class="inline text-[1em] leading-7">ISSN</span> <a href="https://search.worldcat.org/issn/1687-6369" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">1687-6369</a>. <span class="inline text-[1em] leading-7">PMC</span> <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2581742" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">2581742</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/19009036" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">19009036</a>.</span></div></li><li id="15" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Campbell SC, Lane BR (2012). &quot;Malignant Renal Tumors&quot;. In Wein AJ, Kavoussi LR (eds.). <em>Campbell-Walsh Urology</em>. Elselvier. <span class="inline text-[1em] leading-7">ISBN</span> 978-1455775675.</span></div></li><li id="18" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Palapattu GS, Kristo B, Rajfer J (2002). <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1475999" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Paraneoplastic syndromes in urologic malignancy: the many faces of renal cell carcinoma&quot;</a>. <em>Reviews in Urology</em>. <strong>4</strong> (4): 163â€“170. <span class="inline text-[1em] leading-7">ISSN</span> <a href="https://search.worldcat.org/issn/1523-6161" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">1523-6161</a>. <span class="inline text-[1em] leading-7">PMC</span> <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1475999" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">1475999</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/16985675" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">16985675</a>.</span></div></li><li id="19" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Ljungberg B, Albiges L, Abu-Ghanem Y, Bensalah K, Dabestani S, FernÃ¡ndez-Pello S, Giles RH, Hofmann F, Hora M, Kuczyk MA, Kuusk T, Lam TB, Marconi L, Merseburger AS, Powles T (2019-05-01). <a href="https://linkinghub.elsevier.com/retrieve/pii/S0302283819301526" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;European Association of Urology Guidelines on Renal Cell Carcinoma: The 2019 Update&quot;</a>. <em>European Urology</em>. <strong>75</strong> (5): 799â€“810. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1016%2Fj.eururo.2019.02.011" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1016/j.eururo.2019.02.011</a>. <span class="inline text-[1em] leading-7">ISSN</span> <a href="https://search.worldcat.org/issn/0302-2838" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">0302-2838</a>.</span></div></li><li id="20" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Tahbaz R, Schmid M, Merseburger AS (2018). &quot;Prevention of kidney cancer incidence and recurrence: lifestyle, medication and nutrition&quot;. <em>Current Opinion in Urology</em>. <strong>28</strong> (1): 62â€“79. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1097%2FMOU.0000000000000454" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1097/MOU.0000000000000454</a>. <span class="inline text-[1em] leading-7">ISSN</span> <a href="https://search.worldcat.org/issn/1473-6586" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">1473-6586</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/29059103" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">29059103</a>. <span class="inline text-[1em] leading-7">S2CID</span> <a href="https://api.semanticscholar.org/CorpusID:25998957" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">25998957</a>.</span></div></li><li id="21" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.cancer.net/cancer-types/kidney-cancer/risk-factors-and-prevention" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Kidney Cancer - Risk Factors and Prevention&quot;</a>. <em>Cancer.Net</em>. 2012-06-25. <a href="https://web.archive.org/web/20191202230918/https://www.cancer.net/cancer-types/kidney-cancer/risk-factors-and-prevention" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">Archived</a> from the original on 2019-12-02. Retrieved 2019-12-02.</span></div></li><li id="22" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Cheungpasitporn W, Thongprayoon C, O&#x27;Corragain OA, Edmonds PJ, Ungprasert P, Kittanamongkolchai W, Erickson SB (9 September 2014). <a href="https://doi.org/10.1093%2Fqjmed%2Fhcu195" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;The Risk of Kidney Cancer in Patients with Kidney Stones: A Systematic Review and Meta-analysis&quot;</a>. <em>QJM</em>. <strong>108</strong> (3): 205â€“12. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1093%2Fqjmed%2Fhcu195" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1093/qjmed/hcu195</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/25208892" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">25208892</a>.</span></div></li><li id="23" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="http://cancerhelp.cancerresearchuk.org/type/kidney-cancer/about/risks-and-causes-of-kidney-cancer" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Risks and causes of kidney cancer&quot;</a>. 2017-08-30. <a href="https://web.archive.org/web/20111027201549/http://cancerhelp.cancerresearchuk.org/type/kidney-cancer/about/risks-and-causes-of-kidney-cancer" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">Archived</a> from the original on 2011-10-27. Retrieved 2011-11-30.</span></div></li><li id="24" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Hunt JD, van der Hel OL, McMillan GP, Boffetta P, Brennan P (2005-03-10). <a href="https://doi.org/10.1002%2Fijc.20618" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Renal cell carcinoma in relation to cigarette smoking: meta-analysis of 24 studies&quot;</a>. <em>International Journal of Cancer</em>. <strong>114</strong> (1): 101â€“108. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1002%2Fijc.20618" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1002/ijc.20618</a>. <span class="inline text-[1em] leading-7">ISSN</span> <a href="https://search.worldcat.org/issn/0020-7136" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">0020-7136</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/15523697" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">15523697</a>. <span class="inline text-[1em] leading-7">S2CID</span> <a href="https://api.semanticscholar.org/CorpusID:10136386" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10136386</a>.</span></div></li><li id="25" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">SÃ¡nchez-MartÃ­n FM, MillÃ¡n-RodrÃ­guez F, Urdaneta-Pignalosa G, Rubio-Briones J, Villavicencio-Mavrich H (2008). <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2629071" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Small Renal Masses: Incidental Diagnosis, Clinical Symptoms, and Prognostic Factors&quot;</a>. <em>Advances in Urology</em>. <strong>2008</strong> : 310694. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1155%2F2008%2F310694" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1155/2008/310694</a>. <span class="inline text-[1em] leading-7">ISSN</span> <a href="https://search.worldcat.org/issn/1687-6369" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">1687-6369</a>. <span class="inline text-[1em] leading-7">PMC</span> <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2629071" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">2629071</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/19165347" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">19165347</a>.</span></div></li><li id="26" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Motzer RJ, Jonasch E, Agarwal N, Bhayani S, Bro WP, Chang SS, <span class="inline text-[1em] leading-7">Toni Choueiri</span>, Costello BA, Derweesh IH, Fishman M, Gallagher TH (2017-06-01). <a href="https://jnccn.org/view/journals/jnccn/15/6/article-p804.xml" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Kidney Cancer, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology&quot;</a>. <em>Journal of the National Comprehensive Cancer Network</em>. <strong>15</strong> (6): 804â€“834. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.6004%2Fjnccn.2017.0100" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.6004/jnccn.2017.0100</a>. <span class="inline text-[1em] leading-7">ISSN</span> <a href="https://search.worldcat.org/issn/1540-1405" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">1540-1405</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/28596261" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">28596261</a>. <a href="https://web.archive.org/web/20191029185620/https://jnccn.org/view/journals/jnccn/15/6/article-p804.xml" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">Archived</a> from the original on 2019-10-29. Retrieved 2019-10-29.</span></div></li><li id="28" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://web.archive.org/web/20191112221544/https://www.lexico.com/en/definition/cancer" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Cancer | Definition of Cancer by Lexico&quot;</a>. <em>Lexico Dictionaries | English</em>. Archived from <a href="https://www.lexico.com/en/definition/cancer" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">the original</a> on November 12, 2019. Retrieved 2019-11-12.</span></div></li><li id="29" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Israel GM, Bosniak MA (2005). &quot;How I Do It: Evaluating Renal Masses&quot;. <em>Radiology</em>. <strong>236</strong> (2): 441â€“450. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1148%2Fradiol.2362040218" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1148/radiol.2362040218</a>. <span class="inline text-[1em] leading-7">ISSN</span> <a href="https://search.worldcat.org/issn/0033-8419" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">0033-8419</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/16040900" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">16040900</a>. <span class="inline text-[1em] leading-7">S2CID</span> <a href="https://api.semanticscholar.org/CorpusID:1916092" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">1916092</a>.</span></div></li><li id="30" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://radathand.com/radiology-calculators/body-imaging/bosniak-classification-of-renal-cyst-cystic-mass-ct-mri/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Bosniak Calculator For Renal Cystic Masses 2019 (CT/MRI) - Rad At Hand&quot;</a>. <em>radathand.com</em>. 2025-06-22. Retrieved 2025-07-03.</span></div></li><li id="31" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Silverman SG, Pedrosa I, Ellis JH, Hindman NM, Schieda N, Smith AD, Remer EM, Shinagare AB, Curci NE, Raman SS, Wells SA (2019-06-18). <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6677285" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Bosniak Classification of Cystic Renal Masses, Version 2019: An Update Proposal and Needs Assessment&quot;</a>. <em>Radiology</em>. <strong>292</strong> (2): 475â€“488. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1148%2Fradiol.2019182646" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1148/radiol.2019182646</a>. <span class="inline text-[1em] leading-7">ISSN</span> <a href="https://search.worldcat.org/issn/0033-8419" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">0033-8419</a>. <span class="inline text-[1em] leading-7">PMC</span> <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6677285" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">6677285</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/31210616" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">31210616</a>.</span></div></li><li id="32" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://web.archive.org/web/20200215171032/https://www.auanet.org/guidelines/renal-cancer-renal-mass-and-localized-renal-cancer-guideline#x7068" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Renal Cancer: Renal Mass &amp; Localized Renal Cancer Guideline - American Urological Association&quot;</a>. <em><a href="http://www.auanet.org" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">www.auanet.org</a></em>. Archived from <a href="https://www.auanet.org/guidelines/renal-cancer-renal-mass-and-localized-renal-cancer-guideline#x7068" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">the original</a> on 2020-02-15. Retrieved 2019-10-29.</span></div></li><li id="33" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Motzer RJ, Jonasch E, Agarwal N, Bhayani S, Bro WP, Chang SS, Choueiri TK, Costello BA, Derweesh IH, Fishman M, Gallagher TH (2017-06-01). <a href="https://jnccn.org/view/journals/jnccn/15/6/article-p804.xml" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Kidney Cancer, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology&quot;</a>. <em>Journal of the National Comprehensive Cancer Network</em>. <strong>15</strong> (6): 804â€“834. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.6004%2Fjnccn.2017.0100" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.6004/jnccn.2017.0100</a>. <span class="inline text-[1em] leading-7">ISSN</span> <a href="https://search.worldcat.org/issn/1540-1405" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">1540-1405</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/28596261" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">28596261</a>. <a href="https://web.archive.org/web/20191029185620/https://jnccn.org/view/journals/jnccn/15/6/article-p804.xml" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">Archived</a> from the original on 2019-10-29. Retrieved 2019-10-29.</span></div></li><li id="34" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Subramaniam RM, Wilson RF, Turban S, Suarez-Cuervo C, Zhang A, Sherrod C, Aboagye J, Eng J, Choi MJ (2016). <a href="https://www.ncbi.nlm.nih.gov/books/NBK343725/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300"><em>Contrast-Induced Nephropathy: Comparative Effectiveness of Preventive Measures</em></a>. AHRQ Comparative Effectiveness Reviews. Rockville (MD): Agency for Healthcare Research and Quality (US). <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/26866209" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">26866209</a>. <a href="https://web.archive.org/web/20210828135130/https://www.ncbi.nlm.nih.gov/books/NBK343725/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">Archived</a> from the original on 2021-08-28. Retrieved 2019-10-29.</span></div></li><li id="35" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.cdc.gov/cancer/kidney/index.htm" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Kidney Cancer | CDC&quot;</a>. <em><a href="http://www.cdc.gov" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">www.cdc.gov</a></em>. 2019-07-09. <a href="https://web.archive.org/web/20191112221544/https://www.cdc.gov/cancer/kidney/index.htm" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">Archived</a> from the original on 2019-11-12. Retrieved 2019-11-12.</span></div></li><li id="36" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.cancer.gov/types/kidney/patient/kidney-treatment-pdq" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Renal Cell Cancer Treatment (PDQÂ®)â€“Patient Version&quot;</a>. <em>National Cancer Institute</em>. 2004-02-20. <a href="https://web.archive.org/web/20190410020031/https://www.cancer.gov/types/kidney/patient/kidney-treatment-pdq" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">Archived</a> from the original on 2019-04-10. Retrieved 2019-11-12.</span></div></li><li id="37" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.cancer.gov/types/kidney/patient/transitional-cell-treatment-pdq" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Transitional Cell Cancer of the Renal Pelvis and Ureter Treatment (PDQÂ®)â€“Patient Version&quot;</a>. <em>National Cancer Institute</em>. 2004-02-20. <a href="https://web.archive.org/web/20190608225352/https://www.cancer.gov/types/kidney/patient/transitional-cell-treatment-pdq" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">Archived</a> from the original on 2019-06-08. Retrieved 2019-11-12.</span></div></li><li id="38" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Kuroda N, Katto K, Tamura M, Shiotsu T, Hes O, Michal M, Nagashima Y, Ohara M, Hirouchi T, Mizuno K, Hayashi Y, Lee GH (January 2008). &quot;Carcinoid tumor of the renal pelvis: consideration on the histogenesis&quot;. <em>Pathol. Int</em>. <strong>58</strong> (1): 51â€“54. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1111%2Fj.1440-1827.2007.02188.x" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1111/j.1440-1827.2007.02188.x</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/18067641" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">18067641</a>. <span class="inline text-[1em] leading-7">S2CID</span> <a href="https://api.semanticscholar.org/CorpusID:27645211" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">27645211</a>.</span></div></li><li id="39" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Chiu KC, Lin MC, Liang YC, Chen CY (2008). <a href="https://doi.org/10.1080%2F08860220802403192" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Renal carcinosarcoma: case report and review of literature&quot;</a>. <em>Renal Failure</em>. <strong>30</strong> (10): 1034â€“9. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1080%2F08860220802403192" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1080/08860220802403192</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/19016157" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">19016157</a>.</span></div></li><li id="43" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Mantilla JG, Antic T, Tretiakova M (2017). &quot;GATA3 as a valuable marker to distinguish clear cell papillary renal cell carcinomas from morphologic mimics&quot;. <em>Hum Pathol</em>. <strong>66</strong> : 152â€“158. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1016%2Fj.humpath.2017.06.016" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1016/j.humpath.2017.06.016</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/28705707" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">28705707</a>.<code class="text-fg-solar bg-fg-solar-opaque break-all rounded px-2 align-middle font-mono text-sm" node="[object Object]">{{cite journal}}</code>: CS1 maint: multiple names: authors list (link)</span></div></li><li id="44" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Behtash G. Nezami, M.D., Gregory MacLennan, M.D. <a href="https://www.pathologyoutlines.com/topic/kidneytumormalignantrccclear.html" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Kidney tumor - Adult renal cell carcinoma - common - Clear cell&quot;</a>. <em>Pathology Outlines</em>. <a href="https://web.archive.org/web/20211018181509/https://www.pathologyoutlines.com/topic/kidneytumormalignantrccclear.html" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">Archived</a> from the original on 2021-10-18. Retrieved 2021-10-18.<code class="text-fg-solar bg-fg-solar-opaque break-all rounded px-2 align-middle font-mono text-sm" node="[object Object]">{{cite web}}</code>: CS1 maint: multiple names: authors list (link) Topic Completed: 20 April 2021. Minor changes: 20 April 2021</span></div></li><li id="45" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Motzer RJ, Jonasch E, Agarwal N, Bhayani S, Bro WP, Chang SS, Choueiri TK, Costello BA, Derweesh IH, Fishman M, Gallagher TH (2017-06-01). <a href="https://jnccn.org/view/journals/jnccn/15/6/article-p804.xml" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Kidney Cancer, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology&quot;</a>. <em>Journal of the National Comprehensive Cancer Network</em>. <strong>15</strong> (6): 804â€“834. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.6004%2Fjnccn.2017.0100" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.6004/jnccn.2017.0100</a>. <span class="inline text-[1em] leading-7">ISSN</span> <a href="https://search.worldcat.org/issn/1540-1405" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">1540-1405</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/28596261" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">28596261</a>. <a href="https://web.archive.org/web/20191029185620/https://jnccn.org/view/journals/jnccn/15/6/article-p804.xml" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">Archived</a> from the original on 2019-10-29. Retrieved 2019-10-29.</span></div></li><li id="46" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Patel HD, Johnson MH, Pierorazio PM, Sozio SM, Sharma R, Iyoha E, Bass EB, Allaf ME (May 2016). <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5609078" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Diagnostic Accuracy and Risks of Biopsy in the Diagnosis of a Renal Mass Suspicious for Localized Renal Cell Carcinoma: Systematic Review of the Literature&quot;</a>. <em>The Journal of Urology</em>. <strong>195</strong> (5): 1340â€“1347. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1016%2Fj.juro.2015.11.029" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1016/j.juro.2015.11.029</a>. <span class="inline text-[1em] leading-7">ISSN</span> <a href="https://search.worldcat.org/issn/1527-3792" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">1527-3792</a>. <span class="inline text-[1em] leading-7">PMC</span> <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5609078" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">5609078</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/26901507" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">26901507</a>.</span></div></li><li id="47" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.cancer.org/cancer/kidney-cancer/detection-diagnosis-staging/staging.html" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Kidney Cancer Stages | Renal Cell Carcinoma Staging&quot;</a>. <em><a href="http://www.cancer.org" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">www.cancer.org</a></em>. <a href="https://web.archive.org/web/20190727155332/https://www.cancer.org/cancer/kidney-cancer/detection-diagnosis-staging/staging.html" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">Archived</a> from the original on 2019-07-27. Retrieved 2019-11-12.</span></div></li><li id="48" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><em>AJCC cancer staging manual</em>. Edge, Stephen B., American Joint Committee on Cancer. (7th ed.). New York: Springer. 2010. <span class="inline text-[1em] leading-7">ISBN</span> 9780387884400. <span class="inline text-[1em] leading-7">OCLC</span> <a href="https://search.worldcat.org/oclc/316431417" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">316431417</a>.<code class="text-fg-solar bg-fg-solar-opaque break-all rounded px-2 align-middle font-mono text-sm" node="[object Object]">{{cite book}}</code>: CS1 maint: others (link)</span></div></li><li id="49" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.cancer.org/cancer/kidney-cancer/detection-diagnosis-staging/staging.html" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Kidney Cancer Stages&quot;</a>. <em>cancer.org</em>. <a href="https://web.archive.org/web/20190727155332/https://www.cancer.org/cancer/kidney-cancer/detection-diagnosis-staging/staging.html" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">Archived</a> from the original on 2019-07-27. Retrieved 2019-11-12. Last Revised: February 1, 2020</span></div></li><li id="50" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Swami U, Nussenzveig RH, Haaland B, Agarwal N (2019). <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6462602" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Revisiting AJCC TNM staging for renal cell carcinoma: quest for improvement&quot;</a>. <em>Annals of Translational Medicine</em>. <strong>7</strong> (S1): S18. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.21037%2Fatm.2019.01.50" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.21037/atm.2019.01.50</a>. <span class="inline text-[1em] leading-7">ISSN</span> <a href="https://search.worldcat.org/issn/2305-5839" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">2305-5839</a>. <span class="inline text-[1em] leading-7">PMC</span> <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6462602" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">6462602</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/31032299" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">31032299</a>.</span></div></li><li id="51" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://web.archive.org/web/20170222223224/https://old.cancer.org/acs/groups/cid/documents/webcontent/003107-pdf.pdf" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Kidney Cancer (Adult) â€“ Renal Cell Carcinoma&quot;</a> (PDF). <em><span class="inline text-[1em] leading-7">American Cancer Society</span></em>. Archived from <a href="https://old.cancer.org/acs/groups/cid/documents/webcontent/003107-pdf.pdf" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">the original</a> (PDF) on 2017-02-22. Last Revised: May 16, 2016</span></div></li><li id="52" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="http://cancerhelp.cancerresearchuk.org/type/kidney-cancer/treatment/types/early-stage-kidney-cancer#surgery" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Early stage and locally advanced kidney cancer treatment&quot;</a>. 2017-08-30. <a href="https://web.archive.org/web/20121010071247/http://cancerhelp.cancerresearchuk.org/type/kidney-cancer/treatment/types/early-stage-kidney-cancer#surgery" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">Archived</a> from the original on 2012-10-10. Retrieved 2011-11-30.</span></div></li><li id="53" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="http://cancerhelp.cancerresearchuk.org/type/kidney-cancer/treatment/types/advanced-kidney-cancer#other" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Advanced kidney cancer&quot;</a>. 2017-08-30. <a href="https://web.archive.org/web/20121010121828/http://cancerhelp.cancerresearchuk.org/type/kidney-cancer/treatment/types/advanced-kidney-cancer#other" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">Archived</a> from the original on 2012-10-10. Retrieved 2011-11-30.</span></div></li><li id="55" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="http://hemonc.org/Renal_cancer" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Renal cell carcinoma | HemOnc.org - A Hematology Oncology Wiki&quot;</a>. <em>hemonc.org</em>. <a href="https://web.archive.org/web/20160828122702/http://hemonc.org/Renal_cancer" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">Archived</a> from the original on 2016-08-28. Retrieved 2012-05-08.</span></div></li><li id="56" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="http://www.nccn.org/professionals/physician_gls/pdf/kidney.pdf" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;National Comprehensive Cancer Network&quot;</a> (PDF). <a href="https://web.archive.org/web/20090306103023/http://www.nccn.org/professionals/physician_gls/PDF/kidney.pdf" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">Archived</a> (PDF) from the original on 2009-03-06. Retrieved 2012-05-08.</span></div></li><li id="57" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="http://cancerhelp.cancerresearchuk.org/type/kidney-cancer/treatment/biological/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Biological therapy for kidney cancer&quot;</a>. 2017-08-30. <a href="https://web.archive.org/web/20111128083012/http://cancerhelp.cancerresearchuk.org/type/kidney-cancer/treatment/biological/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">Archived</a> from the original on 2011-11-28. Retrieved 2011-11-30.</span></div></li><li id="60" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://web.archive.org/web/20180125101444/https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm473971.htm" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;FDA approves Opdivo to treat advanced form of kidney cancer&quot;</a>. <em><span class="inline text-[1em] leading-7">Food and Drug Administration</span></em>. Archived from <a href="https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm473971.htm" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">the original</a> on 2018-01-25. Retrieved 2019-12-16.</span></div></li><li id="61" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Philips GK, Atkins MB (2014). <a href="https://doi.org/10.14694%2FEdBook_AM.2014.34.e222" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;New agents and new targets for renal cell carcinoma&quot;</a>. <em>American Society of Clinical Oncology Educational Book / ASCO. American Society of Clinical Oncology. Meeting</em>. <strong>34</strong> (34): e222-7. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.14694%2FEdBook_AM.2014.34.e222" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.14694/EdBook_AM.2014.34.e222</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/24857106" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">24857106</a>.</span></div></li><li id="66" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://web.archive.org/web/20120406063913/http://cancerhelp.cancerresearchuk.org/about-cancer/cancer-questions/wilms-tumour" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Wilms&#x27; tumour (kidney cancer in children)&quot;</a>. 2017-08-30. Archived from <a href="http://cancerhelp.cancerresearchuk.org/about-cancer/cancer-questions/wilms-tumour" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">the original</a> on 2012-04-06.</span></div></li></ol></div><div class="text-fg-secondary text-xs [&amp;_*]:mb-2"><hr class="border-border-l1 my-8 rounded-sm border-t"/>
<span class="mb-4 block break-words text-[1em] leading-7">The content is adapted from <a href="https://en.wikipedia.org/wiki/Kidney_cancer" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">Wikipedia</a>, licensed under Creative Commons Attribution-ShareAlike 4.0 License.</span></div></div></div><div class="hidden min-[1400px]:block"></div></div></div><!--$--><!--/$--><div role="region" aria-label="Notifications (F8)" tabindex="-1" style="pointer-events:none"><ol tabindex="-1" class="pointer-events-none fixed top-0 z-[100] flex max-h-screen w-full flex-col-reverse p-4 max-sm:left-0 sm:bottom-0 sm:right-0 sm:top-auto sm:max-w-[420px] sm:flex-col pl-16 pr-2 pt-16 sm:px-4"></ol></div><script type="application/json" id="server-client-data-experimentation">{"status":"uninitialized"}</script><script src="/_next/static/chunks/webpack-e121ed42680f327e.js" nonce="ZDI3MzMxYzUtYzY2YS00M2M3LThmMmMtODg3ZDMzYTJjZmMw" id="_R_" async=""></script><script nonce="ZDI3MzMxYzUtYzY2YS00M2M3LThmMmMtODg3ZDMzYTJjZmMw">(self.__next_f=self.__next_f||[]).push([0])</script><script nonce="ZDI3MzMxYzUtYzY2YS00M2M3LThmMmMtODg3ZDMzYTJjZmMw">self.__next_f.push([1,"1:\"$Sreact.fragment\"\n3:I[91363,[],\"\"]\n4:I[23775,[],\"\"]\n5:I[57654,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"7618\",\"static/chunks/7618-43536a8fb0dd3bfe.js\",\"3699\",\"static/chunks/app/page/%5Bslug%5D/layout-55a344716dd57c44.js\"],\"PageHeaderProvider\"]\n6:I[17618,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"7618\",\"static/chunks/7618-43536a8fb0dd3bfe.js\",\"3699\",\"static/chunks/app/page/%5Bslug%5D/layout-55a344716dd57c44.js\"],\"HeaderContent\"]\n7:I[25529,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"7720\",\"static/chunks/7720-3a1e7e411adba2d3.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"7618\",\"static/chunks/7618-43536a8fb0dd3bfe.js\",\"6751\",\"static/chunks/app/page/%5Bslug%5D/not-found-69a3edc7db5749d6.js\"],\"default\"]\n9:I[6666,[],\"OutletBoundary\"]\nb:I[80415,[],\"AsyncMetadataOutlet\"]\nd:I[6666,[],\"ViewportBoundary\"]\nf:I[6666,[],\"MetadataBoundary\"]\n10:\"$Sreact.suspense\"\n12:I[95909,[\"4219\",\"static/chunks/app/global-error-4d07d20223cd4b4c.js\"],\"default\"]\n"])</script><script nonce="ZDI3MzMxYzUtYzY2YS00M2M3LThmMmMtODg3ZDMzYTJjZmMw">self.__next_f.push([1,"13:I[51498,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"ConstantsProvider\"]\n"])</script><script nonce="ZDI3MzMxYzUtYzY2YS00M2M3LThmMmMtODg3ZDMzYTJjZmMw">self.__next_f.push([1,"14:I[91073,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"default\"]\n"])</script><script nonce="ZDI3MzMxYzUtYzY2YS00M2M3LThmMmMtODg3ZDMzYTJjZmMw">self.__next_f.push([1,"15:I[38642,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"default\"]\n"])</script><script nonce="ZDI3MzMxYzUtYzY2YS00M2M3LThmMmMtODg3ZDMzYTJjZmMw">self.__next_f.push([1,"16:I[99648,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"4684\",\"static/chunks/24cf1b50-159cca90b09285e0.js\",\"1829\",\"static/chunks/9ffa21ba-c069766d809bd4c7.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"7720\",\"static/chunks/7720-3a1e7e411adba2d3.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"600\",\"static/chunks/600-9a9fcafaaa6c1c4c.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"5448\",\"static/chunks/5448-2a3cfd853d899c9a.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"8\",\"static/chunks/8-8ca70ca619d8e099.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"6304\",\"static/chunks/app/page/%5Bslug%5D/page-540a27b6839afde5.js\"],\"default\"]\n"])</script><script nonce="ZDI3MzMxYzUtYzY2YS00M2M3LThmMmMtODg3ZDMzYTJjZmMw">self.__next_f.push([1,"17:I[78825,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"default\"]\n"])</script><script nonce="ZDI3MzMxYzUtYzY2YS00M2M3LThmMmMtODg3ZDMzYTJjZmMw">self.__next_f.push([1,"18:I[8550,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"MixpanelProvider\"]\n"])</script><script nonce="ZDI3MzMxYzUtYzY2YS00M2M3LThmMmMtODg3ZDMzYTJjZmMw">self.__next_f.push([1,"19:I[12290,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"MobileTocProvider\"]\n"])</script><script nonce="ZDI3MzMxYzUtYzY2YS00M2M3LThmMmMtODg3ZDMzYTJjZmMw">self.__next_f.push([1,"1a:I[53947,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"NuqsAdapter\"]\n"])</script><script nonce="ZDI3MzMxYzUtYzY2YS00M2M3LThmMmMtODg3ZDMzYTJjZmMw">self.__next_f.push([1,"1b:I[91873,[\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"8039\",\"static/chunks/app/error-4a29e9399afba038.js\"],\"default\"]\n1c:I[5091,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"7720\",\"static/chunks/7720-3a1e7e411adba2d3.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"7618\",\"static/chunks/7618-43536a8fb0dd3bfe.js\",\"4345\",\"static/chunks/app/not-found-dd95690acf732f18.js\"],\"default\"]\n"])</script><script nonce="ZDI3MzMxYzUtYzY2YS00M2M3LThmMmMtODg3ZDMzYTJjZmMw">self.__next_f.push([1,"1d:I[16091,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"default\"]\n"])</script><script nonce="ZDI3MzMxYzUtYzY2YS00M2M3LThmMmMtODg3ZDMzYTJjZmMw">self.__next_f.push([1,":HL[\"/_next/static/media/1f2316909698f815.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"ZDI3MzMxYzUtYzY2YS00M2M3LThmMmMtODg3ZDMzYTJjZmMw\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/media/3d4419af2cf8609b.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"ZDI3MzMxYzUtYzY2YS00M2M3LThmMmMtODg3ZDMzYTJjZmMw\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/media/4dec29efcaeb336c.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"ZDI3MzMxYzUtYzY2YS00M2M3LThmMmMtODg3ZDMzYTJjZmMw\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/media/74452ea3ef0f9101.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"ZDI3MzMxYzUtYzY2YS00M2M3LThmMmMtODg3ZDMzYTJjZmMw\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/media/904ef0a86fe32a00.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"ZDI3MzMxYzUtYzY2YS00M2M3LThmMmMtODg3ZDMzYTJjZmMw\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/media/d886a03bcda7ad8f.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"ZDI3MzMxYzUtYzY2YS00M2M3LThmMmMtODg3ZDMzYTJjZmMw\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/media/e1447589d6f59c4b.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"ZDI3MzMxYzUtYzY2YS00M2M3LThmMmMtODg3ZDMzYTJjZmMw\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/media/f5a90156f8995c8c.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"ZDI3MzMxYzUtYzY2YS00M2M3LThmMmMtODg3ZDMzYTJjZmMw\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/css/62c4caba71dfda84.css\",\"style\",{\"nonce\":\"ZDI3MzMxYzUtYzY2YS00M2M3LThmMmMtODg3ZDMzYTJjZmMw\"}]\n:HL[\"/_next/static/css/eb3d87f98fe1565f.css\",\"style\",{\"nonce\":\"ZDI3MzMxYzUtYzY2YS00M2M3LThmMmMtODg3ZDMzYTJjZmMw\"}]\n:HL[\"/_next/static/css/1b5e561215938d4d.css\",\"style\",{\"nonce\":\"ZDI3MzMxYzUtYzY2YS00M2M3LThmMmMtODg3ZDMzYTJjZmMw\"}]\n:HL[\"/_next/static/css/0227d069a630d414.css\",\"style\",{\"nonce\":\"ZDI3MzMxYzUtYzY2YS00M2M3LThmMmMtODg3ZDMzYTJjZmMw\"}]\n:HL[\"/_next/static/css/f87fff2ab93d05a7.css\",\"style\",{\"nonce\":\"ZDI3MzMxYzUtYzY2YS00M2M3LThmMmMtODg3ZDMzYTJjZmMw\"}]\n"])</script><script nonce="ZDI3MzMxYzUtYzY2YS00M2M3LThmMmMtODg3ZDMzYTJjZmMw">self.__next_f.push([1,"0:{\"P\":null,\"b\":\"BpM29AX4fmgcUxZ_6t0le\",\"p\":\"\",\"c\":[\"\",\"page\",\"Kidney_cancer\"],\"i\":false,\"f\":[[[\"\",{\"children\":[\"page\",{\"children\":[[\"slug\",\"Kidney_cancer\",\"d\"],{\"children\":[\"__PAGE__\",{}]}]}]},\"$undefined\",\"$undefined\",true],[\"\",[\"$\",\"$1\",\"c\",{\"children\":[[[\"$\",\"link\",\"0\",{\"rel\":\"stylesheet\",\"href\":\"/_next/static/css/62c4caba71dfda84.css\",\"precedence\":\"next\",\"crossOrigin\":\"$undefined\",\"nonce\":\"ZDI3MzMxYzUtYzY2YS00M2M3LThmMmMtODg3ZDMzYTJjZmMw\"}],[\"$\",\"link\",\"1\",{\"rel\":\"stylesheet\",\"href\":\"/_next/static/css/eb3d87f98fe1565f.css\",\"precedence\":\"next\",\"crossOrigin\":\"$undefined\",\"nonce\":\"ZDI3MzMxYzUtYzY2YS00M2M3LThmMmMtODg3ZDMzYTJjZmMw\"}],[\"$\",\"link\",\"2\",{\"rel\":\"stylesheet\",\"href\":\"/_next/static/css/1b5e561215938d4d.css\",\"precedence\":\"next\",\"crossOrigin\":\"$undefined\",\"nonce\":\"ZDI3MzMxYzUtYzY2YS00M2M3LThmMmMtODg3ZDMzYTJjZmMw\"}],[\"$\",\"link\",\"3\",{\"rel\":\"stylesheet\",\"href\":\"/_next/static/css/0227d069a630d414.css\",\"precedence\":\"next\",\"crossOrigin\":\"$undefined\",\"nonce\":\"ZDI3MzMxYzUtYzY2YS00M2M3LThmMmMtODg3ZDMzYTJjZmMw\"}]],\"$L2\"]}],{\"children\":[\"page\",[\"$\",\"$1\",\"c\",{\"children\":[null,[\"$\",\"$L3\",null,{\"parallelRouterKey\":\"children\",\"error\":\"$undefined\",\"errorStyles\":\"$undefined\",\"errorScripts\":\"$undefined\",\"template\":[\"$\",\"$L4\",null,{}],\"templateStyles\":\"$undefined\",\"templateScripts\":\"$undefined\",\"notFound\":\"$undefined\",\"forbidden\":\"$undefined\",\"unauthorized\":\"$undefined\"}]]}],{\"children\":[[\"slug\",\"Kidney_cancer\",\"d\"],[\"$\",\"$1\",\"c\",{\"children\":[null,[\"$\",\"$L5\",null,{\"children\":[[\"$\",\"$L6\",null,{\"maxWidth\":\"full\",\"mobileOptions\":{\"right\":{\"showFixedIssues\":true,\"showThemeSwitcher\":true,\"showSearch\":true,\"showTableOfContents\":true}}}],[\"$\",\"$L3\",null,{\"parallelRouterKey\":\"children\",\"error\":\"$undefined\",\"errorStyles\":\"$undefined\",\"errorScripts\":\"$undefined\",\"template\":[\"$\",\"$L4\",null,{}],\"templateStyles\":\"$undefined\",\"templateScripts\":\"$undefined\",\"notFound\":[[\"$\",\"$L7\",null,{}],[]],\"forbidden\":\"$undefined\",\"unauthorized\":\"$undefined\"}]]}]]}],{\"children\":[\"__PAGE__\",[\"$\",\"$1\",\"c\",{\"children\":[\"$L8\",[[\"$\",\"link\",\"0\",{\"rel\":\"stylesheet\",\"href\":\"/_next/static/css/f87fff2ab93d05a7.css\",\"precedence\":\"next\",\"crossOrigin\":\"$undefined\",\"nonce\":\"ZDI3MzMxYzUtYzY2YS00M2M3LThmMmMtODg3ZDMzYTJjZmMw\"}]],[\"$\",\"$L9\",null,{\"children\":[\"$La\",[\"$\",\"$Lb\",null,{\"promise\":\"$@c\"}]]}]]}],{},null,false]},null,false]},null,false]},null,false],[\"$\",\"$1\",\"h\",{\"children\":[null,[[\"$\",\"$Ld\",null,{\"children\":\"$Le\"}],[\"$\",\"meta\",null,{\"name\":\"next-size-adjust\",\"content\":\"\"}]],[\"$\",\"$Lf\",null,{\"children\":[\"$\",\"div\",null,{\"hidden\":true,\"children\":[\"$\",\"$10\",null,{\"fallback\":null,\"children\":\"$L11\"}]}]}]]}],false]],\"m\":\"$undefined\",\"G\":[\"$12\",[]],\"s\":false,\"S\":false}\n"])</script><script nonce="ZDI3MzMxYzUtYzY2YS00M2M3LThmMmMtODg3ZDMzYTJjZmMw">self.__next_f.push([1,"2:[\"$\",\"html\",null,{\"lang\":\"en\",\"className\":\"bg-surface-base antialiased\",\"suppressHydrationWarning\":true,\"children\":[[\"$\",\"head\",null,{\"children\":[[\"$\",\"title\",null,{\"children\":\"Grokipedia\"}],[\"$\",\"meta\",null,{\"name\":\"description\",\"content\":\"Grokipedia is an open source, comprehensive collection of all knowledge.\"}],[\"$\",\"link\",null,{\"rel\":\"icon\",\"type\":\"image/x-icon\",\"href\":\"/favicon.ico\",\"sizes\":\"48x48\"}],[\"$\",\"link\",null,{\"rel\":\"icon\",\"href\":\"/images/icon-dark.png\",\"media\":\"(prefers-color-scheme: light)\",\"type\":\"image/png\"}],[\"$\",\"link\",null,{\"rel\":\"icon\",\"href\":\"/images/icon-light.png\",\"media\":\"(prefers-color-scheme: dark)\",\"type\":\"image/png\"}],[\"$\",\"link\",null,{\"rel\":\"apple-touch-icon\",\"href\":\"/icon-192x192.png\"}],[\"$\",\"link\",null,{\"rel\":\"manifest\",\"href\":\"/manifest.webmanifest\"}],[\"$\",\"meta\",null,{\"name\":\"robots\",\"content\":\"index, follow\"}],[\"$\",\"meta\",null,{\"name\":\"googlebot\",\"content\":\"index, follow, max-snippet:-1\"}],[\"$\",\"meta\",null,{\"property\":\"og:title\",\"content\":\"Grokipedia\"}],[\"$\",\"meta\",null,{\"property\":\"og:description\",\"content\":\"Grokipedia is an open source, comprehensive collection of all knowledge.\"}],[\"$\",\"meta\",null,{\"property\":\"og:url\",\"content\":\"https://grokipedia.com\"}],[\"$\",\"meta\",null,{\"property\":\"og:site_name\",\"content\":\"Grokipedia\"}],[\"$\",\"meta\",null,{\"property\":\"og:locale\",\"content\":\"en_US\"}],[\"$\",\"meta\",null,{\"property\":\"og:type\",\"content\":\"website\"}],[\"$\",\"meta\",null,{\"property\":\"og:image\",\"content\":\"https://grokipedia.com/icon-512x512.png\"}],[\"$\",\"meta\",null,{\"property\":\"og:image:width\",\"content\":\"512\"}],[\"$\",\"meta\",null,{\"property\":\"og:image:height\",\"content\":\"512\"}],[\"$\",\"meta\",null,{\"property\":\"og:image:alt\",\"content\":\"Grokipedia\"}],[\"$\",\"meta\",null,{\"name\":\"twitter:card\",\"content\":\"summary\"}],[\"$\",\"meta\",null,{\"name\":\"twitter:creator\",\"content\":\"@Grokipedia\"}],[\"$\",\"meta\",null,{\"name\":\"twitter:title\",\"content\":\"Grokipedia\"}],[\"$\",\"meta\",null,{\"name\":\"twitter:description\",\"content\":\"Grokipedia is an open source, comprehensive collection of all knowledge.\"}],[\"$\",\"meta\",null,{\"name\":\"twitter:image\",\"content\":\"https://grokipedia.com/icon-512x512.png\"}]]}],[\"$\",\"body\",null,{\"className\":\"flex h-[100svh] w-full flex-col __variable_13c637 __variable_8a0ba0 __variable_779740 __variable_2484fd __variable_525cc3 __variable_13486b\",\"children\":[[\"$\",\"$L13\",null,{\"children\":[\"$\",\"$L14\",null,{\"children\":[\"$\",\"$L15\",null,{\"defaultTheme\":\"dark\",\"nonce\":\"ZDI3MzMxYzUtYzY2YS00M2M3LThmMmMtODg3ZDMzYTJjZmMw\",\"children\":[\"$\",\"$L16\",null,{\"children\":[\"$\",\"$L17\",null,{\"children\":[\"$\",\"$L18\",null,{\"children\":[\"$\",\"$L19\",null,{\"children\":[\"$\",\"$L1a\",null,{\"children\":[[\"$\",\"$L3\",null,{\"parallelRouterKey\":\"children\",\"error\":\"$1b\",\"errorStyles\":[],\"errorScripts\":[],\"template\":[\"$\",\"$L4\",null,{}],\"templateStyles\":\"$undefined\",\"templateScripts\":\"$undefined\",\"notFound\":[[\"$\",\"$L1c\",null,{}],[]],\"forbidden\":\"$undefined\",\"unauthorized\":\"$undefined\"}],[\"$\",\"$L1d\",null,{}]]}]}]}]}]}]}]}]}],[\"$\",\"script\",null,{\"type\":\"application/json\",\"id\":\"server-client-data-experimentation\",\"children\":\"{\\\"status\\\":\\\"uninitialized\\\"}\"}]]}]]}]\n"])</script><script nonce="ZDI3MzMxYzUtYzY2YS00M2M3LThmMmMtODg3ZDMzYTJjZmMw">self.__next_f.push([1,"e:[[\"$\",\"meta\",\"0\",{\"charSet\":\"utf-8\"}],[\"$\",\"meta\",\"1\",{\"name\":\"viewport\",\"content\":\"width=device-width, initial-scale=1, interactive-widget=resizes-content\"}]]\na:null\n"])</script><script nonce="ZDI3MzMxYzUtYzY2YS00M2M3LThmMmMtODg3ZDMzYTJjZmMw">self.__next_f.push([1,"1e:I[42712,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"4684\",\"static/chunks/24cf1b50-159cca90b09285e0.js\",\"1829\",\"static/chunks/9ffa21ba-c069766d809bd4c7.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"7720\",\"static/chunks/7720-3a1e7e411adba2d3.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"600\",\"static/chunks/600-9a9fcafaaa6c1c4c.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"5448\",\"static/chunks/5448-2a3cfd853d899c9a.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"8\",\"static/chunks/8-8ca70ca619d8e099.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"6304\",\"static/chunks/app/page/%5Bslug%5D/page-540a27b6839afde5.js\"],\"HydrationBoundary\"]\n"])</script><script nonce="ZDI3MzMxYzUtYzY2YS00M2M3LThmMmMtODg3ZDMzYTJjZmMw">self.__next_f.push([1,"21:I[6367,[],\"IconMark\"]\n1f:T60ff,"])</script><script nonce="ZDI3MzMxYzUtYzY2YS00M2M3LThmMmMtODg3ZDMzYTJjZmMw">self.__next_f.push([1,"# Kidney cancer\n\n| **Attribute** | **Details** |\n|---------------|-------------|\n| Other names | Renal cancer |\n| Specialty | Oncology, nephrology, urology |\n| Symptoms | Blood in the urine, lump in the abdomen, back pain[1][2][3] |\n| Usual onset | After the age of 45[4] |\n| Types | Renal cell carcinoma (RCC), transitional cell carcinoma (TCC), Wilms tumor[4] |\n| Risk factors | Smoking, certain pain medications, previous bladder cancer, being overweight, high blood pressure, certain chemicals, family history[1][2] |\n| Diagnostic method | Tissue biopsy[1][2][3] |\n| Treatment | Surgery, radiation therapy, chemotherapy, immunotherapy, targeted therapy[1][2][3] |\n| Prognosis | Five-year survival ~78% (US, 2024)[4] |\n| Frequency | 434,800 (2022) |\n| Deaths | 156,000 (2022) |\n\n**Kidney cancer** , also known as **renal cancer** , is a group of cancers that starts in the kidney.[4] Symptoms may include blood in the urine, a lump in the abdomen, or back pain.[1][2][3] Fever, weight loss, and tiredness may also occur.[1][2][3] Complications can include spread to the lungs or brain.[6]\n\nThe main types of kidney cancer are renal cell cancer (RCC), transitional cell cancer (TCC), and Wilms' tumor.[7] RCC makes up approximately 80% of kidney cancers, and TCC accounts for most of the rest.[8] Risk factors for RCC and TCC include smoking, certain pain medications, previous bladder cancer, being overweight, high blood pressure, certain chemicals, and a family history.[1][2] Risk factors for Wilms' tumor include a family history and certain genetic disorders such as WAGR syndrome.[3] Diagnosis may be suspected based on symptoms, urine testing, and medical imaging.[1][2][3] It is confirmed by tissue biopsy.[1][2][3]\n\nTreatment may include surgery, radiation therapy, chemotherapy, immunotherapy, and targeted therapy.[1][2][3] Kidney cancer newly affected about 434,800 people and resulted in 156,000 deaths globally in 2022. Onset is usually after the age of 45.[4] Males are affected more often than females.[4] The overall five-year survival rate is 78% in the United States, 73% in Canada, 70% in China, and 66% in Europe (as of 2024).[11] For cancers that are confined to the kidney, the five-year survival rate is 93%, if it has spread to the surrounding lymph nodes it is 72%, and if it has spread widely, it is 16%. Kidney cancer has been identified as the 14th most common form of cancer,[13] and is responsible for about 2% of the world's cancer cases and 2% of deaths. The incidence of kidney cancer has continued to increase since 1930 and is projected to double by 2050. Renal cancer is more commonly found in populations of urban areas than rural areas.[14]\n# Kidney Cancer Signs and Symptoms\n\n## Signs and symptoms\n\nDue to increased use of abdominal imaging for other conditions, the majority of kidney cancers (over 50%) are now detected incidentally before symptoms develop. Early on, kidney masses do not typically cause any symptoms and are undetectable on physical examination.[15] As kidney cancer becomes more advanced it classically results in blood in the urine, flank or back pain, and a mass.[15] Other symptoms that are consistent with advanced disease include weight loss, fever, night sweats, palpable swollen lymph nodes in the neck, non-reducing varicocele, bone pain, continuous cough, and bilateral lower leg swelling.[15]\n\nThe classic triad of visible blood in the urine (hematuria), flank pain and palpable abdominal mass occurs in approximately 5-10% of the cases. RCC may present with signs and symptoms caused by the substances the cancer cells produce (i.e. paraneoplastic syndromes). \n\nParaneoplastic syndromes caused by kidney cancer can be broadly classified as endocrine and non-endocrine. Endocrine dysfunctions include increase in blood calcium levels (hypercalcemia), high blood pressure (hypertension), increased red blood cells (polycythemia), liver dysfunction, milky nipple discharge unrelated to normal breast-feeding (galactorrhea), and Cushing's syndrome. Non-endocrine dysfunctions include deposition of protein in tissue (amyloidosis), decrease in hemoglobin or red blood cells (anemia), disorders of nerves, muscles (neuromyopathies), blood vessels (vasculopathy) and blood clotting mechanisms (coagulopathy).[18]\n# Kidney Cancer Causes\n\n## Causes\n\nFactors that increase the risk of kidney cancer include smoking, high blood pressure, obesity, inherited genetic conditions, and a family history of kidney cancer in first-degree relatives.[19] Long-term dialysis for advanced kidney disease is also a risk factor.[20][21]\n\nOther possible risk factors, such as kidney stones, are under investigation.[22][23]\n\nApproximately 20% of kidney cancer cases are attributable to smoking.[21] Smokers have a 1.3 times higher risk of developing kidney cancer compared to non-smokers. Moreover, there is a dose-dependent increased risk of cancer development. Men who smoke more than 20 cigarettes per day have twice the risk. Likewise, women who smoke more than 20 cigarettes per day have 1.5 times the risk of non-smokers. After 10 years of smoking cessation, a substantial reduction is seen in the risk of developing kidney cancer.[24]\n\nOther modifiable risk factors include type 2 diabetes and chronic kidney disease. The incidence of kidney cancer is projected to double globally by 2050, largely due to rising obesity rates.\n# Diagnosis\n\nDue to the increase in ultrasound and [CT imaging](CT_scan \"CT scan\") for nonspecific abdominal complaints, kidney masses are frequently incidentally diagnosed on medical imaging.[15][25][26] Approximately 50% (37â€“61%) of renal cell carcinoma (the most common type of kidney cancer) are diagnosed incidentally by abdominal imaging for nonspecific abdominal complaints.\n\nKidney masses can be classified by the nature of the cells in the growth, or by its appearance on [radiography](Radiography \"Radiography\").[15] The term cancer refers to a [malignant tumor](Cancer \"Cancer\"), which is an uncontrolled growth of abnormal cells.[28] However, kidney masses can be due to growth of normal tissue (benign), inflammatory (a reaction of the immune system), or vascular (cells of the blood vessels). \n\n## Medical imaging\n\nSince there is a large differential diagnosis for a kidney tumor, the first step is to characterize the mass with medical imaging to assess its likelihood of being benign or malignant. [Ultrasonography](Medical_ultrasound \"Medical ultrasound\") is sometimes used to evaluate a suspected kidney mass, as it can characterize cystic and solid kidney masses without radiation exposure and at relatively low cost.[15] Radiologically tumors are grouped based on appearance into simple cystic, complex cystic, or solid.[15] The most important differentiating feature of a cancerous and non-cancerous tumor on imaging is enhancement.[29][30] Simple cysts, which are defined by strict criteria[31] are safe to be monitored if the person does not have any symptoms.[15] However, all masses that are not clearly simple cysts should be further evaluated and confirmed by alternate imaging techniques.[32][15]\n\nComputed tomography (CT) of the abdomen administered with and without IV contrast is the ideal imaging to diagnose and determine the stage of kidney cancer.[33][32][15] There is tentative evidence that iodinated contrast agents may cause worsening of kidney function in people with chronic kidney disease (CKD) with a [glomerular filtration rate](Glomerular_filtration_rate \"Glomerular filtration rate\") (GFR) less than 45ml/min/1.73m2 and should therefore be given cautiously to such persons.[34]\n\nAbdominal [magnetic resonance imaging](Magnetic_resonance_imaging \"Magnetic resonance imaging\") (MRI) is an alternative imaging method that can be used to characterize and stage a kidney mass.[33][32][15] It may be suggested if contrast material cannot be given.[33] MRI can also evaluate the [inferior vena cava](Inferior_vena_cava \"Inferior vena cava\") if the mass is suspected to extend outside the kidney.[33]\n\nSince the lungs are the most common organ for kidney cancer to spread to, a [chest X-ray](Chest_radiograph \"Chest radiograph\") or CT scan may be ordered based on the person's risk for metastatic disease.[15][32]\n\n## Histopathologic classification\n\nThe most common type of kidney malignancy is [renal cell carcinoma](Renal_cell_carcinoma \"Renal cell carcinoma\"),[35] which is thought to originate from cells in the [proximal convoluted tubule](Proximal_convoluted_tubule \"Proximal convoluted tubule\") of the [nephron](Nephron \"Nephron\").[15][36] Another type of kidney cancer although less common, is [transitional cell cancer](Transitional_cell_carcinoma \"Transitional cell carcinoma\") (TCC) or urothelial carcinoma of the [renal pelvis](Renal_pelvis \"Renal pelvis\").[37] The renal pelvis is the part of the kidney that collects urine and drains it into a tube called the [ureter](Ureter \"Ureter\").[37] The cells that line the renal pelvis are called [transitional cells](Transitional_epithelium \"Transitional epithelium\"), and are also sometimes called urothelial cells. The transitional/urothelial cells in the renal pelvis are the same type of cells that line the ureter and [bladder](Bladder \"Bladder\"). For this reason TCC of the renal pelvis is distinct from RCC and is thought to behave more like [bladder cancer](Bladder_cancer \"Bladder cancer\").[37] Other rare types of kidney cancers that can arise from the urothelial cells of the renal pelvis are [squamous cell carcinoma](Squamous_cell_carcinoma \"Squamous cell carcinoma\") and [adenocarcinoma](Adenocarcinoma \"Adenocarcinoma\").[15]\n\nOther causes of kidney cancer include the following:[15]\n\n* [Sarcoma](Sarcoma \"Sarcoma\") â€“ for example [leiomyosarcoma](Leiomyosarcoma \"Leiomyosarcoma\"), [liposarcoma](Liposarcoma \"Liposarcoma\"), [angiosarcoma](Angiosarcoma \"Angiosarcoma\"), [clear-cell sarcoma](Clear-cell_sarcoma_of_the_kidney \"Clear-cell sarcoma of the kidney\") and [rhabdomyosarcoma](Rhabdomyosarcoma \"Rhabdomyosarcoma\") are types of sarcomas that have occurred in the kidney\n* Metastatic tumor from distant organ\n* [Lymphoma](Lymphoma \"Lymphoma\")\n* [Wilms tumor](Wilms'_tumor \"Wilms' tumor\") â€“ an embryonic tumor that is the most common type of kidney cancer in children\n* [Carcinoid tumor](Carcinoid_tumor \"Carcinoid tumor\") of the renal pelvis[38]\n* [Carcinosarcoma](Carcinosarcoma \"Carcinosarcoma\")[39]\n\nIn children, [Wilms tumor](Wilms'_tumor \"Wilms' tumor\") is the most common type of kidney cancer.[15] [Mesoblastic nephroma](Mesoblastic_nephroma \"Mesoblastic nephroma\"), although rare, also typically presents in childhood. \n\nRenal cell carcinoma has been further divided into sub-types based on histological features and genetic abnormalities. The 2022 [WHO](World_Health_Organization \"World Health Organization\") Classification of Tumours of the Urinary and Male Genital Systems (5th edition) describes these categories, incorporating molecular and genetic features:\n\n* Clear cell renal cell carcinoma\n* Papillary renal cell carcinoma (type 1, type 2)\n* Chromophobe renal cell carcinoma\n* Collecting duct carcinoma\n* Renal medullary carcinoma\n* MiT family translocation renal cell carcinoma\n* Succinate dehydrogenase (SDH)-deficient renal cell carcinoma\n* FKHR (FOXG1)-altered renal cell carcinoma\n* Eosinophilic solid and cystic renal cell carcinoma\n* Other molecularly defined renal carcinomas (e.g., EWSR1::PATZ1, etc.)\n* Clear cell papillary renal cell tumor (formerly carcinoma; low malignant potential)\n\nTumors that are considered benign include [angiomyolipoma](Angiomyolipoma \"Angiomyolipoma\"), [oncocytoma](Oncocytoma \"Oncocytoma\"), [reninoma (juxtaglomerular cell tumor)](Reninoma \"Reninoma\"), and renal adenoma.[15]\n\n## Immunohistochemistry\n\nTypical [immunohistochemistry](Immunohistochemistry \"Immunohistochemistry\") for various kidney cancer types.[43][44]\n\n| Type                  | PAX8 | CD10 | CAIX       | RCC | Melanocytic markers | Vimentin | CK7 | HMWCK | CD117 / KIT | AMACR | GATA3 |\n|-----------------------|------|------|------------|-----|---------------------|----------|-----|-------|-------------|-------|-------|\n| Clear cell RCC        | +    | +    | + (box-like) | +   | -                   | +        | -   | -     | -           | -/+   | -     |\n| Papillary RCC         | +    | +    | +/-        | +   | -                   | +        | +   | -     | -           | +     | -     |\n| Clear cell papillary RCC | +    | -    | + (cup-like) | +/- | -                   | +        | +   | +/-   | -           | -     | +/-   |\n| Chromophobe RCC       | +    | -/+  | -          | +/- | -                   | -        | +   | -     | +           | -     | +/-   |\n| Oncocytoma            | +    | -/+  | -          | -   | -                   | -        | Focal | -     | +           | -/+   | -     |\n| Angiomyolipoma        | -    | -    | -/+        | -   | +                   | -/+      | -   | -     | -           | -     | -     |\n| Collecting duct carcinoma | +    | -    | -/+        | -   | -                   | +        | +/- | +     | -           | -     | -     |\n| Tubulocystic carcinoma | +    | +    | +/-        | +   | -                   | +/-      | -/+ | -     | -           | +/-   | -     |\n| Translocation RCC     | +    | +/-  | -/+        | +/- | +/-                 | +        | -   | -     | -           | +/-   | -     |\n| MTSCC                 | +    | -/+  | -/+        | +/- | -                   | +        | +   | -/+   | -           | +/-   | -     |\n\nLegend: \n\n* + = usually positive\n* +/- = frequently positive\n* -/+ = occasionally positive\n* - = usually negative\n\n## Laboratory studies\n\nPeople with suspected kidney cancer should also have their kidney function evaluated to help determine treatment options. Blood tests to determine kidney function include a [comprehensive metabolic panel](Comprehensive_metabolic_panel \"Comprehensive metabolic panel\") (CMP) and a [complete blood count](Complete_blood_count \"Complete blood count\") (CBC).[45][32] In addition, these tests help understand the overall health of the person, which can be affected by [metastatic disease](Metastasis \"Metastasis\") (disease that is outside of the kidney). For example, liver or bone involvement could result in abnormal liver enzymes, electrolyte abnormalities, or [anemia](Anemia \"Anemia\"). A urine sample should also be collected for [urinalysis](Urinalysis \"Urinalysis\").[32][15]\n\n## Biopsy\n\nThe utility of renal mass biopsy (RMB) lies in that it can confirm malignancy with reliability, can direct therapy based on diagnosis, and can provide drainage.[32]\n\nOnce imaging has been completed, renal mass biopsy should be considered if there is a high likelihood that the mass is hematologic, metastatic, inflammatory, or infectious.[32] These types of lesions would not be managed surgically, differing from cancer originating from the kidney. Cancer originating outside the kidney and lymphoma are managed systemically.[15][32]\n\nRMB can accurately diagnose malignancy, however, it cannot reliably diagnose benign disease. In other words, if the biopsy shows cancer, there is a 99.8% chance that kidney cancer is present (Positive Predictive Value= 99.8%). A negative biopsy does not rule out a diagnosis of cancer.[46]\n\n## Staging\n\nThe TNM staging system is commonly used for renal cell carcinoma; other types of kidney cancer, such as transitional cell carcinoma and Wilms tumor, use different staging systems.[47] The first step of staging follows the [TNM staging system](TNM_staging_system \"TNM staging system\") proposed by the Union International Contre le Cancer that is widely used among cancers in other organs.[15] The TNM staging system classifies the primary tumor (T), lymph nodes (N) and distant metastasis (M) of the disease. The [American Joint Committee on Cancer](American_Joint_Committee_on_Cancer \"American Joint Committee on Cancer\") (AJCC) published a Cancer Staging Manual revision in 2010 that describes the values of TMN for renal cell carcinoma.[48][15]\n\nLymph node involvement is classified as either regional lymph node metastasis (N1), or no involvement (N0).[48] Similarly, M1 describes distant metastasis, while M0 describes no distant metastasis.[48]\n\nThe primary tumor of renal cell carcinoma is categorized in the table below, as according to the AJCC 8th Edition Cancer Staging Manual:[49][50]\n\n| Stage | TNM                  | Description |\n|-------|----------------------|-------------|\n|       | **Tx**, N0, M0       | Tumor cannot be assessed |\n|       | **T0**, N0, M0       | No evidence of primary tumor |\n| I     | **T1**, N0, M0       | Tumor â‰¤7 cm; limited to kidney |\n|       | **T1a**, N0, M0      | Tumor â‰¤4 cm; limited to kidney |\n|       | **T1b**, N0, M0      | Tumor 4-â‰¤7 cm; limited to kidney |\n| II    | **T2**, N0, M0       | Tumor \u003e7 cm; limited to kidney |\n|       | **T2a**, N0, M0      | Tumor 7-â‰¤10 cm; limited to kidney |\n|       | **T2b**, N0, M0      | Tumor \u003e10 cm; limited to kidney |\n| III   | **T3**, N0, M0       | Tumor extends to major veins or perinephric tissue but not into ipsilateral adrenal gland nor beyond Gerota's fascia |\n|       | **T3a**, N0, M0      | Tumor grossly extends into renal vein or its segmental branches, or tumor invades the pelvicalyceal system, or tumor invades perirenal and/or renal sinus fat but not beyond Gerota's fascia |\n|       | **T3b**, N0, M0      | Tumor grossly extends into vena cava below the diaphragm |\n|       | **T3c**, N0, M0      | Tumor grossly extends into vena cava above the diaphragm or invades the wall of the vena cava |\n|       | **T1-T3, N1**, M0    | The main tumor can be any size and may be outside the kidney, but it has not spread beyond Gerota's fascia. The cancer has spread to regional lymph nodes (N1) but has not spread to distant lymph nodes or other organs (M0). |\n| IV    | **T4**, any N, M0    | Tumor invades beyond Gerota's fascia |\n|       | Any T, any N, **M1** | Tumor has spread to distant lymph nodes and/or other organs. |\n\nThe lungs are the most common site for metastasis,[32] with other common sites including bone, brain, liver, [adrenal gland](Adrenal_gland \"Adrenal gland\") and distant lymph nodes.[45][51][48]\n## Treatment\n\nTreatment for kidney cancer depends on the type and stage of the disease. Surgery is the most common treatment as kidney cancer does not often respond to [chemotherapy](https://en.wikipedia.org/wiki/Chemotherapy) and [radiotherapy](https://en.wikipedia.org/wiki/Radiotherapy). Surgical complexity can be estimated by the [RENAL Nephrometry Scoring System](https://en.wikipedia.org/wiki/RENAL_Nephrometry_Scoring_System). If the cancer has not spread it will usually be removed by surgery. In some cases this involves [removing the whole kidney](https://en.wikipedia.org/wiki/Nephrectomy) however most tumors are amenable to [partial removal](https://en.wikipedia.org/wiki/Nephrectomy) to eradicate the tumor and preserve the remaining normal portion of the kidney. Surgery is not always possible â€“ for example, the patient may have other medical conditions that prevent it, or the cancer may have spread around the body and doctors may not be able to remove it.[52] If the cancer cannot be treated with surgery, other techniques such as [freezing the tumour](https://en.wikipedia.org/wiki/Cryotherapy) or [treating it with high temperatures](https://en.wikipedia.org/wiki/Radiofrequency_ablation) may be used. However, these are not yet used as standard treatments for kidney cancer.[53] Evidence from the KEYNOTE-564 study supports the use of adjuvant pembrolizumab for high-risk clear cell renal cell carcinoma (RCC) following surgery, with long-term follow-up confirming improvements in disease-free and overall survival (48-month OS: 91.2% vs. 86.0% placebo; HR 0.62).\n\nOther treatment options include targeted therapies such as [everolimus](https://en.wikipedia.org/wiki/Everolimus), [temsirolimus](https://en.wikipedia.org/wiki/Temsirolimus), [sorafenib](https://en.wikipedia.org/wiki/Sorafenib), [sunitinib](https://en.wikipedia.org/wiki/Sunitinib), [pazopanib](https://en.wikipedia.org/wiki/Pazopanib), and [axitinib](https://en.wikipedia.org/wiki/Axitinib), as well as [immunotherapy](https://en.wikipedia.org/wiki/Immunotherapy) including [interferon](https://en.wikipedia.org/wiki/Interferon) and [interleukin-2](https://en.wikipedia.org/wiki/Interleukin-2).[55][56][57] For advanced clear cell RCC, preferred first-line systemic therapies include combinations of immune checkpoint inhibitors with tyrosine kinase inhibitors, such as pembrolizumab + axitinib, nivolumab + cabozantinib, or lenvatinib + pembrolizumab, or immune checkpoint inhibitor monotherapy like nivolumab + ipilimumab for intermediate/poor-risk patients. Adjuvant pembrolizumab is recommended for patients with high-risk clear cell RCC following nephrectomy. Subsequent-line therapies depend on prior treatments and may include cabozantinib, axitinib, or belzutifan. In the second-line setting, [nivolumab](https://en.wikipedia.org/wiki/Nivolumab) and [cabozantinib](https://en.wikipedia.org/wiki/Cabozantinib) remain options following certain prior therapies.[60][61] [Lenvatinib](https://en.wikipedia.org/wiki/Lenvatinib) + pembrolizumab is approved for first-line use in advanced RCC (as of 2021).\n\nIn [Wilms' tumor](https://en.wikipedia.org/wiki/Wilms%27_tumor), chemotherapy, radiotherapy and surgery are the accepted treatments, depending on the stage of the disease when it is diagnosed.[66]\n\n### Children\n\nThe majority of kidney cancers in children are Wilms' tumors, treated with a multimodal approach including surgery (nephrectomy), chemotherapy (e.g., vincristine, dactinomycin, doxorubicin based on stage), and radiation therapy for higher-risk cases. Treatment is guided by risk stratification from protocols like those from the Children's Oncology Group, with overall survival exceeding 90% for most patients.\n# Epidemiology\n\nIn 2022, kidney cancer accounted for 434,840 new cases worldwide (about 2.2% of all cancers), with 155,953 deaths (1.7% of cancer deaths). Incidence rates are highest in Europe and Northern America (ASR 15-20/100,000) and lowest in Africa and parts of Asia (\u003c5/100,000).\n\n## Age\n\nKidney cancer incidence increases with age, with a median diagnosis age of 65 years and peak in the 65-74 age group (30% of cases). Nearly half of cases occur before age 65. Pediatric renal tumors (primarily Wilms tumor) represent about 1-2% of all kidney cancer cases.\n\n## Sex\n\nIncidence is about twice as high in men (23.8/100,000) as in women (12.0/100,000), possibly due to hormonal or behavioral differences. Mortality declines have been similar across sexes in recent years.\n\n## International variations\n\nAge-standardized incidence rates vary widely. In 2022, Belarus had the highest rate (22.9/100,000 in males), followed by Latvia and Czechia; low-risk countries like China, Thailand, and many in Africa have rates under 2/100,000. Since the 2000s, incidence has stabilized or increased in most countries, with decreases reported in a few (e.g., Austria, Poland). Variations partly reflect healthcare access and screening/diagnostic practices, leading to underreporting in low-income regions.\n\nGlobal incidence is projected to nearly double by 2050 (to ~800,000 cases annually), driven by aging populations, obesity, and improved detection.\n\n## Race\n\nIn the US, overall incidence is highest among non-Hispanic Whites (18.3/100,000), followed by non-Hispanic Blacks (16.5/100,000) and Hispanics (14.0/100,000); rates are lowest in Asians/Pacific Islanders (~10/100,000). Among men, non-Hispanic American Indian/Alaska Native have the highest (39.2/100,000), followed closely by non-Hispanic Black, Hispanic, and non-Hispanic White (all ~24-26/100,000). Mortality is higher among non-Hispanic Blacks (4.0/100,000) and American Indian/Alaska Native (~4.5/100,000) than non-Hispanic Whites (3.6/100,000).\n\n## Screening\n\nRoutine screening for kidney cancer is not recommended due to low prevalence and lack of cost-effective tests; most cases are detected incidentally via imaging. Improving registries and access in low-resource settings could better track and reduce disparities.\n\n## United States\n\nThe American Cancer Society estimates 80,980 new kidney cancer cases and 14,510 deaths in the US for 2025. Incidence has been stable since 2013 (17.5/100,000 overall), reflecting a true increase offset by earlier detection of indolent tumors.\n\n## Europe\n\nGLOBOCAN 2022 estimates 145,721 new kidney cancer cases in Europe, accounting for ~3% of all cancers. Incidence rates are among the world's highest (ASR ~15/100,000 overall). In the UK, ~13,900 cases occur annually (2017-2019 average), projected to rise 15% to ~21,900 by 2038-2040; it ranks as the 8th most common cancer."])</script><script nonce="ZDI3MzMxYzUtYzY2YS00M2M3LThmMmMtODg3ZDMzYTJjZmMw">self.__next_f.push([1,"8:[\"$\",\"$L1e\",null,{\"state\":{\"mutations\":[],\"queries\":[{\"dehydratedAt\":1761887062762,\"state\":{\"data\":{\"page\":{\"citations\":[{\"id\":\"1\",\"title\":\"_**a**_ _**b**_ _**c**_ _**d**_ _**e**_ _**f**_ _**g**_ _**h**_ _**i**_ _**j**_ [\\\"Renal Cell Cancer Treatment\\\"](https://www.cancer.gov/types/kidney/patient/kidney-treatment-pdq). _National Cancer Institute_. 2019. [Archived](https://web.archive.org/web/20190410020031/https://www.cancer.gov/types/kidney/patient/kidney-treatment-pdq) from the original on 10 April 2019. Retrieved 8 June 2019.\",\"description\":\"1. ^ _**a**_ _**b**_ _**c**_ _**d**_ _**e**_ _**f**_ _**g**_ _**h**_ _**i**_ _**j**_ [\\\"Renal Cell Cancer Treatment\\\"](https://www.cancer.gov/types/kidney/patient/kidney-treatment-pdq). _National Cancer Institute_. 2019. [Archived](https://web.archive.org/web/20190410020031/https://www.cancer.gov/types/kidney/patient/kidney-treatment-pdq) from the original on 10 April 2019. Retrieved 8 June 2019.\",\"url\":\"https://www.cancer.gov/types/kidney/patient/kidney-treatment-pdq\",\"favicon\":\"\"},{\"id\":\"2\",\"title\":\"_**a**_ _**b**_ _**c**_ _**d**_ _**e**_ _**f**_ _**g**_ _**h**_ _**i**_ _**j**_ [\\\"Transitional Cell Cancer (Kidney/Ureter) Treatment\\\"](https://www.cancer.gov/types/kidney/patient/transitional-cell-treatment-pdq). _National Cancer Institute_. 2019. [Archived](https://web.archive.org/web/20190608225352/https://www.cancer.gov/types/kidney/patient/transitional-cell-treatment-pdq) from the original on 8 June 2019. Retrieved 8 June 2019.\",\"description\":\"2. ^ _**a**_ _**b**_ _**c**_ _**d**_ _**e**_ _**f**_ _**g**_ _**h**_ _**i**_ _**j**_ [\\\"Transitional Cell Cancer (Kidney/Ureter) Treatment\\\"](https://www.cancer.gov/types/kidney/patient/transitional-cell-treatment-pdq). _National Cancer Institute_. 2019. [Archived](https://web.archive.org/web/20190608225352/https://www.cancer.gov/types/kidney/patient/transitional-cell-treatment-pdq) from the original on 8 June 2019. Retrieved 8 June 2019.\",\"url\":\"https://www.cancer.gov/types/kidney/patient/transitional-cell-treatment-pdq\",\"favicon\":\"\"},{\"id\":\"3\",\"title\":\"_**a**_ _**b**_ _**c**_ _**d**_ _**e**_ _**f**_ _**g**_ _**h**_ _**i**_ [\\\"Wilms Tumor and Other Childhood Kidney Tumors Treatment\\\"](https://www.cancer.gov/types/kidney/patient/wilms-treatment-pdq). _National Cancer Institute_. 2019. [Archived](https://web.archive.org/web/20190410020021/https://www.cancer.gov/types/kidney/patient/wilms-treatment-pdq) from the original on 10 April 2019. Retrieved 8 June 2019.\",\"description\":\"3. ^ _**a**_ _**b**_ _**c**_ _**d**_ _**e**_ _**f**_ _**g**_ _**h**_ _**i**_ [\\\"Wilms Tumor and Other Childhood Kidney Tumors Treatment\\\"](https://www.cancer.gov/types/kidney/patient/wilms-treatment-pdq). _National Cancer Institute_. 2019. [Archived](https://web.archive.org/web/20190410020021/https://www.cancer.gov/types/kidney/patient/wilms-treatment-pdq) from the original on 10 April 2019. Retrieved 8 June 2019.\",\"url\":\"https://www.cancer.gov/types/kidney/patient/wilms-treatment-pdq\",\"favicon\":\"\"},{\"id\":\"4\",\"title\":\"_**a**_ _**b**_ _**c**_ _**d**_ _**e**_ _**f**_ _**g**_ _**h**_ [\\\"Cancer of the Kidney and Renal Pelvis - Cancer Stat Facts\\\"](https://seer.cancer.gov/statfacts/html/kidrp.html). _SEER_. [Archived](https://web.archive.org/web/20190611034844/https://seer.cancer.gov/statfacts/html/kidrp.html) from the original on 11 June 2019. Retrieved 30 May 2019.\",\"description\":\"4. ^ _**a**_ _**b**_ _**c**_ _**d**_ _**e**_ _**f**_ _**g**_ _**h**_ [\\\"Cancer of the Kidney and Renal Pelvis - Cancer Stat Facts\\\"](https://seer.cancer.gov/statfacts/html/kidrp.html). _SEER_. [Archived](https://web.archive.org/web/20190611034844/https://seer.cancer.gov/statfacts/html/kidrp.html) from the original on 11 June 2019. Retrieved 30 May 2019.\",\"url\":\"https://seer.cancer.gov/statfacts/html/kidrp.html\",\"favicon\":\"\"},{\"id\":\"5\",\"title\":\"_**a**_ _**b**_ _**c**_ [\\\"Cancer today\\\"](http://gco.iarc.fr/today/online-analysis-table?v=2018\u0026mode=cancer\u0026mode_population=continents\u0026population=900\u0026populations=900\u0026key=asr\u0026sex=0\u0026cancer=39\u0026type=0\u0026statistic=5\u0026prevalence=0\u0026population_group=0\u0026ages_group%5B%5D=0\u0026ages_group%5B%5D=17\u0026nb_items=5\u0026group_cancer=1\u0026include_nmsc=1\u0026include_nmsc_other=1). _IARC_. [Archived](https://web.archive.org/web/20190527015010/http://gco.iarc.fr/today/online-analysis-table?v=2018\u0026mode=cancer\u0026mode_population=continents\u0026population=900\u0026populations=900\u0026key=asr\u0026sex=0\u0026cancer=39\u0026type=0\u0026statistic=5\u0026prevalence=0\u0026population_group=0\u0026ages_group%5B%5D=0\u0026ages_group%5D=17\u0026nb_items=5\u0026group_cancer=1\u0026include_nmsc=1\u0026include_nmsc_other=1) from the original on 27 May 2019. Retrieved 30 May 2019.\",\"description\":\"5. ^ _**a**_ _**b**_ _**c**_ [\\\"Cancer today\\\"](http://gco.iarc.fr/today/online-analysis-table?v=2018\u0026mode=cancer\u0026mode_population=continents\u0026population=900\u0026populations=900\u0026key=asr\u0026sex=0\u0026cancer=39\u0026type=0\u0026statistic=5\u0026prevalence=0\u0026population_group=0\u0026ages_group%5B%5D=0\u0026ages_group%5B%5D=17\u0026nb_items=5\u0026group_cancer=1\u0026include_nmsc=1\u0026include_nmsc_other=1). _IARC_. [Archived](https://web.archive.org/web/20190527015010/http://gco.iarc.fr/today/online-analysis-table?v=2018\u0026mode=cancer\u0026mode_population=continents\u0026population=900\u0026populations=900\u0026key=asr\u0026sex=0\u0026cancer=39\u0026type=0\u0026statistic=5\u0026prevalence=0\u0026population_group=0\u0026ages_group%5B%5D=0\u0026ages_group%5D=17\u0026nb_items=5\u0026group_cancer=1\u0026include_nmsc=1\u0026include_nmsc_other=1) from the original on 27 May 2019. Retrieved 30 May 2019.\",\"url\":\"http://gco.iarc.fr/today/online-analysis-table?v=2018\u0026mode=cancer\u0026mode_population=continents\u0026population=900\u0026populations=900\u0026key=asr\u0026sex=0\u0026cancer=39\u0026type=0\u0026statistic=5\u0026prevalence=0\u0026population_group=0\u0026ages_group%5B%5D=0\u0026ages_group%5B%5D=17\u0026nb_items=5\u0026group_cancer=1\u0026include_nmsc=1\u0026include_nmsc_other=1\",\"favicon\":\"\"},{\"id\":\"6\",\"title\":\"** Sommers MS, Fannin E (2014). [_Diseases and Disorders: A Nursing Therapeutics Manual_](https://books.google.com/books?id=pIEsBQAAQBAJ\u0026pg=PA657). F.A. Davis. p. 657\\\\. [ISBN](ISBN_\\\\(identifier\\\\) \\\"ISBN \\\\(identifier\\\\)\\\") 9780803644878.\",\"description\":\"6. **^** Sommers MS, Fannin E (2014). [_Diseases and Disorders: A Nursing Therapeutics Manual_](https://books.google.com/books?id=pIEsBQAAQBAJ\u0026pg=PA657). F.A. Davis. p. 657\\\\. [ISBN](ISBN_\\\\(identifier\\\\) \\\"ISBN \\\\(identifier\\\\)\\\") 9780803644878.\",\"url\":\"https://books.google.com/books?id=pIEsBQAAQBAJ\u0026pg=PA657\",\"favicon\":\"\"},{\"id\":\"7\",\"title\":\"** [\\\"Kidney Cancer\\\"](https://www.cancer.gov/types/kidney?redirect=true). _National Cancer Institute_. 2019. [Archived](https://web.archive.org/web/20200815203015/https://www.cancer.gov/types/kidney?redirect=true) from the original on 15 August 2020. Retrieved 8 June 2019.\",\"description\":\"7. **^** [\\\"Kidney Cancer\\\"](https://www.cancer.gov/types/kidney?redirect=true). _National Cancer Institute_. 2019. [Archived](https://web.archive.org/web/20200815203015/https://www.cancer.gov/types/kidney?redirect=true) from the original on 15 August 2020. Retrieved 8 June 2019.\",\"url\":\"https://www.cancer.gov/types/kidney?redirect=true\",\"favicon\":\"\"},{\"id\":\"8\",\"title\":\"** Mulders PF, Brouwers AH, Hulsbergen-van der Kaa CA, van Lin EN, Osanto S, de Mulder PH (February 2008). \\\"[Guideline 'Renal cell carcinoma']\\\". _Ned Tijdschr Geneeskd_ (in Dutch). **152** (7): 376â€“80\\\\. [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [18380384](https://pubmed.ncbi.nlm.nih.gov/18380384).\",\"description\":\"8. **^** Mulders PF, Brouwers AH, Hulsbergen-van der Kaa CA, van Lin EN, Osanto S, de Mulder PH (February 2008). \\\"[Guideline 'Renal cell carcinoma']\\\". _Ned Tijdschr Geneeskd_ (in Dutch). **152** (7): 376â€“80\\\\. [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [18380384](https://pubmed.ncbi.nlm.nih.gov/18380384).\",\"url\":\"PMID_\\\\(identifier\\\\\",\"favicon\":\"\"},{\"id\":\"9\",\"title\":\"** [\\\"Survival statistics for kidney cancer - Canadian Cancer Society\\\"](https://www.cancer.ca/en/cancer-information/cancer-type/kidney/prognosis-and-survival/survival-statistics/?region=on). _www.cancer.ca_. [Archived](https://web.archive.org/web/20190617123321/http://www.cancer.ca/en/cancer-information/cancer-type/kidney/prognosis-and-survival/survival-statistics/?region=on) from the original on 2019-06-17. Retrieved 2019-12-02.\",\"description\":\"9. **^** [\\\"Survival statistics for kidney cancer - Canadian Cancer Society\\\"](https://www.cancer.ca/en/cancer-information/cancer-type/kidney/prognosis-and-survival/survival-statistics/?region=on). _www.cancer.ca_. [Archived](https://web.archive.org/web/20190617123321/http://www.cancer.ca/en/cancer-information/cancer-type/kidney/prognosis-and-survival/survival-statistics/?region=on) from the original on 2019-06-17. Retrieved 2019-12-02.\",\"url\":\"https://www.cancer.ca/en/cancer-information/cancer-type/kidney/prognosis-and-survival/survival-statistics/?region=on\",\"favicon\":\"\"},{\"id\":\"10\",\"title\":\"** [\\\"European Network of Cancer Registries\\\"](https://www.encr.eu/sites/default/files/factsheets/ENCR_Factsheet_Kidney_2017.pdf) (PDF). [Archived](https://web.archive.org/web/20201229173037/https://www.encr.eu/sites/default/files/factsheets/ENCR_Factsheet_Kidney_2017.pdf) (PDF) from the original on 2020-12-29. Retrieved 2019-12-02.\",\"description\":\"10. **^** [\\\"European Network of Cancer Registries\\\"](https://www.encr.eu/sites/default/files/factsheets/ENCR_Factsheet_Kidney_2017.pdf) (PDF). [Archived](https://web.archive.org/web/20201229173037/https://www.encr.eu/sites/default/files/factsheets/ENCR_Factsheet_Kidney_2017.pdf) (PDF) from the original on 2020-12-29. Retrieved 2019-12-02.\",\"url\":\"https://www.encr.eu/sites/default/files/factsheets/ENCR_Factsheet_Kidney_2017.pdf\",\"favicon\":\"\"},{\"id\":\"11\",\"title\":\"** Zeng H, Chen W, Zheng R, Zhang S, Ji JS, Zou X, Xia C, Sun K, Yang Z, Li H, Wang N (2018). [\\\"Changing cancer survival in China during 2003â€“15: a pooled analysis of 17 population-based cancer registries\\\"](https://doi.org/10.1016%2FS2214-109X%2818%2930127-X). _The Lancet Global Health_. **6** (5): e555 â€“ e567. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1016/S2214-109X(18)30127-X](https://doi.org/10.1016%2FS2214-109X%2818%2930127-X). [hdl](Hdl_\\\\(identifier\\\\) \\\"Hdl \\\\(identifier\\\\)\\\"):[10072/386179](https://hdl.handle.net/10072%2F386179). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [29653628](https://pubmed.ncbi.nlm.nih.gov/29653628).\",\"description\":\"11. **^** Zeng H, Chen W, Zheng R, Zhang S, Ji JS, Zou X, Xia C, Sun K, Yang Z, Li H, Wang N (2018). [\\\"Changing cancer survival in China during 2003â€“15: a pooled analysis of 17 population-based cancer registries\\\"](https://doi.org/10.1016%2FS2214-109X%2818%2930127-X). _The Lancet Global Health_. **6** (5): e555 â€“ e567. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1016/S2214-109X(18)30127-X](https://doi.org/10.1016%2FS2214-109X%2818%2930127-X). [hdl](Hdl_\\\\(identifier\\\\) \\\"Hdl \\\\(identifier\\\\)\\\"):[10072/386179](https://hdl.handle.net/10072%2F386179). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [29653628](https://pubmed.ncbi.nlm.nih.gov/29653628).\",\"url\":\"https://doi.org/10.1016%2FS2214-109X%2818%2930127-X\",\"favicon\":\"\"},{\"id\":\"12\",\"title\":\"_**a**_ _**b**_ _**c**_ _**d**_ _**e**_ _**f**_ _**g**_ _**h**_ _**i**_ Scelo G, Larose TL (2018-12-20). [\\\"Epidemiology and Risk Factors for Kidney Cancer\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6299342). _Journal of Clinical Oncology_. **36** (36): 3574â€“3581\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1200/JCO.2018.79.1905](https://doi.org/10.1200%2FJCO.2018.79.1905). [ISSN](ISSN_\\\\(identifier\\\\) \\\"ISSN \\\\(identifier\\\\)\\\") [0732-183X](https://search.worldcat.org/issn/0732-183X). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [6299342](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6299342). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [30372394](https://pubmed.ncbi.nlm.nih.gov/30372394).\",\"description\":\"12. ^ _**a**_ _**b**_ _**c**_ _**d**_ _**e**_ _**f**_ _**g**_ _**h**_ _**i**_ Scelo G, Larose TL (2018-12-20). [\\\"Epidemiology and Risk Factors for Kidney Cancer\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6299342). _Journal of Clinical Oncology_. **36** (36): 3574â€“3581\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1200/JCO.2018.79.1905](https://doi.org/10.1200%2FJCO.2018.79.1905). [ISSN](ISSN_\\\\(identifier\\\\) \\\"ISSN \\\\(identifier\\\\)\\\") [0732-183X](https://search.worldcat.org/issn/0732-183X). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [6299342](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6299342). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [30372394](https://pubmed.ncbi.nlm.nih.gov/30372394).\",\"url\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6299342\",\"favicon\":\"\"},{\"id\":\"13\",\"title\":\"** Padala SA, Barsouk A, Thandra KC, Saginala K, Mohammed A, Vakiti A, Rawla P, Barsouk A (June 2020). [\\\"Epidemiology of Renal Cell Carcinoma\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7239575). _World Journal of Oncology_. **11** (3): 79â€“87\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.14740/wjon1279](https://doi.org/10.14740%2Fwjon1279). [ISSN](ISSN_\\\\(identifier\\\\) \\\"ISSN \\\\(identifier\\\\)\\\") [1920-4531](https://search.worldcat.org/issn/1920-4531). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [7239575](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7239575). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [32494314](https://pubmed.ncbi.nlm.nih.gov/32494314).\",\"description\":\"13. **^** Padala SA, Barsouk A, Thandra KC, Saginala K, Mohammed A, Vakiti A, Rawla P, Barsouk A (June 2020). [\\\"Epidemiology of Renal Cell Carcinoma\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7239575). _World Journal of Oncology_. **11** (3): 79â€“87\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.14740/wjon1279](https://doi.org/10.14740%2Fwjon1279). [ISSN](ISSN_\\\\(identifier\\\\) \\\"ISSN \\\\(identifier\\\\)\\\") [1920-4531](https://search.worldcat.org/issn/1920-4531). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [7239575](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7239575). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [32494314](https://pubmed.ncbi.nlm.nih.gov/32494314).\",\"url\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7239575\",\"favicon\":\"\"},{\"id\":\"14\",\"title\":\"_**a**_ _**b**_ _**c**_ _**d**_ Pascual D, Borque A (2008-11-04). [\\\"Epidemiology of Kidney Cancer\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2581742). _Advances in Urology_. **2008** : e782381. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1155/2008/782381](https://doi.org/10.1155%2F2008%2F782381). [ISSN](ISSN_\\\\(identifier\\\\) \\\"ISSN \\\\(identifier\\\\)\\\") [1687-6369](https://search.worldcat.org/issn/1687-6369). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [2581742](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2581742). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [19009036](https://pubmed.ncbi.nlm.nih.gov/19009036).\",\"description\":\"14. ^ _**a**_ _**b**_ _**c**_ _**d**_ Pascual D, Borque A (2008-11-04). [\\\"Epidemiology of Kidney Cancer\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2581742). _Advances in Urology_. **2008** : e782381. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1155/2008/782381](https://doi.org/10.1155%2F2008%2F782381). [ISSN](ISSN_\\\\(identifier\\\\) \\\"ISSN \\\\(identifier\\\\)\\\") [1687-6369](https://search.worldcat.org/issn/1687-6369). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [2581742](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2581742). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [19009036](https://pubmed.ncbi.nlm.nih.gov/19009036).\",\"url\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2581742\",\"favicon\":\"\"},{\"id\":\"15\",\"title\":\"_**a**_ _**b**_ _**c**_ _**d**_ _**e**_ _**f**_ _**g**_ _**h**_ _**i**_ _**j**_ _**k**_ _**l**_ _**m**_ _**n**_ _**o**_ _**p**_ _**q**_ _**r**_ _**s**_ _**t**_ _**u**_ _**v**_ Campbell SC, Lane BR (2012). \\\"Malignant Renal Tumors\\\". In Wein AJ, Kavoussi LR (eds.). _Campbell-Walsh Urology_. Elselvier. [ISBN](ISBN_\\\\(identifier\\\\) \\\"ISBN \\\\(identifier\\\\)\\\") 978-1455775675.\",\"description\":\"15. ^ _**a**_ _**b**_ _**c**_ _**d**_ _**e**_ _**f**_ _**g**_ _**h**_ _**i**_ _**j**_ _**k**_ _**l**_ _**m**_ _**n**_ _**o**_ _**p**_ _**q**_ _**r**_ _**s**_ _**t**_ _**u**_ _**v**_ Campbell SC, Lane BR (2012). \\\"Malignant Renal Tumors\\\". In Wein AJ, Kavoussi LR (eds.). _Campbell-Walsh Urology_. Elselvier. [ISBN](ISBN_\\\\(identifier\\\\) \\\"ISBN \\\\(identifier\\\\)\\\") 978-1455775675.\",\"url\":\"ISBN_\\\\(identifier\\\\\",\"favicon\":\"\"},{\"id\":\"16\",\"title\":\"** Hidayat K, Du X, Zou SY, Shi BM (July 2017). \\\"Blood pressure and kidney cancer risk: meta-analysis of prospective studies\\\". _Journal of Hypertension_. **35** (7): 1333â€“1344\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1097/HJH.0000000000001286](https://doi.org/10.1097%2FHJH.0000000000001286). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [28157813](https://pubmed.ncbi.nlm.nih.gov/28157813). [S2CID](S2CID_\\\\(identifier\\\\) \\\"S2CID \\\\(identifier\\\\)\\\") [3454741](https://api.semanticscholar.org/CorpusID:3454741).\",\"description\":\"16. **^** Hidayat K, Du X, Zou SY, Shi BM (July 2017). \\\"Blood pressure and kidney cancer risk: meta-analysis of prospective studies\\\". _Journal of Hypertension_. **35** (7): 1333â€“1344\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1097/HJH.0000000000001286](https://doi.org/10.1097%2FHJH.0000000000001286). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [28157813](https://pubmed.ncbi.nlm.nih.gov/28157813). [S2CID](S2CID_\\\\(identifier\\\\) \\\"S2CID \\\\(identifier\\\\)\\\") [3454741](https://api.semanticscholar.org/CorpusID:3454741).\",\"url\":\"Doi_\\\\(identifier\\\\\",\"favicon\":\"\"},{\"id\":\"17\",\"title\":\"** Professionals SO. [\\\"EAU Guidelines: Renal Cell Carcinoma\\\"](https://uroweb.org/guideline/renal-cell-carcinoma/#note_103). _Uroweb_. [Archived](https://web.archive.org/web/20190813031110/https://uroweb.org/guideline/renal-cell-carcinoma/#note_103) from the original on 2019-08-13. Retrieved 2019-12-03.\",\"description\":\"17. **^** Professionals SO. [\\\"EAU Guidelines: Renal Cell Carcinoma\\\"](https://uroweb.org/guideline/renal-cell-carcinoma/#note_103). _Uroweb_. [Archived](https://web.archive.org/web/20190813031110/https://uroweb.org/guideline/renal-cell-carcinoma/#note_103) from the original on 2019-08-13. Retrieved 2019-12-03.\",\"url\":\"https://uroweb.org/guideline/renal-cell-carcinoma/#note_103\",\"favicon\":\"\"},{\"id\":\"18\",\"title\":\"** Palapattu GS, Kristo B, Rajfer J (2002). [\\\"Paraneoplastic syndromes in urologic malignancy: the many faces of renal cell carcinoma\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1475999). _Reviews in Urology_. **4** (4): 163â€“170\\\\. [ISSN](ISSN_\\\\(identifier\\\\) \\\"ISSN \\\\(identifier\\\\)\\\") [1523-6161](https://search.worldcat.org/issn/1523-6161). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [1475999](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1475999). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [16985675](https://pubmed.ncbi.nlm.nih.gov/16985675).\",\"description\":\"18. **^** Palapattu GS, Kristo B, Rajfer J (2002). [\\\"Paraneoplastic syndromes in urologic malignancy: the many faces of renal cell carcinoma\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1475999). _Reviews in Urology_. **4** (4): 163â€“170\\\\. [ISSN](ISSN_\\\\(identifier\\\\) \\\"ISSN \\\\(identifier\\\\)\\\") [1523-6161](https://search.worldcat.org/issn/1523-6161). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [1475999](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1475999). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [16985675](https://pubmed.ncbi.nlm.nih.gov/16985675).\",\"url\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1475999\",\"favicon\":\"\"},{\"id\":\"19\",\"title\":\"** Ljungberg B, Albiges L, Abu-Ghanem Y, Bensalah K, Dabestani S, FernÃ¡ndez-Pello S, Giles RH, Hofmann F, Hora M, Kuczyk MA, Kuusk T, Lam TB, Marconi L, Merseburger AS, Powles T (2019-05-01). [\\\"European Association of Urology Guidelines on Renal Cell Carcinoma: The 2019 Update\\\"](https://linkinghub.elsevier.com/retrieve/pii/S0302283819301526). _European Urology_. **75** (5): 799â€“810\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1016/j.eururo.2019.02.011](https://doi.org/10.1016%2Fj.eururo.2019.02.011). [ISSN](ISSN_\\\\(identifier\\\\) \\\"ISSN \\\\(identifier\\\\)\\\") [0302-2838](https://search.worldcat.org/issn/0302-2838).\",\"description\":\"19. **^** Ljungberg B, Albiges L, Abu-Ghanem Y, Bensalah K, Dabestani S, FernÃ¡ndez-Pello S, Giles RH, Hofmann F, Hora M, Kuczyk MA, Kuusk T, Lam TB, Marconi L, Merseburger AS, Powles T (2019-05-01). [\\\"European Association of Urology Guidelines on Renal Cell Carcinoma: The 2019 Update\\\"](https://linkinghub.elsevier.com/retrieve/pii/S0302283819301526). _European Urology_. **75** (5): 799â€“810\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1016/j.eururo.2019.02.011](https://doi.org/10.1016%2Fj.eururo.2019.02.011). [ISSN](ISSN_\\\\(identifier\\\\) \\\"ISSN \\\\(identifier\\\\)\\\") [0302-2838](https://search.worldcat.org/issn/0302-2838).\",\"url\":\"https://linkinghub.elsevier.com/retrieve/pii/S0302283819301526\",\"favicon\":\"\"},{\"id\":\"20\",\"title\":\"** Tahbaz R, Schmid M, Merseburger AS (2018). \\\"Prevention of kidney cancer incidence and recurrence: lifestyle, medication and nutrition\\\". _Current Opinion in Urology_. **28** (1): 62â€“79\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1097/MOU.0000000000000454](https://doi.org/10.1097%2FMOU.0000000000000454). [ISSN](ISSN_\\\\(identifier\\\\) \\\"ISSN \\\\(identifier\\\\)\\\") [1473-6586](https://search.worldcat.org/issn/1473-6586). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [29059103](https://pubmed.ncbi.nlm.nih.gov/29059103). [S2CID](S2CID_\\\\(identifier\\\\) \\\"S2CID \\\\(identifier\\\\)\\\") [25998957](https://api.semanticscholar.org/CorpusID:25998957).\",\"description\":\"20. **^** Tahbaz R, Schmid M, Merseburger AS (2018). \\\"Prevention of kidney cancer incidence and recurrence: lifestyle, medication and nutrition\\\". _Current Opinion in Urology_. **28** (1): 62â€“79\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1097/MOU.0000000000000454](https://doi.org/10.1097%2FMOU.0000000000000454). [ISSN](ISSN_\\\\(identifier\\\\) \\\"ISSN \\\\(identifier\\\\)\\\") [1473-6586](https://search.worldcat.org/issn/1473-6586). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [29059103](https://pubmed.ncbi.nlm.nih.gov/29059103). [S2CID](S2CID_\\\\(identifier\\\\) \\\"S2CID \\\\(identifier\\\\)\\\") [25998957](https://api.semanticscholar.org/CorpusID:25998957).\",\"url\":\"Doi_\\\\(identifier\\\\\",\"favicon\":\"\"},{\"id\":\"21\",\"title\":\"_**a**_ _**b**_ [\\\"Kidney Cancer - Risk Factors and Prevention\\\"](https://www.cancer.net/cancer-types/kidney-cancer/risk-factors-and-prevention). _Cancer.Net_. 2012-06-25. [Archived](https://web.archive.org/web/20191202230918/https://www.cancer.net/cancer-types/kidney-cancer/risk-factors-and-prevention) from the original on 2019-12-02. Retrieved 2019-12-02.\",\"description\":\"21. ^ _**a**_ _**b**_ [\\\"Kidney Cancer - Risk Factors and Prevention\\\"](https://www.cancer.net/cancer-types/kidney-cancer/risk-factors-and-prevention). _Cancer.Net_. 2012-06-25. [Archived](https://web.archive.org/web/20191202230918/https://www.cancer.net/cancer-types/kidney-cancer/risk-factors-and-prevention) from the original on 2019-12-02. Retrieved 2019-12-02.\",\"url\":\"https://www.cancer.net/cancer-types/kidney-cancer/risk-factors-and-prevention\",\"favicon\":\"\"},{\"id\":\"22\",\"title\":\"** Cheungpasitporn W, Thongprayoon C, O'Corragain OA, Edmonds PJ, Ungprasert P, Kittanamongkolchai W, Erickson SB (9 September 2014). [\\\"The Risk of Kidney Cancer in Patients with Kidney Stones: A Systematic Review and Meta-analysis\\\"](https://doi.org/10.1093%2Fqjmed%2Fhcu195). _QJM_. **108** (3): 205â€“12\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1093/qjmed/hcu195](https://doi.org/10.1093%2Fqjmed%2Fhcu195). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [25208892](https://pubmed.ncbi.nlm.nih.gov/25208892).\",\"description\":\"22. **^** Cheungpasitporn W, Thongprayoon C, O'Corragain OA, Edmonds PJ, Ungprasert P, Kittanamongkolchai W, Erickson SB (9 September 2014). [\\\"The Risk of Kidney Cancer in Patients with Kidney Stones: A Systematic Review and Meta-analysis\\\"](https://doi.org/10.1093%2Fqjmed%2Fhcu195). _QJM_. **108** (3): 205â€“12\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1093/qjmed/hcu195](https://doi.org/10.1093%2Fqjmed%2Fhcu195). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [25208892](https://pubmed.ncbi.nlm.nih.gov/25208892).\",\"url\":\"https://doi.org/10.1093%2Fqjmed%2Fhcu195\",\"favicon\":\"\"},{\"id\":\"23\",\"title\":\"** [\\\"Risks and causes of kidney cancer\\\"](http://cancerhelp.cancerresearchuk.org/type/kidney-cancer/about/risks-and-causes-of-kidney-cancer). 2017-08-30. [Archived](https://web.archive.org/web/20111027201549/http://cancerhelp.cancerresearchuk.org/type/kidney-cancer/about/risks-and-causes-of-kidney-cancer) from the original on 2011-10-27. Retrieved 2011-11-30.\",\"description\":\"23. **^** [\\\"Risks and causes of kidney cancer\\\"](http://cancerhelp.cancerresearchuk.org/type/kidney-cancer/about/risks-and-causes-of-kidney-cancer). 2017-08-30. [Archived](https://web.archive.org/web/20111027201549/http://cancerhelp.cancerresearchuk.org/type/kidney-cancer/about/risks-and-causes-of-kidney-cancer) from the original on 2011-10-27. Retrieved 2011-11-30.\",\"url\":\"http://cancerhelp.cancerresearchuk.org/type/kidney-cancer/about/risks-and-causes-of-kidney-cancer\",\"favicon\":\"\"},{\"id\":\"24\",\"title\":\"** Hunt JD, van der Hel OL, McMillan GP, Boffetta P, Brennan P (2005-03-10). [\\\"Renal cell carcinoma in relation to cigarette smoking: meta-analysis of 24 studies\\\"](https://doi.org/10.1002%2Fijc.20618). _International Journal of Cancer_. **114** (1): 101â€“108\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1002/ijc.20618](https://doi.org/10.1002%2Fijc.20618). [ISSN](ISSN_\\\\(identifier\\\\) \\\"ISSN \\\\(identifier\\\\)\\\") [0020-7136](https://search.worldcat.org/issn/0020-7136). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [15523697](https://pubmed.ncbi.nlm.nih.gov/15523697). [S2CID](S2CID_\\\\(identifier\\\\) \\\"S2CID \\\\(identifier\\\\)\\\") [10136386](https://api.semanticscholar.org/CorpusID:10136386).\",\"description\":\"24. **^** Hunt JD, van der Hel OL, McMillan GP, Boffetta P, Brennan P (2005-03-10). [\\\"Renal cell carcinoma in relation to cigarette smoking: meta-analysis of 24 studies\\\"](https://doi.org/10.1002%2Fijc.20618). _International Journal of Cancer_. **114** (1): 101â€“108\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1002/ijc.20618](https://doi.org/10.1002%2Fijc.20618). [ISSN](ISSN_\\\\(identifier\\\\) \\\"ISSN \\\\(identifier\\\\)\\\") [0020-7136](https://search.worldcat.org/issn/0020-7136). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [15523697](https://pubmed.ncbi.nlm.nih.gov/15523697). [S2CID](S2CID_\\\\(identifier\\\\) \\\"S2CID \\\\(identifier\\\\)\\\") [10136386](https://api.semanticscholar.org/CorpusID:10136386).\",\"url\":\"https://doi.org/10.1002%2Fijc.20618\",\"favicon\":\"\"},{\"id\":\"25\",\"title\":\"** SÃ¡nchez-MartÃ­n FM, MillÃ¡n-RodrÃ­guez F, Urdaneta-Pignalosa G, Rubio-Briones J, Villavicencio-Mavrich H (2008). [\\\"Small Renal Masses: Incidental Diagnosis, Clinical Symptoms, and Prognostic Factors\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2629071). _Advances in Urology_. **2008** : 310694. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1155/2008/310694](https://doi.org/10.1155%2F2008%2F310694). [ISSN](ISSN_\\\\(identifier\\\\) \\\"ISSN \\\\(identifier\\\\)\\\") [1687-6369](https://search.worldcat.org/issn/1687-6369). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [2629071](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2629071). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [19165347](https://pubmed.ncbi.nlm.nih.gov/19165347).\",\"description\":\"25. **^** SÃ¡nchez-MartÃ­n FM, MillÃ¡n-RodrÃ­guez F, Urdaneta-Pignalosa G, Rubio-Briones J, Villavicencio-Mavrich H (2008). [\\\"Small Renal Masses: Incidental Diagnosis, Clinical Symptoms, and Prognostic Factors\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2629071). _Advances in Urology_. **2008** : 310694. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1155/2008/310694](https://doi.org/10.1155%2F2008%2F310694). [ISSN](ISSN_\\\\(identifier\\\\) \\\"ISSN \\\\(identifier\\\\)\\\") [1687-6369](https://search.worldcat.org/issn/1687-6369). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [2629071](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2629071). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [19165347](https://pubmed.ncbi.nlm.nih.gov/19165347).\",\"url\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2629071\",\"favicon\":\"\"},{\"id\":\"26\",\"title\":\"** Motzer RJ, Jonasch E, Agarwal N, Bhayani S, Bro WP, Chang SS, [Toni Choueiri](Toni_Choueiri \\\"Toni Choueiri\\\"), Costello BA, Derweesh IH, Fishman M, Gallagher TH (2017-06-01). [\\\"Kidney Cancer, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology\\\"](https://jnccn.org/view/journals/jnccn/15/6/article-p804.xml). _Journal of the National Comprehensive Cancer Network_. **15** (6): 804â€“834\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.6004/jnccn.2017.0100](https://doi.org/10.6004%2Fjnccn.2017.0100). [ISSN](ISSN_\\\\(identifier\\\\) \\\"ISSN \\\\(identifier\\\\)\\\") [1540-1405](https://search.worldcat.org/issn/1540-1405). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [28596261](https://pubmed.ncbi.nlm.nih.gov/28596261). [Archived](https://web.archive.org/web/20191029185620/https://jnccn.org/view/journals/jnccn/15/6/article-p804.xml) from the original on 2019-10-29. Retrieved 2019-10-29.\",\"description\":\"26. **^** Motzer RJ, Jonasch E, Agarwal N, Bhayani S, Bro WP, Chang SS, [Toni Choueiri](Toni_Choueiri \\\"Toni Choueiri\\\"), Costello BA, Derweesh IH, Fishman M, Gallagher TH (2017-06-01). [\\\"Kidney Cancer, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology\\\"](https://jnccn.org/view/journals/jnccn/15/6/article-p804.xml). _Journal of the National Comprehensive Cancer Network_. **15** (6): 804â€“834\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.6004/jnccn.2017.0100](https://doi.org/10.6004%2Fjnccn.2017.0100). [ISSN](ISSN_\\\\(identifier\\\\) \\\"ISSN \\\\(identifier\\\\)\\\") [1540-1405](https://search.worldcat.org/issn/1540-1405). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [28596261](https://pubmed.ncbi.nlm.nih.gov/28596261). [Archived](https://web.archive.org/web/20191029185620/https://jnccn.org/view/journals/jnccn/15/6/article-p804.xml) from the original on 2019-10-29. Retrieved 2019-10-29.\",\"url\":\"Toni_Choueiri \\\"Toni Choueiri\\\"\",\"favicon\":\"\"},{\"id\":\"27\",\"title\":\"** Silverman SG, Israel GM, Herts BR, Richie JP (October 2008). \\\"Management of the incidental renal mass\\\". _Radiology_. **249** (1): 16â€“31\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1148/radiol.2491070783](https://doi.org/10.1148%2Fradiol.2491070783). [ISSN](ISSN_\\\\(identifier\\\\) \\\"ISSN \\\\(identifier\\\\)\\\") [1527-1315](https://search.worldcat.org/issn/1527-1315). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [18796665](https://pubmed.ncbi.nlm.nih.gov/18796665). [S2CID](S2CID_\\\\(identifier\\\\) \\\"S2CID \\\\(identifier\\\\)\\\") [23327389](https://api.semanticscholar.org/CorpusID:23327389).\",\"description\":\"27. **^** Silverman SG, Israel GM, Herts BR, Richie JP (October 2008). \\\"Management of the incidental renal mass\\\". _Radiology_. **249** (1): 16â€“31\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1148/radiol.2491070783](https://doi.org/10.1148%2Fradiol.2491070783). [ISSN](ISSN_\\\\(identifier\\\\) \\\"ISSN \\\\(identifier\\\\)\\\") [1527-1315](https://search.worldcat.org/issn/1527-1315). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [18796665](https://pubmed.ncbi.nlm.nih.gov/18796665). [S2CID](S2CID_\\\\(identifier\\\\) \\\"S2CID \\\\(identifier\\\\)\\\") [23327389](https://api.semanticscholar.org/CorpusID:23327389).\",\"url\":\"Doi_\\\\(identifier\\\\\",\"favicon\":\"\"},{\"id\":\"28\",\"title\":\"** [\\\"Cancer | Definition of Cancer by Lexico\\\"](https://web.archive.org/web/20191112221544/https://www.lexico.com/en/definition/cancer). _Lexico Dictionaries | English_. Archived from [the original](https://www.lexico.com/en/definition/cancer) on November 12, 2019. Retrieved 2019-11-12.\",\"description\":\"28. **^** [\\\"Cancer | Definition of Cancer by Lexico\\\"](https://web.archive.org/web/20191112221544/https://www.lexico.com/en/definition/cancer). _Lexico Dictionaries | English_. Archived from [the original](https://www.lexico.com/en/definition/cancer) on November 12, 2019. Retrieved 2019-11-12.\",\"url\":\"https://web.archive.org/web/20191112221544/https://www.lexico.com/en/definition/cancer\",\"favicon\":\"\"},{\"id\":\"29\",\"title\":\"** Israel GM, Bosniak MA (2005). \\\"How I Do It: Evaluating Renal Masses\\\". _Radiology_. **236** (2): 441â€“450\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1148/radiol.2362040218](https://doi.org/10.1148%2Fradiol.2362040218). [ISSN](ISSN_\\\\(identifier\\\\) \\\"ISSN \\\\(identifier\\\\)\\\") [0033-8419](https://search.worldcat.org/issn/0033-8419). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [16040900](https://pubmed.ncbi.nlm.nih.gov/16040900). [S2CID](S2CID_\\\\(identifier\\\\) \\\"S2CID \\\\(identifier\\\\)\\\") [1916092](https://api.semanticscholar.org/CorpusID:1916092).\",\"description\":\"29. **^** Israel GM, Bosniak MA (2005). \\\"How I Do It: Evaluating Renal Masses\\\". _Radiology_. **236** (2): 441â€“450\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1148/radiol.2362040218](https://doi.org/10.1148%2Fradiol.2362040218). [ISSN](ISSN_\\\\(identifier\\\\) \\\"ISSN \\\\(identifier\\\\)\\\") [0033-8419](https://search.worldcat.org/issn/0033-8419). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [16040900](https://pubmed.ncbi.nlm.nih.gov/16040900). [S2CID](S2CID_\\\\(identifier\\\\) \\\"S2CID \\\\(identifier\\\\)\\\") [1916092](https://api.semanticscholar.org/CorpusID:1916092).\",\"url\":\"Doi_\\\\(identifier\\\\\",\"favicon\":\"\"},{\"id\":\"30\",\"title\":\"** [\\\"Bosniak Calculator For Renal Cystic Masses 2019 (CT/MRI) - Rad At Hand\\\"](https://radathand.com/radiology-calculators/body-imaging/bosniak-classification-of-renal-cyst-cystic-mass-ct-mri/). _radathand.com_. 2025-06-22. Retrieved 2025-07-03.\",\"description\":\"30. **^** [\\\"Bosniak Calculator For Renal Cystic Masses 2019 (CT/MRI) - Rad At Hand\\\"](https://radathand.com/radiology-calculators/body-imaging/bosniak-classification-of-renal-cyst-cystic-mass-ct-mri/). _radathand.com_. 2025-06-22. Retrieved 2025-07-03.\",\"url\":\"https://radathand.com/radiology-calculators/body-imaging/bosniak-classification-of-renal-cyst-cystic-mass-ct-mri/\",\"favicon\":\"\"},{\"id\":\"31\",\"title\":\"** Silverman SG, Pedrosa I, Ellis JH, Hindman NM, Schieda N, Smith AD, Remer EM, Shinagare AB, Curci NE, Raman SS, Wells SA (2019-06-18). [\\\"Bosniak Classification of Cystic Renal Masses, Version 2019: An Update Proposal and Needs Assessment\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6677285). _Radiology_. **292** (2): 475â€“488\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1148/radiol.2019182646](https://doi.org/10.1148%2Fradiol.2019182646). [ISSN](ISSN_\\\\(identifier\\\\) \\\"ISSN \\\\(identifier\\\\)\\\") [0033-8419](https://search.worldcat.org/issn/0033-8419). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [6677285](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6677285). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [31210616](https://pubmed.ncbi.nlm.nih.gov/31210616).\",\"description\":\"31. **^** Silverman SG, Pedrosa I, Ellis JH, Hindman NM, Schieda N, Smith AD, Remer EM, Shinagare AB, Curci NE, Raman SS, Wells SA (2019-06-18). [\\\"Bosniak Classification of Cystic Renal Masses, Version 2019: An Update Proposal and Needs Assessment\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6677285). _Radiology_. **292** (2): 475â€“488\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1148/radiol.2019182646](https://doi.org/10.1148%2Fradiol.2019182646). [ISSN](ISSN_\\\\(identifier\\\\) \\\"ISSN \\\\(identifier\\\\)\\\") [0033-8419](https://search.worldcat.org/issn/0033-8419). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [6677285](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6677285). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [31210616](https://pubmed.ncbi.nlm.nih.gov/31210616).\",\"url\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6677285\",\"favicon\":\"\"},{\"id\":\"32\",\"title\":\"_**a**_ _**b**_ _**c**_ _**d**_ _**e**_ _**f**_ _**g**_ _**h**_ _**i**_ _**j**_ [\\\"Renal Cancer: Renal Mass \u0026 Localized Renal Cancer Guideline - American Urological Association\\\"](https://web.archive.org/web/20200215171032/https://www.auanet.org/guidelines/renal-cancer-renal-mass-and-localized-renal-cancer-guideline#x7068). _www.auanet.org_. Archived from [the original](https://www.auanet.org/guidelines/renal-cancer-renal-mass-and-localized-renal-cancer-guideline#x7068) on 2020-02-15. Retrieved 2019-10-29.\",\"description\":\"32. ^ _**a**_ _**b**_ _**c**_ _**d**_ _**e**_ _**f**_ _**g**_ _**h**_ _**i**_ _**j**_ [\\\"Renal Cancer: Renal Mass \u0026 Localized Renal Cancer Guideline - American Urological Association\\\"](https://web.archive.org/web/20200215171032/https://www.auanet.org/guidelines/renal-cancer-renal-mass-and-localized-renal-cancer-guideline#x7068). _www.auanet.org_. Archived from [the original](https://www.auanet.org/guidelines/renal-cancer-renal-mass-and-localized-renal-cancer-guideline#x7068) on 2020-02-15. Retrieved 2019-10-29.\",\"url\":\"https://web.archive.org/web/20200215171032/https://www.auanet.org/guidelines/renal-cancer-renal-mass-and-localized-renal-cancer-guideline#x7068\",\"favicon\":\"\"},{\"id\":\"33\",\"title\":\"_**a**_ _**b**_ _**c**_ _**d**_ Motzer RJ, Jonasch E, Agarwal N, Bhayani S, Bro WP, Chang SS, Choueiri TK, Costello BA, Derweesh IH, Fishman M, Gallagher TH (2017-06-01). [\\\"Kidney Cancer, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology\\\"](https://jnccn.org/view/journals/jnccn/15/6/article-p804.xml). _Journal of the National Comprehensive Cancer Network_. **15** (6): 804â€“834\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.6004/jnccn.2017.0100](https://doi.org/10.6004%2Fjnccn.2017.0100). [ISSN](ISSN_\\\\(identifier\\\\) \\\"ISSN \\\\(identifier\\\\)\\\") [1540-1405](https://search.worldcat.org/issn/1540-1405). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [28596261](https://pubmed.ncbi.nlm.nih.gov/28596261). [Archived](https://web.archive.org/web/20191029185620/https://jnccn.org/view/journals/jnccn/15/6/article-p804.xml) from the original on 2019-10-29. Retrieved 2019-10-29.\",\"description\":\"33. ^ _**a**_ _**b**_ _**c**_ _**d**_ Motzer RJ, Jonasch E, Agarwal N, Bhayani S, Bro WP, Chang SS, Choueiri TK, Costello BA, Derweesh IH, Fishman M, Gallagher TH (2017-06-01). [\\\"Kidney Cancer, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology\\\"](https://jnccn.org/view/journals/jnccn/15/6/article-p804.xml). _Journal of the National Comprehensive Cancer Network_. **15** (6): 804â€“834\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.6004/jnccn.2017.0100](https://doi.org/10.6004%2Fjnccn.2017.0100). [ISSN](ISSN_\\\\(identifier\\\\) \\\"ISSN \\\\(identifier\\\\)\\\") [1540-1405](https://search.worldcat.org/issn/1540-1405). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [28596261](https://pubmed.ncbi.nlm.nih.gov/28596261). [Archived](https://web.archive.org/web/20191029185620/https://jnccn.org/view/journals/jnccn/15/6/article-p804.xml) from the original on 2019-10-29. Retrieved 2019-10-29.\",\"url\":\"https://jnccn.org/view/journals/jnccn/15/6/article-p804.xml\",\"favicon\":\"\"},{\"id\":\"34\",\"title\":\"** Subramaniam RM, Wilson RF, Turban S, Suarez-Cuervo C, Zhang A, Sherrod C, Aboagye J, Eng J, Choi MJ (2016). [_Contrast-Induced Nephropathy: Comparative Effectiveness of Preventive Measures_](https://www.ncbi.nlm.nih.gov/books/NBK343725/). AHRQ Comparative Effectiveness Reviews. Rockville (MD): Agency for Healthcare Research and Quality (US). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [26866209](https://pubmed.ncbi.nlm.nih.gov/26866209). [Archived](https://web.archive.org/web/20210828135130/https://www.ncbi.nlm.nih.gov/books/NBK343725/) from the original on 2021-08-28. Retrieved 2019-10-29.\",\"description\":\"34. **^** Subramaniam RM, Wilson RF, Turban S, Suarez-Cuervo C, Zhang A, Sherrod C, Aboagye J, Eng J, Choi MJ (2016). [_Contrast-Induced Nephropathy: Comparative Effectiveness of Preventive Measures_](https://www.ncbi.nlm.nih.gov/books/NBK343725/). AHRQ Comparative Effectiveness Reviews. Rockville (MD): Agency for Healthcare Research and Quality (US). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [26866209](https://pubmed.ncbi.nlm.nih.gov/26866209). [Archived](https://web.archive.org/web/20210828135130/https://www.ncbi.nlm.nih.gov/books/NBK343725/) from the original on 2021-08-28. Retrieved 2019-10-29.\",\"url\":\"https://www.ncbi.nlm.nih.gov/books/NBK343725/\",\"favicon\":\"\"},{\"id\":\"35\",\"title\":\"** [\\\"Kidney Cancer | CDC\\\"](https://www.cdc.gov/cancer/kidney/index.htm). _www.cdc.gov_. 2019-07-09. [Archived](https://web.archive.org/web/20191112221544/https://www.cdc.gov/cancer/kidney/index.htm) from the original on 2019-11-12. Retrieved 2019-11-12.\",\"description\":\"35. **^** [\\\"Kidney Cancer | CDC\\\"](https://www.cdc.gov/cancer/kidney/index.htm). _www.cdc.gov_. 2019-07-09. [Archived](https://web.archive.org/web/20191112221544/https://www.cdc.gov/cancer/kidney/index.htm) from the original on 2019-11-12. Retrieved 2019-11-12.\",\"url\":\"https://www.cdc.gov/cancer/kidney/index.htm\",\"favicon\":\"\"},{\"id\":\"36\",\"title\":\"** [\\\"Renal Cell Cancer Treatment (PDQÂ®)â€“Patient Version\\\"](https://www.cancer.gov/types/kidney/patient/kidney-treatment-pdq). _National Cancer Institute_. 2004-02-20. [Archived](https://web.archive.org/web/20190410020031/https://www.cancer.gov/types/kidney/patient/kidney-treatment-pdq) from the original on 2019-04-10. Retrieved 2019-11-12.\",\"description\":\"36. **^** [\\\"Renal Cell Cancer Treatment (PDQÂ®)â€“Patient Version\\\"](https://www.cancer.gov/types/kidney/patient/kidney-treatment-pdq). _National Cancer Institute_. 2004-02-20. [Archived](https://web.archive.org/web/20190410020031/https://www.cancer.gov/types/kidney/patient/kidney-treatment-pdq) from the original on 2019-04-10. Retrieved 2019-11-12.\",\"url\":\"https://www.cancer.gov/types/kidney/patient/kidney-treatment-pdq\",\"favicon\":\"\"},{\"id\":\"37\",\"title\":\"_**a**_ _**b**_ _**c**_ [\\\"Transitional Cell Cancer of the Renal Pelvis and Ureter Treatment (PDQÂ®)â€“Patient Version\\\"](https://www.cancer.gov/types/kidney/patient/transitional-cell-treatment-pdq). _National Cancer Institute_. 2004-02-20. [Archived](https://web.archive.org/web/20190608225352/https://www.cancer.gov/types/kidney/patient/transitional-cell-treatment-pdq) from the original on 2019-06-08. Retrieved 2019-11-12.\",\"description\":\"37. ^ _**a**_ _**b**_ _**c**_ [\\\"Transitional Cell Cancer of the Renal Pelvis and Ureter Treatment (PDQÂ®)â€“Patient Version\\\"](https://www.cancer.gov/types/kidney/patient/transitional-cell-treatment-pdq). _National Cancer Institute_. 2004-02-20. [Archived](https://web.archive.org/web/20190608225352/https://www.cancer.gov/types/kidney/patient/transitional-cell-treatment-pdq) from the original on 2019-06-08. Retrieved 2019-11-12.\",\"url\":\"https://www.cancer.gov/types/kidney/patient/transitional-cell-treatment-pdq\",\"favicon\":\"\"},{\"id\":\"38\",\"title\":\"** Kuroda N, Katto K, Tamura M, Shiotsu T, Hes O, Michal M, Nagashima Y, Ohara M, Hirouchi T, Mizuno K, Hayashi Y, Lee GH (January 2008). \\\"Carcinoid tumor of the renal pelvis: consideration on the histogenesis\\\". _Pathol. Int_. **58** (1): 51â€“54\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1111/j.1440-1827.2007.02188.x](https://doi.org/10.1111%2Fj.1440-1827.2007.02188.x). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [18067641](https://pubmed.ncbi.nlm.nih.gov/18067641). [S2CID](S2CID_\\\\(identifier\\\\) \\\"S2CID \\\\(identifier\\\\)\\\") [27645211](https://api.semanticscholar.org/CorpusID:27645211).\",\"description\":\"38. **^** Kuroda N, Katto K, Tamura M, Shiotsu T, Hes O, Michal M, Nagashima Y, Ohara M, Hirouchi T, Mizuno K, Hayashi Y, Lee GH (January 2008). \\\"Carcinoid tumor of the renal pelvis: consideration on the histogenesis\\\". _Pathol. Int_. **58** (1): 51â€“54\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1111/j.1440-1827.2007.02188.x](https://doi.org/10.1111%2Fj.1440-1827.2007.02188.x). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [18067641](https://pubmed.ncbi.nlm.nih.gov/18067641). [S2CID](S2CID_\\\\(identifier\\\\) \\\"S2CID \\\\(identifier\\\\)\\\") [27645211](https://api.semanticscholar.org/CorpusID:27645211).\",\"url\":\"Doi_\\\\(identifier\\\\\",\"favicon\":\"\"},{\"id\":\"39\",\"title\":\"** Chiu KC, Lin MC, Liang YC, Chen CY (2008). [\\\"Renal carcinosarcoma: case report and review of literature\\\"](https://doi.org/10.1080%2F08860220802403192). _Renal Failure_. **30** (10): 1034â€“9\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1080/08860220802403192](https://doi.org/10.1080%2F08860220802403192). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [19016157](https://pubmed.ncbi.nlm.nih.gov/19016157).\",\"description\":\"39. **^** Chiu KC, Lin MC, Liang YC, Chen CY (2008). [\\\"Renal carcinosarcoma: case report and review of literature\\\"](https://doi.org/10.1080%2F08860220802403192). _Renal Failure_. **30** (10): 1034â€“9\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1080/08860220802403192](https://doi.org/10.1080%2F08860220802403192). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [19016157](https://pubmed.ncbi.nlm.nih.gov/19016157).\",\"url\":\"https://doi.org/10.1080%2F08860220802403192\",\"favicon\":\"\"},{\"id\":\"40\",\"title\":\"** Picozzi S, Casellato S, Bozzini G, Ratti D, Macchi A, Rubino B, Pace G, Carmignani L (November 2013). \\\"Inverted papilloma of the bladder: a review and an analysis of the recent literature of 365 patients\\\". _Urologic Oncology_. **31** (8): 1584â€“1590\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1016/j.urolonc.2012.03.009](https://doi.org/10.1016%2Fj.urolonc.2012.03.009). [ISSN](ISSN_\\\\(identifier\\\\) \\\"ISSN \\\\(identifier\\\\)\\\") [1873-2496](https://search.worldcat.org/issn/1873-2496). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [22520573](https://pubmed.ncbi.nlm.nih.gov/22520573).\",\"description\":\"40. **^** Picozzi S, Casellato S, Bozzini G, Ratti D, Macchi A, Rubino B, Pace G, Carmignani L (November 2013). \\\"Inverted papilloma of the bladder: a review and an analysis of the recent literature of 365 patients\\\". _Urologic Oncology_. **31** (8): 1584â€“1590\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1016/j.urolonc.2012.03.009](https://doi.org/10.1016%2Fj.urolonc.2012.03.009). [ISSN](ISSN_\\\\(identifier\\\\) \\\"ISSN \\\\(identifier\\\\)\\\") [1873-2496](https://search.worldcat.org/issn/1873-2496). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [22520573](https://pubmed.ncbi.nlm.nih.gov/22520573).\",\"url\":\"Doi_\\\\(identifier\\\\\",\"favicon\":\"\"},{\"id\":\"41\",\"title\":\"** Lopez-Beltran A, Scarpelli M, Montironi R, Kirkali Z (May 2006). \\\"2004 WHO classification of the renal tumors of the adults\\\". _European Urology_. **49** (5): 798â€“805\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1016/j.eururo.2005.11.035](https://doi.org/10.1016%2Fj.eururo.2005.11.035). [ISSN](ISSN_\\\\(identifier\\\\) \\\"ISSN \\\\(identifier\\\\)\\\") [0302-2838](https://search.worldcat.org/issn/0302-2838). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [16442207](https://pubmed.ncbi.nlm.nih.gov/16442207).\",\"description\":\"41. **^** Lopez-Beltran A, Scarpelli M, Montironi R, Kirkali Z (May 2006). \\\"2004 WHO classification of the renal tumors of the adults\\\". _European Urology_. **49** (5): 798â€“805\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1016/j.eururo.2005.11.035](https://doi.org/10.1016%2Fj.eururo.2005.11.035). [ISSN](ISSN_\\\\(identifier\\\\) \\\"ISSN \\\\(identifier\\\\)\\\") [0302-2838](https://search.worldcat.org/issn/0302-2838). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [16442207](https://pubmed.ncbi.nlm.nih.gov/16442207).\",\"url\":\"Doi_\\\\(identifier\\\\\",\"favicon\":\"\"},{\"id\":\"42\",\"title\":\"** Thyavihally YB, Tongaonkar HB, Desai SB (September 2005). [\\\"Benign mixed epithelial stromal tumor of the renal pelvis with exophytic growth: case report\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1215508). _Int Semin Surg Oncol_. **2** 18\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1186/1477-7800-2-18](https://doi.org/10.1186%2F1477-7800-2-18). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [1215508](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1215508). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [16150156](https://pubmed.ncbi.nlm.nih.gov/16150156).\",\"description\":\"42. **^** Thyavihally YB, Tongaonkar HB, Desai SB (September 2005). [\\\"Benign mixed epithelial stromal tumor of the renal pelvis with exophytic growth: case report\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1215508). _Int Semin Surg Oncol_. **2** 18\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1186/1477-7800-2-18](https://doi.org/10.1186%2F1477-7800-2-18). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [1215508](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1215508). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [16150156](https://pubmed.ncbi.nlm.nih.gov/16150156).\",\"url\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1215508\",\"favicon\":\"\"},{\"id\":\"43\",\"title\":\"** Mantilla JG, Antic T, Tretiakova M (2017). \\\"GATA3 as a valuable marker to distinguish clear cell papillary renal cell carcinomas from morphologic mimics\\\". _Hum Pathol_. **66** : 152â€“158\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1016/j.humpath.2017.06.016](https://doi.org/10.1016%2Fj.humpath.2017.06.016). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [28705707](https://pubmed.ncbi.nlm.nih.gov/28705707).`{{cite journal}}`: CS1 maint: multiple names: authors list (link)\",\"description\":\"43. **^** Mantilla JG, Antic T, Tretiakova M (2017). \\\"GATA3 as a valuable marker to distinguish clear cell papillary renal cell carcinomas from morphologic mimics\\\". _Hum Pathol_. **66** : 152â€“158\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1016/j.humpath.2017.06.016](https://doi.org/10.1016%2Fj.humpath.2017.06.016). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [28705707](https://pubmed.ncbi.nlm.nih.gov/28705707).`{{cite journal}}`: CS1 maint: multiple names: authors list (link)\",\"url\":\"Doi_\\\\(identifier\\\\\",\"favicon\":\"\"},{\"id\":\"44\",\"title\":\"** Behtash G. Nezami, M.D., Gregory MacLennan, M.D. [\\\"Kidney tumor - Adult renal cell carcinoma - common - Clear cell\\\"](https://www.pathologyoutlines.com/topic/kidneytumormalignantrccclear.html). _Pathology Outlines_. [Archived](https://web.archive.org/web/20211018181509/https://www.pathologyoutlines.com/topic/kidneytumormalignantrccclear.html) from the original on 2021-10-18. Retrieved 2021-10-18.`{{cite web}}`: CS1 maint: multiple names: authors list (link) Topic Completed: 20 April 2021. Minor changes: 20 April 2021\",\"description\":\"44. **^** Behtash G. Nezami, M.D., Gregory MacLennan, M.D. [\\\"Kidney tumor - Adult renal cell carcinoma - common - Clear cell\\\"](https://www.pathologyoutlines.com/topic/kidneytumormalignantrccclear.html). _Pathology Outlines_. [Archived](https://web.archive.org/web/20211018181509/https://www.pathologyoutlines.com/topic/kidneytumormalignantrccclear.html) from the original on 2021-10-18. Retrieved 2021-10-18.`{{cite web}}`: CS1 maint: multiple names: authors list (link) Topic Completed: 20 April 2021. Minor changes: 20 April 2021\",\"url\":\"https://www.pathologyoutlines.com/topic/kidneytumormalignantrccclear.html\",\"favicon\":\"\"},{\"id\":\"45\",\"title\":\"_**a**_ _**b**_ Motzer RJ, Jonasch E, Agarwal N, Bhayani S, Bro WP, Chang SS, Choueiri TK, Costello BA, Derweesh IH, Fishman M, Gallagher TH (2017-06-01). [\\\"Kidney Cancer, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology\\\"](https://jnccn.org/view/journals/jnccn/15/6/article-p804.xml). _Journal of the National Comprehensive Cancer Network_. **15** (6): 804â€“834\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.6004/jnccn.2017.0100](https://doi.org/10.6004%2Fjnccn.2017.0100). [ISSN](ISSN_\\\\(identifier\\\\) \\\"ISSN \\\\(identifier\\\\)\\\") [1540-1405](https://search.worldcat.org/issn/1540-1405). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [28596261](https://pubmed.ncbi.nlm.nih.gov/28596261). [Archived](https://web.archive.org/web/20191029185620/https://jnccn.org/view/journals/jnccn/15/6/article-p804.xml) from the original on 2019-10-29. Retrieved 2019-10-29.\",\"description\":\"45. ^ _**a**_ _**b**_ Motzer RJ, Jonasch E, Agarwal N, Bhayani S, Bro WP, Chang SS, Choueiri TK, Costello BA, Derweesh IH, Fishman M, Gallagher TH (2017-06-01). [\\\"Kidney Cancer, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology\\\"](https://jnccn.org/view/journals/jnccn/15/6/article-p804.xml). _Journal of the National Comprehensive Cancer Network_. **15** (6): 804â€“834\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.6004/jnccn.2017.0100](https://doi.org/10.6004%2Fjnccn.2017.0100). [ISSN](ISSN_\\\\(identifier\\\\) \\\"ISSN \\\\(identifier\\\\)\\\") [1540-1405](https://search.worldcat.org/issn/1540-1405). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [28596261](https://pubmed.ncbi.nlm.nih.gov/28596261). [Archived](https://web.archive.org/web/20191029185620/https://jnccn.org/view/journals/jnccn/15/6/article-p804.xml) from the original on 2019-10-29. Retrieved 2019-10-29.\",\"url\":\"https://jnccn.org/view/journals/jnccn/15/6/article-p804.xml\",\"favicon\":\"\"},{\"id\":\"46\",\"title\":\"** Patel HD, Johnson MH, Pierorazio PM, Sozio SM, Sharma R, Iyoha E, Bass EB, Allaf ME (May 2016). [\\\"Diagnostic Accuracy and Risks of Biopsy in the Diagnosis of a Renal Mass Suspicious for Localized Renal Cell Carcinoma: Systematic Review of the Literature\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5609078). _The Journal of Urology_. **195** (5): 1340â€“1347\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1016/j.juro.2015.11.029](https://doi.org/10.1016%2Fj.juro.2015.11.029). [ISSN](ISSN_\\\\(identifier\\\\) \\\"ISSN \\\\(identifier\\\\)\\\") [1527-3792](https://search.worldcat.org/issn/1527-3792). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [5609078](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5609078). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [26901507](https://pubmed.ncbi.nlm.nih.gov/26901507).\",\"description\":\"46. **^** Patel HD, Johnson MH, Pierorazio PM, Sozio SM, Sharma R, Iyoha E, Bass EB, Allaf ME (May 2016). [\\\"Diagnostic Accuracy and Risks of Biopsy in the Diagnosis of a Renal Mass Suspicious for Localized Renal Cell Carcinoma: Systematic Review of the Literature\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5609078). _The Journal of Urology_. **195** (5): 1340â€“1347\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1016/j.juro.2015.11.029](https://doi.org/10.1016%2Fj.juro.2015.11.029). [ISSN](ISSN_\\\\(identifier\\\\) \\\"ISSN \\\\(identifier\\\\)\\\") [1527-3792](https://search.worldcat.org/issn/1527-3792). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [5609078](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5609078). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [26901507](https://pubmed.ncbi.nlm.nih.gov/26901507).\",\"url\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5609078\",\"favicon\":\"\"},{\"id\":\"47\",\"title\":\"** [\\\"Kidney Cancer Stages | Renal Cell Carcinoma Staging\\\"](https://www.cancer.org/cancer/kidney-cancer/detection-diagnosis-staging/staging.html). _www.cancer.org_. [Archived](https://web.archive.org/web/20190727155332/https://www.cancer.org/cancer/kidney-cancer/detection-diagnosis-staging/staging.html) from the original on 2019-07-27. Retrieved 2019-11-12.\",\"description\":\"47. **^** [\\\"Kidney Cancer Stages | Renal Cell Carcinoma Staging\\\"](https://www.cancer.org/cancer/kidney-cancer/detection-diagnosis-staging/staging.html). _www.cancer.org_. [Archived](https://web.archive.org/web/20190727155332/https://www.cancer.org/cancer/kidney-cancer/detection-diagnosis-staging/staging.html) from the original on 2019-07-27. Retrieved 2019-11-12.\",\"url\":\"https://www.cancer.org/cancer/kidney-cancer/detection-diagnosis-staging/staging.html\",\"favicon\":\"\"},{\"id\":\"48\",\"title\":\"_**a**_ _**b**_ _**c**_ _**d**_ _AJCC cancer staging manual_. Edge, Stephen B., American Joint Committee on Cancer. (7th ed.). New York: Springer. 2010. [ISBN](ISBN_\\\\(identifier\\\\) \\\"ISBN \\\\(identifier\\\\)\\\") 9780387884400. [OCLC](OCLC_\\\\(identifier\\\\) \\\"OCLC \\\\(identifier\\\\)\\\") [316431417](https://search.worldcat.org/oclc/316431417).`{{cite book}}`: CS1 maint: others (link)\",\"description\":\"48. ^ _**a**_ _**b**_ _**c**_ _**d**_ _AJCC cancer staging manual_. Edge, Stephen B., American Joint Committee on Cancer. (7th ed.). New York: Springer. 2010. [ISBN](ISBN_\\\\(identifier\\\\) \\\"ISBN \\\\(identifier\\\\)\\\") 9780387884400. [OCLC](OCLC_\\\\(identifier\\\\) \\\"OCLC \\\\(identifier\\\\)\\\") [316431417](https://search.worldcat.org/oclc/316431417).`{{cite book}}`: CS1 maint: others (link)\",\"url\":\"ISBN_\\\\(identifier\\\\\",\"favicon\":\"\"},{\"id\":\"49\",\"title\":\"** [\\\"Kidney Cancer Stages\\\"](https://www.cancer.org/cancer/kidney-cancer/detection-diagnosis-staging/staging.html). _cancer.org_. [Archived](https://web.archive.org/web/20190727155332/https://www.cancer.org/cancer/kidney-cancer/detection-diagnosis-staging/staging.html) from the original on 2019-07-27. Retrieved 2019-11-12. Last Revised: February 1, 2020\",\"description\":\"49. **^** [\\\"Kidney Cancer Stages\\\"](https://www.cancer.org/cancer/kidney-cancer/detection-diagnosis-staging/staging.html). _cancer.org_. [Archived](https://web.archive.org/web/20190727155332/https://www.cancer.org/cancer/kidney-cancer/detection-diagnosis-staging/staging.html) from the original on 2019-07-27. Retrieved 2019-11-12. Last Revised: February 1, 2020\",\"url\":\"https://www.cancer.org/cancer/kidney-cancer/detection-diagnosis-staging/staging.html\",\"favicon\":\"\"},{\"id\":\"50\",\"title\":\"** Swami U, Nussenzveig RH, Haaland B, Agarwal N (2019). [\\\"Revisiting AJCC TNM staging for renal cell carcinoma: quest for improvement\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6462602). _Annals of Translational Medicine_. **7** (S1): S18. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.21037/atm.2019.01.50](https://doi.org/10.21037%2Fatm.2019.01.50). [ISSN](ISSN_\\\\(identifier\\\\) \\\"ISSN \\\\(identifier\\\\)\\\") [2305-5839](https://search.worldcat.org/issn/2305-5839). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [6462602](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6462602). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [31032299](https://pubmed.ncbi.nlm.nih.gov/31032299).\",\"description\":\"50. **^** Swami U, Nussenzveig RH, Haaland B, Agarwal N (2019). [\\\"Revisiting AJCC TNM staging for renal cell carcinoma: quest for improvement\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6462602). _Annals of Translational Medicine_. **7** (S1): S18. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.21037/atm.2019.01.50](https://doi.org/10.21037%2Fatm.2019.01.50). [ISSN](ISSN_\\\\(identifier\\\\) \\\"ISSN \\\\(identifier\\\\)\\\") [2305-5839](https://search.worldcat.org/issn/2305-5839). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [6462602](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6462602). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [31032299](https://pubmed.ncbi.nlm.nih.gov/31032299).\",\"url\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6462602\",\"favicon\":\"\"},{\"id\":\"51\",\"title\":\"** [\\\"Kidney Cancer (Adult) â€“ Renal Cell Carcinoma\\\"](https://web.archive.org/web/20170222223224/https://old.cancer.org/acs/groups/cid/documents/webcontent/003107-pdf.pdf) (PDF). _[American Cancer Society](American_Cancer_Society \\\"American Cancer Society\\\")_. Archived from [the original](https://old.cancer.org/acs/groups/cid/documents/webcontent/003107-pdf.pdf) (PDF) on 2017-02-22. Last Revised: May 16, 2016\",\"description\":\"51. **^** [\\\"Kidney Cancer (Adult) â€“ Renal Cell Carcinoma\\\"](https://web.archive.org/web/20170222223224/https://old.cancer.org/acs/groups/cid/documents/webcontent/003107-pdf.pdf) (PDF). _[American Cancer Society](American_Cancer_Society \\\"American Cancer Society\\\")_. Archived from [the original](https://old.cancer.org/acs/groups/cid/documents/webcontent/003107-pdf.pdf) (PDF) on 2017-02-22. Last Revised: May 16, 2016\",\"url\":\"https://web.archive.org/web/20170222223224/https://old.cancer.org/acs/groups/cid/documents/webcontent/003107-pdf.pdf\",\"favicon\":\"\"},{\"id\":\"52\",\"title\":\"** [\\\"Early stage and locally advanced kidney cancer treatment\\\"](http://cancerhelp.cancerresearchuk.org/type/kidney-cancer/treatment/types/early-stage-kidney-cancer#surgery). 2017-08-30. [Archived](https://web.archive.org/web/20121010071247/http://cancerhelp.cancerresearchuk.org/type/kidney-cancer/treatment/types/early-stage-kidney-cancer#surgery) from the original on 2012-10-10. Retrieved 2011-11-30.\",\"description\":\"52. **^** [\\\"Early stage and locally advanced kidney cancer treatment\\\"](http://cancerhelp.cancerresearchuk.org/type/kidney-cancer/treatment/types/early-stage-kidney-cancer#surgery). 2017-08-30. [Archived](https://web.archive.org/web/20121010071247/http://cancerhelp.cancerresearchuk.org/type/kidney-cancer/treatment/types/early-stage-kidney-cancer#surgery) from the original on 2012-10-10. Retrieved 2011-11-30.\",\"url\":\"http://cancerhelp.cancerresearchuk.org/type/kidney-cancer/treatment/types/early-stage-kidney-cancer#surgery\",\"favicon\":\"\"},{\"id\":\"53\",\"title\":\"** [\\\"Advanced kidney cancer\\\"](http://cancerhelp.cancerresearchuk.org/type/kidney-cancer/treatment/types/advanced-kidney-cancer#other). 2017-08-30. [Archived](https://web.archive.org/web/20121010121828/http://cancerhelp.cancerresearchuk.org/type/kidney-cancer/treatment/types/advanced-kidney-cancer#other) from the original on 2012-10-10. Retrieved 2011-11-30.\",\"description\":\"53. **^** [\\\"Advanced kidney cancer\\\"](http://cancerhelp.cancerresearchuk.org/type/kidney-cancer/treatment/types/advanced-kidney-cancer#other). 2017-08-30. [Archived](https://web.archive.org/web/20121010121828/http://cancerhelp.cancerresearchuk.org/type/kidney-cancer/treatment/types/advanced-kidney-cancer#other) from the original on 2012-10-10. Retrieved 2011-11-30.\",\"url\":\"http://cancerhelp.cancerresearchuk.org/type/kidney-cancer/treatment/types/advanced-kidney-cancer#other\",\"favicon\":\"\"},{\"id\":\"54\",\"title\":\"** Choueiri TK, et al. (2021-08-19). [\\\"Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma\\\"](https://doi.org/10.1056%2Fnejmoa2106391). _New England Journal of Medicine_. **385** (8): 683â€“694\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1056/nejmoa2106391](https://doi.org/10.1056%2Fnejmoa2106391). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [34407342](https://pubmed.ncbi.nlm.nih.gov/34407342). [S2CID](S2CID_\\\\(identifier\\\\) \\\"S2CID \\\\(identifier\\\\)\\\") [237215136](https://api.semanticscholar.org/CorpusID:237215136).\",\"description\":\"54. **^** Choueiri TK, et al. (2021-08-19). [\\\"Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma\\\"](https://doi.org/10.1056%2Fnejmoa2106391). _New England Journal of Medicine_. **385** (8): 683â€“694\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1056/nejmoa2106391](https://doi.org/10.1056%2Fnejmoa2106391). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [34407342](https://pubmed.ncbi.nlm.nih.gov/34407342). [S2CID](S2CID_\\\\(identifier\\\\) \\\"S2CID \\\\(identifier\\\\)\\\") [237215136](https://api.semanticscholar.org/CorpusID:237215136).\",\"url\":\"https://doi.org/10.1056%2Fnejmoa2106391\",\"favicon\":\"\"},{\"id\":\"55\",\"title\":\"** [\\\"Renal cell carcinoma | HemOnc.org - A Hematology Oncology Wiki\\\"](http://hemonc.org/Renal_cancer). _hemonc.org_. [Archived](https://web.archive.org/web/20160828122702/http://hemonc.org/Renal_cancer) from the original on 2016-08-28. Retrieved 2012-05-08.\",\"description\":\"55. **^** [\\\"Renal cell carcinoma | HemOnc.org - A Hematology Oncology Wiki\\\"](http://hemonc.org/Renal_cancer). _hemonc.org_. [Archived](https://web.archive.org/web/20160828122702/http://hemonc.org/Renal_cancer) from the original on 2016-08-28. Retrieved 2012-05-08.\",\"url\":\"http://hemonc.org/Renal_cancer\",\"favicon\":\"\"},{\"id\":\"56\",\"title\":\"** [\\\"National Comprehensive Cancer Network\\\"](http://www.nccn.org/professionals/physician_gls/pdf/kidney.pdf) (PDF). [Archived](https://web.archive.org/web/20090306103023/http://www.nccn.org/professionals/physician_gls/PDF/kidney.pdf) (PDF) from the original on 2009-03-06. Retrieved 2012-05-08.\",\"description\":\"56. **^** [\\\"National Comprehensive Cancer Network\\\"](http://www.nccn.org/professionals/physician_gls/pdf/kidney.pdf) (PDF). [Archived](https://web.archive.org/web/20090306103023/http://www.nccn.org/professionals/physician_gls/PDF/kidney.pdf) (PDF) from the original on 2009-03-06. Retrieved 2012-05-08.\",\"url\":\"http://www.nccn.org/professionals/physician_gls/pdf/kidney.pdf\",\"favicon\":\"\"},{\"id\":\"57\",\"title\":\"** [\\\"Biological therapy for kidney cancer\\\"](http://cancerhelp.cancerresearchuk.org/type/kidney-cancer/treatment/biological/). 2017-08-30. [Archived](https://web.archive.org/web/20111128083012/http://cancerhelp.cancerresearchuk.org/type/kidney-cancer/treatment/biological/) from the original on 2011-11-28. Retrieved 2011-11-30.\",\"description\":\"57. **^** [\\\"Biological therapy for kidney cancer\\\"](http://cancerhelp.cancerresearchuk.org/type/kidney-cancer/treatment/biological/). 2017-08-30. [Archived](https://web.archive.org/web/20111128083012/http://cancerhelp.cancerresearchuk.org/type/kidney-cancer/treatment/biological/) from the original on 2011-11-28. Retrieved 2011-11-30.\",\"url\":\"http://cancerhelp.cancerresearchuk.org/type/kidney-cancer/treatment/biological/\",\"favicon\":\"\"},{\"id\":\"58\",\"title\":\"** Jonasch, Eric, Messner, Carolyn (August 2012). [\\\"CancerCare Connect â€“ Treatment Update: Kidney Cancer\\\"](https://web.archive.org/web/20110925154318/http://media.cancercare.org/publications/original/16-ccc_kidney_cancer.pdf) (PDF). Cancer Care, Inc. Archived from [the original](http://media.cancercare.org/publications/original/16-ccc_kidney_cancer.pdf) (PDF) on 2011-09-25. Retrieved 2012-08-29.\",\"description\":\"58. **^** Jonasch, Eric, Messner, Carolyn (August 2012). [\\\"CancerCare Connect â€“ Treatment Update: Kidney Cancer\\\"](https://web.archive.org/web/20110925154318/http://media.cancercare.org/publications/original/16-ccc_kidney_cancer.pdf) (PDF). Cancer Care, Inc. Archived from [the original](http://media.cancercare.org/publications/original/16-ccc_kidney_cancer.pdf) (PDF) on 2011-09-25. Retrieved 2012-08-29.\",\"url\":\"https://web.archive.org/web/20110925154318/http://media.cancercare.org/publications/original/16-ccc_kidney_cancer.pdf\",\"favicon\":\"\"},{\"id\":\"59\",\"title\":\"_**a**_ _**b**_ Syn NL, Teng MW, Mok TS, Soo RA (2017). \\\"De-novo and acquired resistance to immune checkpoint targeting\\\". _The Lancet Oncology_. **18** (12): e731 â€“ e741. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1016/s1470-2045(17)30607-1](https://doi.org/10.1016%2Fs1470-2045%2817%2930607-1). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [29208439](https://pubmed.ncbi.nlm.nih.gov/29208439).\",\"description\":\"59. ^ _**a**_ _**b**_ Syn NL, Teng MW, Mok TS, Soo RA (2017). \\\"De-novo and acquired resistance to immune checkpoint targeting\\\". _The Lancet Oncology_. **18** (12): e731 â€“ e741. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1016/s1470-2045(17)30607-1](https://doi.org/10.1016%2Fs1470-2045%2817%2930607-1). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [29208439](https://pubmed.ncbi.nlm.nih.gov/29208439).\",\"url\":\"Doi_\\\\(identifier\\\\\",\"favicon\":\"\"},{\"id\":\"60\",\"title\":\"** [\\\"FDA approves Opdivo to treat advanced form of kidney cancer\\\"](https://web.archive.org/web/20180125101444/https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm473971.htm). _[Food and Drug Administration](Food_and_Drug_Administration \\\"Food and Drug Administration\\\")_. Archived from [the original](https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm473971.htm) on 2018-01-25. Retrieved 2019-12-16.\",\"description\":\"60. **^** [\\\"FDA approves Opdivo to treat advanced form of kidney cancer\\\"](https://web.archive.org/web/20180125101444/https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm473971.htm). _[Food and Drug Administration](Food_and_Drug_Administration \\\"Food and Drug Administration\\\")_. Archived from [the original](https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm473971.htm) on 2018-01-25. Retrieved 2019-12-16.\",\"url\":\"https://web.archive.org/web/20180125101444/https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm473971.htm\",\"favicon\":\"\"},{\"id\":\"61\",\"title\":\"** Philips GK, Atkins MB (2014). [\\\"New agents and new targets for renal cell carcinoma\\\"](https://doi.org/10.14694%2FEdBook_AM.2014.34.e222). _American Society of Clinical Oncology Educational Book / ASCO. American Society of Clinical Oncology. Meeting_. **34** (34): e222-7. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.14694/EdBook_AM.2014.34.e222](https://doi.org/10.14694%2FEdBook_AM.2014.34.e222). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [24857106](https://pubmed.ncbi.nlm.nih.gov/24857106).\",\"description\":\"61. **^** Philips GK, Atkins MB (2014). [\\\"New agents and new targets for renal cell carcinoma\\\"](https://doi.org/10.14694%2FEdBook_AM.2014.34.e222). _American Society of Clinical Oncology Educational Book / ASCO. American Society of Clinical Oncology. Meeting_. **34** (34): e222-7. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.14694/EdBook_AM.2014.34.e222](https://doi.org/10.14694%2FEdBook_AM.2014.34.e222). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [24857106](https://pubmed.ncbi.nlm.nih.gov/24857106).\",\"url\":\"https://doi.org/10.14694%2FEdBook_AM.2014.34.e222\",\"favicon\":\"\"},{\"id\":\"62\",\"title\":\"** [\\\"Drugs@FDA: FDA Approved Drug Products\\\"](https://web.archive.org/web/20210829142843/https://www.accessdata.fda.gov/scripts/cder/daf/). Archived from [the original](http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Overview\u0026DrugName=CABOMETYX) on 2021-08-29. Retrieved 2016-04-25.\",\"description\":\"62. **^** [\\\"Drugs@FDA: FDA Approved Drug Products\\\"](https://web.archive.org/web/20210829142843/https://www.accessdata.fda.gov/scripts/cder/daf/). Archived from [the original](http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Overview\u0026DrugName=CABOMETYX) on 2021-08-29. Retrieved 2016-04-25.\",\"url\":\"https://web.archive.org/web/20210829142843/https://www.accessdata.fda.gov/scripts/cder/daf/\",\"favicon\":\"\"},{\"id\":\"63\",\"title\":\"** [\\\"CABOMETYXâ„¢ (cabozantinib)\\\"](https://web.archive.org/web/20220130174141/https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208692s000lbl.pdf) (PDF). _fda.gov_. Archived from [the original](https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208692s000lbl.pdf) (PDF) on 30 January 2022. Retrieved 6 July 2024.\",\"description\":\"63. **^** [\\\"CABOMETYXâ„¢ (cabozantinib)\\\"](https://web.archive.org/web/20220130174141/https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208692s000lbl.pdf) (PDF). _fda.gov_. Archived from [the original](https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208692s000lbl.pdf) (PDF) on 30 January 2022. Retrieved 6 July 2024.\",\"url\":\"https://web.archive.org/web/20220130174141/https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208692s000lbl.pdf\",\"favicon\":\"\"},{\"id\":\"64\",\"title\":\"** Kinget L, Naulaerts S, Govaerts J, Vanmeerbeek I, Sprooten J, Laureano RS, et al. (June 2024). \\\"A spatial architecture-embedding HLA signature to predict clinical response to immunotherapy in renal cell carcinoma\\\". _Nature Medicine_. **30** (6): 1667â€“1679\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1038/s41591-024-02978-9](https://doi.org/10.1038%2Fs41591-024-02978-9). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [38773341](https://pubmed.ncbi.nlm.nih.gov/38773341).\",\"description\":\"64. **^** Kinget L, Naulaerts S, Govaerts J, Vanmeerbeek I, Sprooten J, Laureano RS, et al. (June 2024). \\\"A spatial architecture-embedding HLA signature to predict clinical response to immunotherapy in renal cell carcinoma\\\". _Nature Medicine_. **30** (6): 1667â€“1679\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1038/s41591-024-02978-9](https://doi.org/10.1038%2Fs41591-024-02978-9). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [38773341](https://pubmed.ncbi.nlm.nih.gov/38773341).\",\"url\":\"Doi_\\\\(identifier\\\\\",\"favicon\":\"\"},{\"id\":\"65\",\"title\":\"** [\\\"LENVIMAâ„¢\\\"](https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/206947s000lbl.pdf) (PDF). _fda.gov_. [Archived](https://web.archive.org/web/20240624112504/https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/206947s000lbl.pdf) (PDF) from the original on 24 June 2024. Retrieved 6 July 2024.\",\"description\":\"65. **^** [\\\"LENVIMAâ„¢\\\"](https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/206947s000lbl.pdf) (PDF). _fda.gov_. [Archived](https://web.archive.org/web/20240624112504/https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/206947s000lbl.pdf) (PDF) from the original on 24 June 2024. Retrieved 6 July 2024.\",\"url\":\"https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/206947s000lbl.pdf\",\"favicon\":\"\"},{\"id\":\"66\",\"title\":\"_**a**_ _**b**_ [\\\"Wilms' tumour (kidney cancer in children)\\\"](https://web.archive.org/web/20120406063913/http://cancerhelp.cancerresearchuk.org/about-cancer/cancer-questions/wilms-tumour). 2017-08-30. Archived from [the original](http://cancerhelp.cancerresearchuk.org/about-cancer/cancer-questions/wilms-tumour) on 2012-04-06.\",\"description\":\"66. ^ _**a**_ _**b**_ [\\\"Wilms' tumour (kidney cancer in children)\\\"](https://web.archive.org/web/20120406063913/http://cancerhelp.cancerresearchuk.org/about-cancer/cancer-questions/wilms-tumour). 2017-08-30. Archived from [the original](http://cancerhelp.cancerresearchuk.org/about-cancer/cancer-questions/wilms-tumour) on 2012-04-06.\",\"url\":\"https://web.archive.org/web/20120406063913/http://cancerhelp.cancerresearchuk.org/about-cancer/cancer-questions/wilms-tumour\",\"favicon\":\"\"},{\"id\":\"67\",\"title\":\"** Lindblad, P. and Adami H.O, Kidney Cancer, in Textbook of Cancer.\",\"description\":\"67. **^** Lindblad, P. and Adami H.O, Kidney Cancer, in Textbook of Cancer.\",\"url\":\"\",\"favicon\":\"\"},{\"id\":\"68\",\"title\":\"** GLOBOCAN 2002, Cancer Incidence, Mortality and Prevalence Worldwide 2002 estimates. 2006.\",\"description\":\"68. **^** GLOBOCAN 2002, Cancer Incidence, Mortality and Prevalence Worldwide 2002 estimates. 2006.\",\"url\":\"\",\"favicon\":\"\"},{\"id\":\"69\",\"title\":\"** Klaassen Z, Sayyid RK, Wallis CJ (2019). [\\\"Lessons Learned from the Global Epidemiology of Kidney Cancer: A Refresher in Epidemiology 101\\\"](https://linkinghub.elsevier.com/retrieve/pii/S0302283818307231). _European Urology_. **75** (1): 85â€“87\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1016/j.eururo.2018.09.035](https://doi.org/10.1016%2Fj.eururo.2018.09.035). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [30274700](https://pubmed.ncbi.nlm.nih.gov/30274700). [S2CID](S2CID_\\\\(identifier\\\\) \\\"S2CID \\\\(identifier\\\\)\\\") [52900491](https://api.semanticscholar.org/CorpusID:52900491). [Archived](https://web.archive.org/web/20220615191055/https://linkinghub.elsevier.com/retrieve/pii/S0302283818307231) from the original on 2022-06-15. Retrieved 2021-12-01.\",\"description\":\"69. **^** Klaassen Z, Sayyid RK, Wallis CJ (2019). [\\\"Lessons Learned from the Global Epidemiology of Kidney Cancer: A Refresher in Epidemiology 101\\\"](https://linkinghub.elsevier.com/retrieve/pii/S0302283818307231). _European Urology_. **75** (1): 85â€“87\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1016/j.eururo.2018.09.035](https://doi.org/10.1016%2Fj.eururo.2018.09.035). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [30274700](https://pubmed.ncbi.nlm.nih.gov/30274700). [S2CID](S2CID_\\\\(identifier\\\\) \\\"S2CID \\\\(identifier\\\\)\\\") [52900491](https://api.semanticscholar.org/CorpusID:52900491). [Archived](https://web.archive.org/web/20220615191055/https://linkinghub.elsevier.com/retrieve/pii/S0302283818307231) from the original on 2022-06-15. Retrieved 2021-12-01.\",\"url\":\"https://linkinghub.elsevier.com/retrieve/pii/S0302283818307231\",\"favicon\":\"\"},{\"id\":\"70\",\"title\":\"** [\\\"Cancer of the Kidney and Renal Pelvis â€“ SEER Stat Fact Sheets\\\"](https://seer.cancer.gov/statfacts/html/kidrp.html). National Cancer Institute, U.S. National Institutes of Health. [Archived](https://web.archive.org/web/20160329002623/http://seer.cancer.gov/statfacts/html/kidrp.html) from the original on 2016-03-29. Retrieved 2013-02-07.\",\"description\":\"70. **^** [\\\"Cancer of the Kidney and Renal Pelvis â€“ SEER Stat Fact Sheets\\\"](https://seer.cancer.gov/statfacts/html/kidrp.html). National Cancer Institute, U.S. National Institutes of Health. [Archived](https://web.archive.org/web/20160329002623/http://seer.cancer.gov/statfacts/html/kidrp.html) from the original on 2016-03-29. Retrieved 2013-02-07.\",\"url\":\"https://seer.cancer.gov/statfacts/html/kidrp.html\",\"favicon\":\"\"},{\"id\":\"71\",\"title\":\"** Lynch CF, West MM, Davila JA, Platz CE (2007). \\\"Chapter 24: Cancers of the Kidney and Renal Pelvic\\\". In Ries L, Young JL, Keel GE, Eisner MP, Horner MJ (eds.). [_SEER Survival Monograph: Cancer Survival Among Adults: US SEER Program, 1988â€“2001, Patient and Tumor Characteristics_](https://web.archive.org/web/20131010123756/http://seer.cancer.gov/publications/survival/). Vol. NIH Pub. No. 07-6215. Bethesda, MD: National Cancer Institute. pp. 193â€“202\\\\. Archived from [the original](https://seer.cancer.gov/publications/survival) on 2013-10-10.\",\"description\":\"71. **^** Lynch CF, West MM, Davila JA, Platz CE (2007). \\\"Chapter 24: Cancers of the Kidney and Renal Pelvic\\\". In Ries L, Young JL, Keel GE, Eisner MP, Horner MJ (eds.). [_SEER Survival Monograph: Cancer Survival Among Adults: US SEER Program, 1988â€“2001, Patient and Tumor Characteristics_](https://web.archive.org/web/20131010123756/http://seer.cancer.gov/publications/survival/). Vol. NIH Pub. No. 07-6215. Bethesda, MD: National Cancer Institute. pp. 193â€“202\\\\. Archived from [the original](https://seer.cancer.gov/publications/survival) on 2013-10-10.\",\"url\":\"https://web.archive.org/web/20131010123756/http://seer.cancer.gov/publications/survival/\",\"favicon\":\"\"},{\"id\":\"72\",\"title\":\"** Ferlay J, et al. (2007). [\\\"Estimates of the cancer incidence and mortality in Europe in 2006\\\"](https://doi.org/10.1093%2Fannonc%2Fmdl498). _Annals of Oncology_. **18** (3): 581â€“92\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1093/annonc/mdl498](https://doi.org/10.1093%2Fannonc%2Fmdl498). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [17287242](https://pubmed.ncbi.nlm.nih.gov/17287242).\",\"description\":\"72. **^** Ferlay J, et al. (2007). [\\\"Estimates of the cancer incidence and mortality in Europe in 2006\\\"](https://doi.org/10.1093%2Fannonc%2Fmdl498). _Annals of Oncology_. **18** (3): 581â€“92\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1093/annonc/mdl498](https://doi.org/10.1093%2Fannonc%2Fmdl498). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [17287242](https://pubmed.ncbi.nlm.nih.gov/17287242).\",\"url\":\"https://doi.org/10.1093%2Fannonc%2Fmdl498\",\"favicon\":\"\"},{\"id\":\"73\",\"title\":\"** [\\\"Kidney cancer statistics\\\"](http://www.cancerresearchuk.org/cancer-info/cancerstats/types/kidney/). _Cancer Research UK_. [Archived](https://web.archive.org/web/20141017044517/http://www.cancerresearchuk.org/cancer-info/cancerstats/types/kidney/) from the original on 17 October 2014. Retrieved 27 October 2014.\",\"description\":\"73. **^** [\\\"Kidney cancer statistics\\\"](http://www.cancerresearchuk.org/cancer-info/cancerstats/types/kidney/). _Cancer Research UK_. [Archived](https://web.archive.org/web/20141017044517/http://www.cancerresearchuk.org/cancer-info/cancerstats/types/kidney/) from the original on 17 October 2014. Retrieved 27 October 2014.\",\"url\":\"http://www.cancerresearchuk.org/cancer-info/cancerstats/types/kidney/\",\"favicon\":\"\"}],\"images\":[],\"fixedIssues\":[{\"criticality\":\"Critical\",\"issueType\":\"Timeliness/Currency\",\"problematicText\":\"\\\"Kidney cancer newly affected about 403,300 people and resulted in 175,000 deaths globally in 2018.[5]\\\"\",\"explanation\":\"Outdated statistics; GLOBOCAN 2022 reports 434,840 new cases and 155,953 deaths globally, reflecting more recent data up to 2022.\",\"fixedText\":\"Update to \\\"about 434,800 people and resulted in 156,000 deaths globally in 2022\\\" with new citation.\",\"evidenceSource\":\"[], https://gco.iarc.who.int/media/globocan/factsheets/cancers/29-kidney-fact-sheet.pdf\"},{\"criticality\":\"Critical\",\"issueType\":\"Timeliness/Currency\",\"problematicText\":\"\\\"The overall five-year survival rate is 75% in the United States, 71% in Canada, 70% in China, and 60% in Europe.[4][9][10][11]\\\"\",\"explanation\":\"Outdated survival rates; latest data (as of 2024-2025) show US: 78%, Canada: 73%, Europe: 66%, China: ~70% (stable).\",\"fixedText\":\"Update rates to 78% (US), 73% (Canada), 70% (China), 66% (Europe) with new citations where needed.\",\"evidenceSource\":\"[], https://www.cancer.org/cancer/types/kidney-cancer/detection-diagnosis-staging/survival-rates.html ; [], https://cancer.ca/en/cancer-information/cancer-types/kidney/prognosis-and-survival/survival-statistics ; [], https://www.europeanurology.com/article/S0302-2838(25)00345-8/fulltext ; [11]\"},{\"criticality\":\"Critical\",\"issueType\":\"Timeliness/Currency\",\"problematicText\":\"\\\"For cancers that are confined to the kidney, the five-year survival rate is 93%, if it has spread to the surrounding lymph nodes it is 70%, and if it has spread widely, it is 12%.[4]\\\"\",\"explanation\":\"Outdated stage-specific survival; SEER 2014-2020 data: localized 93%, regional 72%, distant 16%.\",\"fixedText\":\"Update to 93% (localized), 72% (regional), 16% (distant).\",\"evidenceSource\":\"[], https://www.cancer.org/cancer/types/kidney-cancer/detection-diagnosis-staging/survival-rates.html\"},{\"criticality\":\"Critical\",\"issueType\":\"Quantitative/Units Error\",\"problematicText\":\"\\\"Kidney cancer has been identified as the 13th most common form of cancer,[12]\\\"\",\"explanation\":\"Inaccurate ranking; GLOBOCAN 2022 ranks kidney cancer as the 14th most common globally.\",\"fixedText\":\"Update to \\\"14th most common\\\".\",\"evidenceSource\":\"[], https://gco.iarc.who.int/media/globocan/factsheets/cancers/29-kidney-fact-sheet.pdf\"},{\"criticality\":\"Critical\",\"issueType\":\"Missing Information\",\"problematicText\":\"No specific mention of recent projections.\",\"explanation\":\"Recent studies (2025) project kidney cancer cases to double globally by 2050 due to aging populations and risk factors; adds temporal context and significance.\",\"fixedText\":\"Add brief note: \\\"Incidence is projected to double by 2050.\\\"\",\"evidenceSource\":\"[], https://www.foxchase.org/news/kidney-cancer-cases-are-projected-double-2050-says-study\"},{\"criticality\":\"Critical\",\"issueType\":\"Source/Citation Mismatch\",\"problematicText\":\"Other symptoms that are consistent with advanced disease include weight loss, fever, night sweats, palpable swollen lymph nodes in the neck, non-reducing varicocele, bone pain, continuous cough, and bilateral lower leg swelling.[15][16][17]\",\"explanation\":\"Reference [16] is a meta-analysis on blood pressure as a risk factor for kidney cancer, not on symptoms of advanced disease. Reference [17] is EAU guidelines on RCC, which do not detail these specific symptoms based on review.\",\"fixedText\":\"Remove citations [16] and [17] from this sentence, retaining [15] if it supports.\",\"evidenceSource\":\"[16]; [17]; https://uroweb.org/guidelines/renal-cell-carcinoma\"},{\"criticality\":\"Critical\",\"issueType\":\"Quantitative/Units Error\",\"problematicText\":\"The classic triad of visible blood in the urine (hematuria), flank pain and palpable abdominal mass occurs in less than 15% of the cases.\",\"explanation\":\"Recent sources indicate the classic triad occurs in approximately 5-10% of cases, not up to 15%. This overestimation could mislead on rarity.\",\"fixedText\":\"Update to \\\"occurs in approximately 5-10% of cases\\\" and cite an authoritative source.\",\"evidenceSource\":\"Medscape: https://emedicine.medscape.com/article/281340-clinical; UpToDate: https://www.uptodate.com/contents/clinical-manifestations-evaluation-and-staging-of-renal-cell-carcinoma\"},{\"criticality\":\"Critical\",\"issueType\":\"Missing Information\",\"problematicText\":\"[No specific quote; entire first paragraph]\",\"explanation\":\"The section omits that due to widespread use of imaging (CT, ultrasound), the majority (50-70%) of kidney cancers are now discovered incidentally, without symptoms, representing a significant shift in presentation over recent decades.\",\"fixedText\":\"Add sentence: \\\"Due to increased use of abdominal imaging for other conditions, the majority of kidney cancers (over 50%) are now detected incidentally before symptoms develop.\\\"\",\"evidenceSource\":\"BMJ Open: https://bmjopen.bmj.com/content/10/5/e035938; Clinical Radiology: https://www.clinicalradiologyonline.net/article/S0009-9260(20)30492-X/fulltext\"},{\"criticality\":\"Critical\",\"issueType\":\"Source/Citation Mismatch\",\"problematicText\":\"Factors that increase the risk of kidney cancer include smoking, high blood pressure, obesity, faulty genes, a family history of kidney cancer in the first relatives,[19] having kidney disease that needs dialysis, being infected with hepatitis C, and previous treatment for testicular cancer or cervical cancer.[20][21]\",\"explanation\":\"The citations [20] and [21] (Tahbaz 2018 and Cancer.Net) focus on standard risk factors like smoking, obesity, hypertension, dialysis, and family/genetic history but do not mention hepatitis C infection or previous treatment for testicular or cervical cancer as risk factors for kidney cancer. While literature supports hepatitis C and testicular cancer treatment as risks, the current sources do not, leading to unsupported claims.\",\"fixedText\":\"Remove \\\"being infected with hepatitis C, and previous treatment for testicular cancer or cervical cancer\\\" from the list, or add new citations: for hep C [](https://pmc.ncbi.nlm.nih.gov/articles/PMC5108977/), for testicular [](https://www.cancer.org/cancer/types/testicular-cancer/after-treatment/second-cancers.html). Retain dialysis as supported by [21]. Correct \\\"first relatives\\\" to \\\"first-degree relatives\\\". Replace \\\"faulty genes\\\" with \\\"inherited genetic conditions\\\" for precision.\",\"evidenceSource\":\"[21] Cancer.Net risk factors page; literature searches confirm hep C and testicular but not cited here.\"},{\"criticality\":\"Critical\",\"issueType\":\"Source/Citation Mismatch\",\"problematicText\":\"About 25â€“30% of kidney cancer is attributed to smoking.[21]\",\"explanation\":\"Citation [21] (Cancer.Net) discusses smoking as a risk but does not specify the 25-30% attributable fraction. Recent data (as of 2025) estimates 17-20% in the US, though some sources cite up to 30%; the exact figure is not supported by the cited source.\",\"fixedText\":\"Update to \\\"approximately 20% of kidney cancer cases are attributable to smoking\\\" with new citation [](https://stacks.cdc.gov/view/cdc/122203), or remove percentage if not critical.\",\"evidenceSource\":\"[21] Cancer.Net; CDC stacks report 17.4% [](https://stacks.cdc.gov/view/cdc/122203)\"},{\"criticality\":\"Non-Critical\",\"issueType\":\"Missing Information\",\"problematicText\":\"None\",\"explanation\":\"Recent developments (as of 2025) highlight diabetes and chronic kidney disease (beyond dialysis) as emerging modifiable risk factors, not covered here. Incidence projected to double by 2050 due to obesity and related factors.\",\"fixedText\":\"Add sentence: \\\"Other modifiable risk factors include type 2 diabetes and chronic kidney disease. The incidence of kidney cancer is projected to double globally by 2050, largely due to rising obesity rates.[](https://ascopost.com/news/october-2025/kidney-cancer-cases-expected-to-double-by-2050/)\\\"\",\"evidenceSource\":\"European Urology 2025 [](https://www.europeanurology.com/article/S0302-2838%2825%2900345-8/fulltext); ASCO Post 2025 [](https://ascopost.com/news/october-2025/kidney-cancer-cases-expected-to-double-by-2050/)\"},{\"criticality\":\"Critical\",\"issueType\":\"Timeliness/Currency\",\"problematicText\":\"The 2004 [WHO](World_Health_Organization \\\"World Health Organization\\\") Classification of the Renal Tumors of the Adults describes these categories:\",\"explanation\":\"The classification referenced is outdated; the current standard is the 2022 WHO (5th edition) classification of urinary and male genital tumors, which includes significant updates to renal tumor subtypes, such as renaming clear cell papillary RCC to clear cell papillary renal cell tumor, addition of molecularly defined categories, and revisions to papillary RCC.\",\"fixedText\":\"Update to reference the 2022 WHO classification and revise the list of subtypes to reflect current categories, e.g., clear cell RCC, papillary RCC, chromophobe RCC, collecting duct carcinoma, renal medullary carcinoma, MiT family translocation RCC, and new molecularly defined entities like eosinophilic solid and cystic RCC.\",\"evidenceSource\":\"[](https://www.pathologyoutlines.com/topic/kidneytumorWHOclass.html)\"},{\"criticality\":\"Critical\",\"issueType\":\"Scope/Applicability Misstatement\",\"problematicText\":\"Renal cell carcinoma is the only type of kidney cancer that can be staged.\",\"explanation\":\"This is incorrect; other kidney cancers like transitional cell carcinoma (using upper tract urothelial TNM) and Wilms tumor (using NWTS or SIOP staging) have their own staging systems. The section focuses on RCC TNM, but the claim overstates exclusivity.\",\"fixedText\":\"Revise to: \\\"The TNM staging system is commonly used for renal cell carcinoma. Other types of kidney cancer use different staging systems.\\\"\",\"evidenceSource\":\"Ref 47 (AJCC for RCC); [](https://www.cancer.org/cancer/types/kidney-cancer/detection-diagnosis-staging/staging.html) for RCC specificity, but others exist per standard oncology texts.\"},{\"criticality\":\"Critical\",\"issueType\":\"Source/Citation Mismatch\",\"problematicText\":\"Inverted urothelial papilloma â€“ was traditionally regarded as a benign growth. However, there may be an increased risk for recurrence and transformation to TCC.[40]\",\"explanation\":\"The text lists it under \\\"Other causes of kidney cancer,\\\" but inverted urothelial papilloma is a benign neoplasm, not a cause of cancer. Malignant transformation is rare (controversial, \u003c1-2% risk), and ref 40 is about bladder, not specifically renal pelvis; it misclassifies a benign entity as a cancer cause.\",\"fixedText\":\"Remove from \\\"causes of kidney cancer\\\" list; move to benign tumors or omit if not diagnostic focus, as it's rare and benign.\",\"evidenceSource\":\"Ref 40 (2013 review on bladder); [](https://www.ncbi.nlm.nih.gov/books/NBK537218/)\"},{\"criticality\":\"Critical\",\"issueType\":\"Timeliness/Currency\",\"problematicText\":\"More than 60% of renal cell carcinoma (the most common type of kidney cancer), are diagnosed incidentally by abdominal imaging for nonspecific abdominal complaints.[15][27]\",\"explanation\":\"Citations are from 2012 and 2008; recent data (2024) indicate 37-61% or nearly 50%, suggesting the \u003e60% figure may be outdated due to increased screening/imaging.\",\"fixedText\":\"Update to \\\"Approximately 50% (range 37-61%) of renal cell carcinomas are diagnosed incidentally\\\" with new citation.\",\"evidenceSource\":\"[](https://pubmed.ncbi.nlm.nih.gov/39196544/)\"},{\"criticality\":\"Critical\",\"issueType\":\"Missing Information\",\"problematicText\":\"[No specific text; overall histopathologic classification subsection]\",\"explanation\":\"The section lacks mention of updates in diagnostic classifications post-2004, including integration of molecular and genetic testing in 2022 WHO, which is essential for accurate subtyping and prognosis in modern pathology.\",\"fixedText\":\"Add brief note on 2022 updates, emphasizing molecularly defined tumors and low-malignant potential entities like clear cell papillary renal cell tumor.\",\"evidenceSource\":\"[](https://pmc.ncbi.nlm.nih.gov/articles/PMC11100973/)\"},{\"criticality\":\"Critical\",\"issueType\":\"Timeliness/Currency\",\"problematicText\":\"\\\"Sunitinib is the current standard of care in the adjuvant setting along with pazopanib\\\"\",\"explanation\":\"Adjuvant sunitinib is no longer recommended (weak against per EAU 2025); pazopanib was never approved for adjuvant use. Current standard is pembrolizumab for high-risk clear cell RCC post-surgery, based on KEYNOTE-564 showing DFS and OS benefits. Misstating current standards can lead to inappropriate treatment choices.\",\"fixedText\":\"Replace with: Adjuvant pembrolizumab is recommended for patients with high-risk clear cell RCC following nephrectomy.\",\"evidenceSource\":\"EAU 2025 Guidelines[](https://d56bochluxqnz.cloudfront.net/documents/pocket-guidelines/EAU-Pocket-on-Renal-Cell-Carcinoma-2025.pdf); NCCN 2025 Guidelines[](https://www.nccn.org/patients/guidelines/content/PDF/kidney-patient.pdf)\"},{\"criticality\":\"Critical\",\"issueType\":\"Timeliness/Currency\",\"problematicText\":\"\\\"However, the study has yet to yield conclusive findings in relation to overall survival. [54]\\\"\",\"explanation\":\"KEYNOTE-564 follow-up data (as of 2024-2025) show significant OS benefit (HR 0.62, 48-month OS 91.2% vs 86.0%). Claim is outdated, potentially understating the therapy's efficacy.\",\"fixedText\":\"Update to: Long-term follow-up confirmed improvements in disease-free and overall survival.\",\"evidenceSource\":\"NEJM 2024 OS analysis[](https://www.nejm.org/doi/full/10.1056/NEJMoa2312695); ASCO 2025 5-year update[](https://ascopubs.org/doi/10.1200/JCO.2025.43.16_suppl.4514)\"},{\"criticality\":\"Critical\",\"issueType\":\"Scope/Applicability Misstatement\",\"problematicText\":\"\\\"[Immune checkpoint inhibitors](Checkpoint_inhibitor \\\"Checkpoint inhibitor\\\") are also in trials for kidney cancer, and some have gained approval for medical use.[59] In the second line setting, [nivolumab](Nivolumab \\\"Nivolumab\\\") demonstrated an overall survival advantage... [Cabozantinib](Cabozantinib \\\"Cabozantinib\\\") also demonstrated... [Lenvatinib](Lenvatinib \\\"Lenvatinib\\\") in combination with everolimus...\\\"\",\"explanation\":\"Presents outdated treatment landscape: ICIs like nivolumab are now first-line standards in combinations (e.g., nivo+ipi, nivo+cabo); lenvatinib+everolimus is obsolete, replaced by lenvatinib+pembrolizumab as first-line. Focuses on second-line without mentioning first-line, misrepresenting current practice for advanced RCC.\",\"fixedText\":\"Add current first-line options for advanced disease: combinations of immune checkpoint inhibitors with TKIs (e.g., pembrolizumab + axitinib, nivolumab + cabozantinib). Update second-line to subsequent therapies based on prior lines.\",\"evidenceSource\":\"NCCN 2025[](https://www.nccn.org/patients/guidelines/content/PDF/kidney-patient.pdf); EAU 2025[](https://d56bochluxqnz.cloudfront.net/documents/pocket-guidelines/EAU-Pocket-on-Renal-Cell-Carcinoma-2025.pdf)\"},{\"criticality\":\"Critical\",\"issueType\":\"Internal Contradiction\",\"problematicText\":\"The Children subsection describes etiology, onset, and symptoms of Wilms' tumor rather than treatments.\",\"explanation\":\"Under \\\"Treatment \u003e Children\\\", content duplicates Signs and symptoms and Causes sections per article structure, without focusing on pediatric treatment modalities. Misleads as non-treatment info in a treatment subsection.\",\"fixedText\":\"Refocus subsection on treatment for pediatric kidney cancer (primarily Wilms' tumor): surgery, chemotherapy, radiation based on stage; remove duplicative descriptive content.\",\"evidenceSource\":\"Article structure; NCI Wilms treatment[](https://www.cancer.gov/types/kidney/patient/wilms-treatment-pdq)\"},{\"criticality\":\"Critical\",\"issueType\":\"Missing Information\",\"problematicText\":\"No mention of current first-line systemic therapies for metastatic RCC.\",\"explanation\":\"Section omits standard first-line treatments (IO + TKI/IO combos), a key gap in comprehensive treatment overview, especially as incidence and options have evolved.\",\"fixedText\":\"Add: For favorable-risk metastatic clear cell RCC, preferred first-line options include pembrolizumab + axitinib or cabozantinib + nivolumab.\",\"evidenceSource\":\"NCCN 2025; EAU 2025\"},{\"criticality\":\"Critical\",\"issueType\":\"Timeliness/Currency\",\"problematicText\":\"Around 208,500 new cases of kidney cancer are diagnosed in the world each year\",\"explanation\":\"Outdated figure from pre-2010 sources (refs 67-68); GLOBOCAN 2022 reports 434,840 new cases globally, nearly doubling prior estimates due to improved data and rising incidence.\",\"fixedText\":\"Update to 434,840 new cases in 2022 (GLOBOCAN); note as latest available estimate.\",\"evidenceSource\":\"[](https://gco.iarc.who.int/media/globocan/factsheets/cancers/29-kidney-fact-sheet.pdf)\"},{\"criticality\":\"Critical\",\"issueType\":\"Timeliness/Currency\",\"problematicText\":\"The United States' NIH estimates for 2013 around 64,770 new cases of kidney cancer and 13,570 deaths from the disease.\",\"explanation\":\"12-year-old data; SEER 2025 estimates 80,980 new cases and 14,510 deaths, reflecting stable incidence but population growth.\",\"fixedText\":\"Update to 2025 estimates: 80,980 new cases, 14,510 deaths.\",\"evidenceSource\":\"[](https://seer.cancer.gov/statfacts/html/kidrp.html)\"},{\"criticality\":\"Critical\",\"issueType\":\"Timeliness/Currency\",\"problematicText\":\"The most recent estimates of incidence of kidney cancer suggest that there are 63,300 new cases annually in the EU25.\",\"explanation\":\"Refers to outdated EU25 (pre-2007 enlargement); GLOBOCAN 2022 estimates 145,721 new cases across broader Europe, more than double due to updated methodology and scope.\",\"fixedText\":\"Update to 145,721 new cases in Europe (2022); remove EU25 reference.\",\"evidenceSource\":\"[](https://gco.iarc.who.int/media/globocan/factsheets/cancers/29-kidney-fact-sheet.pdf)\"},{\"criticality\":\"Critical\",\"issueType\":\"Timeliness/Currency\",\"problematicText\":\"Kidney cancer is the eighth most common cancer in the UK (around 10,100 people were diagnosed with the disease in 2011)\",\"explanation\":\"13-year-old data; UK incidence now ~13,900 annually (2017-2019 average), projected to rise 15% to ~21,900 by 2038-2040.\",\"fixedText\":\"Update to ~13,900 new cases annually (2017-2019); note projections.\",\"evidenceSource\":\"[](https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/kidney-cancer/incidence)\"},{\"criticality\":\"Critical\",\"issueType\":\"Quantitative/Units Error\",\"problematicText\":\"Black people with kidney cancer have lower mortality rates than Caucasians in the United States.\",\"explanation\":\"Incorrect; SEER data (2018-2022) shows higher age-adjusted mortality for non-Hispanic Black (4.0/100,000) vs. non-Hispanic White (3.6/100,000), driven by disparities in stage at diagnosis and access to care.\",\"fixedText\":\"Correct to: Non-Hispanic Black individuals have higher mortality rates (4.0/100,000) than non-Hispanic Whites (3.6/100,000).\",\"evidenceSource\":\"[](https://seer.cancer.gov/statfacts/html/kidrp.html)\"},{\"criticality\":\"Critical\",\"issueType\":\"Quantitative/Units Error\",\"problematicText\":\"There are higher incidence rates in Black men and Hispanics, an average rate for American Indians, and low rates in Asians in the United States.\",\"explanation\":\"Misleading; overall incidence highest in non-Hispanic Whites (18.3/100,000), followed by Blacks (16.5); for men, Black (25.9) slightly higher than White/Hispanic (24.6), but AI/AN men highest (39.2); Asians lowest (10-11/100,000).\",\"fixedText\":\"Revise to specify rates by group: Highest overall in non-Hispanic Whites; AI/AN highest among men; Asians lowest.\",\"evidenceSource\":\"[](https://seer.cancer.gov/statfacts/html/kidrp.html)\"},{\"criticality\":\"Critical\",\"issueType\":\"Source/Citation Mismatch\",\"problematicText\":\"In both male and female children, renal tumors represent 2% to 6% of kidney cancer, with Wilms' tumor being the most common.[14]\",\"explanation\":\"Overstates; pediatric kidney tumors (mostly Wilms) comprise ~1-2% of all kidney cancers globally (e.g., ~500 US pediatric vs. 80,000 total); ref [14] (2008) likely refers to proportion among childhood cancers, not all kidney cancers.\",\"fixedText\":\"Correct to ~1-2% of all kidney cancer cases are pediatric (Wilms most common); cite recent source.\",\"evidenceSource\":\"Ref [14]; [](https://seer.cancer.gov/statfacts/html/kidrp.html)\"},{\"criticality\":\"Critical\",\"issueType\":\"Scope/Applicability Misstatement\",\"problematicText\":\"**Lifestyle risk factors** [entire subsection]\",\"explanation\":\"Duplicates content appropriately covered in \\\"Causes\\\" section (per article_structure); epidemiology should focus on incidence/prevalence variations, not reiterate risk factors.\",\"fixedText\":\"Remove subsection to avoid duplication; briefly note if risks explain variations (e.g., smoking/obesity in high-incidence areas).\",\"evidenceSource\":\"Article structure\"},{\"criticality\":\"Critical\",\"issueType\":\"Missing Information\",\"problematicText\":\"[No specific text; overall section]\",\"explanation\":\"Lacks recent trends/projections: Global incidence projected to nearly double by 2050 (to ~800,000 cases) due to aging/obesity; US incidence stable since 2013; many European countries stable/increasing.\",\"fixedText\":\"Add paragraph on global trends and projections as of 2022-2025 data.\",\"evidenceSource\":\"[](https://ecancer.org/en/news/27089-kidney-cancer-cases-are-projected-to-double-by-2050-says-study)\"},{\"criticality\":\"Critical\",\"issueType\":\"Timeliness/Currency\",\"problematicText\":\"As of 2018, Czech Republic and Lithuania have the highest incidence rate of kidney cancer worldwide, with an age-standardized rate of 21.9/100,000 in males (Czech Republic) and 18.7/100,000 in males (Lithuania.)\",\"explanation\":\"Outdated; GLOBOCAN 2022 shows Belarus (22.9/100,000 males), Latvia, Czechia highest; low-risk areas (e.g., China, Africa) \u003c2/100,000 still accurate.\",\"fixedText\":\"Update countries/rates to 2022: Belarus highest at 22.9/100,000 (males).\",\"evidenceSource\":\"[](https://gco.iarc.who.int/media/globocan/factsheets/cancers/29-kidney-fact-sheet.pdf)\"}],\"slug\":\"Kidney_cancer\",\"title\":\"Kidney cancer\",\"content\":\"$1f\",\"description\":\"Kidney cancer\\n\\n| Attribute | Details |\\n|---------------|-------------|\\n| Other names | Renal cancer |\\n| Specialty | Oncology, nephrology, urology |\\n| Symptoms | Blood in the urine, lump in the...\",\"metadata\":{\"categories\":[\"Renal cancer\",\"Renal cell carcinoma\",\"RCC\"],\"lastModified\":\"1761553636\",\"contentLength\":\"24831\",\"version\":\"1.0\",\"lastEditor\":\"system\",\"language\":\"en\",\"isRedirect\":false,\"redirectTarget\":\"\",\"isWithheld\":false},\"stats\":{\"totalViews\":\"88713\",\"recentViews\":\"88713\",\"dailyAvgViews\":2957.10009765625,\"qualityScore\":1,\"lastViewed\":\"1761887062\"},\"linkedPages\":null},\"found\":true},\"dataUpdateCount\":1,\"dataUpdatedAt\":1761887062760,\"error\":null,\"errorUpdateCount\":0,\"errorUpdatedAt\":0,\"fetchFailureCount\":0,\"fetchFailureReason\":null,\"fetchMeta\":null,\"isInvalidated\":false,\"status\":\"success\",\"fetchStatus\":\"idle\"},\"queryKey\":[\"page\",\"Kidney_cancer\"],\"queryHash\":\"[\\\"page\\\",\\\"Kidney_cancer\\\"]\"}]},\"children\":\"$L20\"}]\n"])</script><script nonce="ZDI3MzMxYzUtYzY2YS00M2M3LThmMmMtODg3ZDMzYTJjZmMw">self.__next_f.push([1,"c:{\"metadata\":[[\"$\",\"title\",\"0\",{\"children\":\"Kidney cancer\"}],[\"$\",\"meta\",\"1\",{\"name\":\"description\",\"content\":\"Kidney cancer , also known as renal cancer , is a group of cancers that starts in the kidney.[4] Symptoms may include blood in the urine, a lump in the abdomen, or back pain.[1][2][3] Fever, weight loss, and tiredness may also occur.[1][2][3] Complications can include spread to the lungs or brain.[6] The main types of kidney cancer are renal cell cancer (RCC), transitional cell cancer (TCC), and Wilms' tumor.[7] RCC makes up approximately 80% of kidney cancers, and TCC accounts for most of the...\"}],[\"$\",\"meta\",\"2\",{\"name\":\"author\",\"content\":\"system\"}],[\"$\",\"link\",\"3\",{\"rel\":\"manifest\",\"href\":\"/manifest.webmanifest\",\"crossOrigin\":\"$undefined\"}],[\"$\",\"meta\",\"4\",{\"name\":\"keywords\",\"content\":\"Renal cancer, Renal cell carcinoma, RCC\"}],[\"$\",\"meta\",\"5\",{\"name\":\"robots\",\"content\":\"index, follow\"}],[\"$\",\"meta\",\"6\",{\"name\":\"googlebot\",\"content\":\"index, follow, max-snippet:-1\"}],[\"$\",\"link\",\"7\",{\"rel\":\"canonical\",\"href\":\"https://grokipedia.com/page/Kidney_cancer\"}],[\"$\",\"meta\",\"8\",{\"property\":\"og:title\",\"content\":\"Kidney cancer\"}],[\"$\",\"meta\",\"9\",{\"property\":\"og:description\",\"content\":\"Kidney cancer , also known as renal cancer , is a group of cancers that starts in the kidney.[4] Symptoms may include blood in the urine, a lump in the abdomen, or back pain.[1][2][3] Fever, weight loss, and tiredness may also occur.[1][2][3] Complications can include spread to the lungs or brain.[6] The main types of kidney cancer are renal cell cancer (RCC), transitional cell cancer (TCC), and Wilms' tumor.[7] RCC makes up approximately 80% of kidney cancers, and TCC accounts for most of the...\"}],[\"$\",\"meta\",\"10\",{\"property\":\"og:url\",\"content\":\"https://grokipedia.com/page/Kidney_cancer\"}],[\"$\",\"meta\",\"11\",{\"property\":\"og:site_name\",\"content\":\"Grokipedia\"}],[\"$\",\"meta\",\"12\",{\"property\":\"og:locale\",\"content\":\"en\"}],[\"$\",\"meta\",\"13\",{\"property\":\"og:image\",\"content\":\"https://grokipedia.com/icon-512x512.png\"}],[\"$\",\"meta\",\"14\",{\"property\":\"og:image:width\",\"content\":\"512\"}],[\"$\",\"meta\",\"15\",{\"property\":\"og:image:height\",\"content\":\"512\"}],[\"$\",\"meta\",\"16\",{\"property\":\"og:image:alt\",\"content\":\"Kidney cancer\"}],[\"$\",\"meta\",\"17\",{\"property\":\"og:type\",\"content\":\"article\"}],[\"$\",\"meta\",\"18\",{\"property\":\"article:modified_time\",\"content\":\"1970-01-21T09:19:13.636Z\"}],[\"$\",\"meta\",\"19\",{\"name\":\"twitter:card\",\"content\":\"summary\"}],[\"$\",\"meta\",\"20\",{\"name\":\"twitter:creator\",\"content\":\"@Grokipedia\"}],[\"$\",\"meta\",\"21\",{\"name\":\"twitter:title\",\"content\":\"Kidney cancer\"}],[\"$\",\"meta\",\"22\",{\"name\":\"twitter:description\",\"content\":\"Kidney cancer , also known as renal cancer , is a group of cancers that starts in the kidney.[4] Symptoms may include blood in the urine, a lump in the abdomen, or back pain.[1][2][3] Fever, weight loss, and tiredness may also occur.[1][2][3] Complications can include spread to the lungs or brain.[6] The main types of kidney cancer are renal cell cancer (RCC), transitional cell cancer (TCC), and Wilms' tumor.[7] RCC makes up approximately 80% of kidney cancers, and TCC accounts for most of the...\"}],[\"$\",\"meta\",\"23\",{\"name\":\"twitter:image\",\"content\":\"https://grokipedia.com/icon-512x512.png\"}],[\"$\",\"link\",\"24\",{\"rel\":\"icon\",\"href\":\"/favicon.ico\",\"type\":\"image/x-icon\",\"sizes\":\"16x16\"}],[\"$\",\"$L21\",\"25\",{}]],\"error\":null,\"digest\":\"$undefined\"}\n"])</script><script nonce="ZDI3MzMxYzUtYzY2YS00M2M3LThmMmMtODg3ZDMzYTJjZmMw">self.__next_f.push([1,"11:\"$c:metadata\"\n"])</script><script nonce="ZDI3MzMxYzUtYzY2YS00M2M3LThmMmMtODg3ZDMzYTJjZmMw">self.__next_f.push([1,"22:I[61172,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"4684\",\"static/chunks/24cf1b50-159cca90b09285e0.js\",\"1829\",\"static/chunks/9ffa21ba-c069766d809bd4c7.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"7720\",\"static/chunks/7720-3a1e7e411adba2d3.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"600\",\"static/chunks/600-9a9fcafaaa6c1c4c.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"5448\",\"static/chunks/5448-2a3cfd853d899c9a.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"8\",\"static/chunks/8-8ca70ca619d8e099.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"6304\",\"static/chunks/app/page/%5Bslug%5D/page-540a27b6839afde5.js\"],\"PageEditorProvider\"]\n"])</script><script nonce="ZDI3MzMxYzUtYzY2YS00M2M3LThmMmMtODg3ZDMzYTJjZmMw">self.__next_f.push([1,"23:I[63493,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"4684\",\"static/chunks/24cf1b50-159cca90b09285e0.js\",\"1829\",\"static/chunks/9ffa21ba-c069766d809bd4c7.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"7720\",\"static/chunks/7720-3a1e7e411adba2d3.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"600\",\"static/chunks/600-9a9fcafaaa6c1c4c.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"5448\",\"static/chunks/5448-2a3cfd853d899c9a.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"8\",\"static/chunks/8-8ca70ca619d8e099.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"6304\",\"static/chunks/app/page/%5Bslug%5D/page-540a27b6839afde5.js\"],\"default\"]\n"])</script><script nonce="ZDI3MzMxYzUtYzY2YS00M2M3LThmMmMtODg3ZDMzYTJjZmMw">self.__next_f.push([1,"20:[\"$\",\"$L22\",null,{\"children\":[\"$\",\"$L23\",null,{\"slug\":\"Kidney_cancer\"}]}]\n"])</script></body></html>